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Abstract 
Atherosclerosis manifests a state of increased oxidative stress characterized by comparable 
lipid and protein oxidation in the affected arterial wall.  While oxidative modification of low 
density lipoprotein (LDL) has been extensively studied, increasing attention has been focused 
recently on oxidation of high-density lipoproteins (HDL) and its functional consequences in 
relation to atherosclerosis.  Oxidative modification is thought to generate “dysfunctional” 
HDL that has lost anti-atherosclerotic activities, including the ability to remove cholesterol 
from lipid-laden cells.  Therefore, there has been much interest in the detection of oxidized 
HDL.  Unfortunately, available methods to detect oxidized HDL are limited at present, in part 
because oxidative modification of HDL is a complex process and ‘oxidized HDL’ is not a 
chemically defined entity.  What is known however is that conversion of methionine (Met) 
residues of apolipoprotein (apo) A-I to methionine sulfoxide (MetO) is a process that occurs 
commonly as HDL undergoes oxidative modification.  For example, human apoA-I+16 
(containing MetO86 or MetO112) and apoA-I+32 (MetO86 plus MetO112) are generated when 
apoA-I reacts with lipid hydroperoxides formed as a consequence of the lipoprotein being 
exposed to 1e−oxidants.  The formation of MetO in apoA−I induced by 2e−oxidants (i.e., 
hydrogen peroxide, hypochlorous acid or myeloperoxidase/hydrogen peroxide/chloride 
system) is associated with an impaired ability of the apolipoprotein to facilitate reactions 
relevant to reverse cholesterol transport.  In addition, a previous study has suggested the 
plasma content of apoA-I+32 to be increased in certain subjects that have an increased risk to 
develop cardiovascular disease (CVD).  Moreover, the MetO content in circulating, 
HDL−associated apoA−I is elevated in type 1 diabetes, a disorder commonly associated with 
increased oxidative stress and a risk factor for atherosclerosis. 
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Therefore, in the present study, an existing HPLC method was applied to HDL samples from 
the Fletcher−Challenge study, a nested case control study, to test the potential usefulness of 
MetO-containing apoA-I as a marker of oxidative stress and/or CVD in a general population.  
Plasma samples whose HDL contained detectable apoA-I+16 and/or apoA-I+32 had 
significantly elevated levels of F2-isoprostanes, a marker of in vivo lipid oxidation, consistent 
with MetO-containing apoA-I
 
being a useful marker of in vivo protein oxidation.  Despite this 
however, there was no significant difference between controls and cases in their 
concentrations of HDL apoA-I+16 and apoA-I+32 or F2-isoprostanes, suggesting that markers 
of protein and lipid oxidation are not associated with the risk of coronary heart disease 
(CHD) in this general population.   
A limitation of the Fletcher−Challenge study was that only 22% of the 534 HDL samples 
analyzed contained apoA-I+16 and/or apoA-I+32.  In addition, the HPLC−based method used is 
expensive and time−consuming and may lack the sensitivity needed for apolipoproteins to 
clinical studies.  Thus, a mouse monoclonal anti-human apoA-I+32 antibody (MOA−1) was 
raised using HPLC−purified apoA-I+32 as immunogen. A sensitive ELISA was then 
developed using a commercial anti-human apoA-I monoclonal antibody as capture and 
biotinylated MOA−1 as detection antibody, respectively.  The assay detected lipid−free 
HPLC−purified human apoA-I+32 in a concentration-dependent manner and with a 
significantly lower limit of detection (i.e., 3 ng/mL) than the HPLC method (1 µg/mL).  The 
ELISA also detected lipid-free apoA-I modified by 2e-oxidants (hydrogen peroxide, 
hypochlorous acid, peroxynitrite), and HDL oxidized by 1e- or 2e-oxidants and present in 
buffer or human plasma.  Moreover, the extent of recognition of MetO by MOA−1 increased 
with increasing numbers of MetO in apoA−I, as assessed by the experiments with 
H2O2−oxidized forms of apoA−I mutants, in which one, two or three Met residues were 
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replaced with Leu.  Their detection was concentration-dependent, reproducible, and exhibited 
a linear response over a physiologically plausible range of concentrations of oxidized HDL.  
In contrast, MOA-I failed to recognize native apoA-I, native apoA-II, apoA-I modified by 
hydroxyl radicals or metal ions, or LDL modified by 2e-oxidants.  Furthermore, MOA−1 did 
not detect other Met−containing proteins oxidized by either hypochlorous acid or hydrogen 
peroxide.  Taken together, the results showed that recognition of oxidized proteins by 
MOA−1 is limited to MetO contained in apoA−I. 
Finally, in a pilot study, plasma samples obtained from subjects with coronary artery disease 
(CAD) proven by angiography, and samples from CAD patients undergoing percutaneous 
coronary intervention (PCI) were analyzed by the ELISA.  The preliminary data obtained 
showed elevated levels of MetO-containing apoA-I in plasma samples of CAD patients 
compared to those of corresponding control subjects.  Unexpectedly, levels of MetO-
containing apoA-I decreased PCI compared to before PCI.  A possible explanation for these 
results is that HDL−associated apoA−I become displaced by acute phase proteins, such as 
serum amyloid A, in response to PCI. 
In summary, the ELISA developed here specifically detects apoA-I containing MetO in HDL 
and human plasma.  As such it may provide a useful tool for investigating the relationship 
between oxidized HDL and CAD. 
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1.1 Introduction 
Cardiovascular disease (CVD) is a major cause of death in developed countries and it is 
increasing in the rest of the world.  Most heart attacks and many cases of cerebral ischemia 
are secondary to the condition of atherosclerosis.  Atherosclerosis is a disease of arteries 
characterized by a local thickening (a result of accumulation of cholesterol deposits, foam 
cells and debris) of the vessel wall.  The clinical effects of atherosclerosis are often evident in 
the coronary, carotid, femoral and iliac arteries and aorta where lesions (plaques) may rapture 
and cause subsequent thrombosis.  Consequently, cardiovascular events, such as stroke and 
myocardial infarction, occur when essential arteries are occluded completely.  The 
mechanisms leading to atherosclerosis are complex and multiple factors are implicated, 
including endothelial dysfunction, recruitment of inflammatory cells and oxidation of lipids 
and proteins, including those of lipoproteins (1,2). 
 
1 Chapter 
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1.2 Atherosclerosis 
1.2.1 Definition of atherosclerosis 
“Atherosclerosis” originates from the Greek words “athero” (meaning “gruel” or “paste”) and 
“sclerosis” (meaning “hardness”).  It is a chronic disease affecting large and medium−sized 
arterial blood vessels, and caused by the formation of multiple plaques within the arteries.  
The advanced atherosclerotic plaque has two major components.  One is the cholesterol− and 
lipid−rich acellular part, also referred to atheroma, where much of the lipids are deposited.  
The other is the surrounding sclerotic area of the plaque, composed of collagen and cellular 
waste products, such as dead cells, calcium and other matrix elements.  This often forms a 
firm, fibrous cap over the advanced atherosclerotic plaque (3). 
1.2.2 Morphology of atherosclerosis 
FEATURES OF NORMAL ARTERY  The normal arterial wall consists of three 
well−defined layers of tunica that surround the arterial lumen.  The inner layer is called 
intima tunica, the middle layer is known as the tunica media, and the outmost layer is tunica 
adventitia (Fig. 1.1).  These three layers are demarcated by concentric layers of elastin.  The 
internal elastic lamina separates the intima from the media, and the external elastic lamina 
separates the media from the adventitia.  Each layer has a distinctive composition of cells and 
extracellular matrix. 
The tunica intima is composed of a thin layer of endothelial cells that line the luminal surface 
of arteries and sit on a basement membrane of extracellular matrix and proteoglycans, itself 
boarded by the internal elastic lamina.  The tunica intima forms a physical and functional 
  
Chapter 1 General Introduction 
  4 
barrier between circulating blood in the lumen and the rest of the vessel wall.  Endothelial 
cells are involved in many critical aspects of vascular biology, including thrombosis, the 
regulation of vascular tone, angiogenesis and leukocyte trafficking (4). 
The tunica media is distinguished from the internal elastic lamina and makes up the bulk of 
the arterial wall.  It consists principally of layers of smooth muscle cells and elastic tissue.  
As the outmost layer, the tunica adventia is bordered by the external elastic lamina and 
consists chiefly of connective tissue with irregularly arranged elastic and collagenous fibers, 
and smooth muscle cells (1).   
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Fig. 1.1.  Histology of a normal coronary artery stained for elastin.  The tunica intima 
delimits the vessel wall towards the lumen of the vessel and comprises its endothelial lining.  
And internal elastic lamina delimits the tunica intima from the tunica media, which is formed 
by a layer of circumferential smooth muscle and variable amounts of connective tissue.  The 
external elastic lamina, is located beneath the smooth muscle.  It delimits the tunica media 
from the tunica adventitia, which consist mainly of connective tissue fibers.  The tunica 
adventitia blends with the connective tissue surrounding the vessel.  The definition of the 
outer limit of the tunica adventitia is therefore somewhat arbitrary.  Adapted from  
http://www.lab.anhb.uwa.edu.au/mb140/CorePages/Vascular/Vascular.htm 
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MORPHOLOGY OF ATHEROSCLEROTIC LESIONS  Atherosclerosis manifests 
itself histologically as arterial lesions known as plaques that have been characterized 
extensively into six major types by the American Heart Association (5-7).  In general, the 
initial, fatty streak, and intermediate lesions are categorized into types I, II and III.  Type I 
and II lesions are early lesions which represent small lipid deposits in the arterial intima (Fig. 
1.2).  They are generally found only in children.  Type I is recognized as an increase in the 
number of intimal macrophages and foam cells.  Type II lesions are usually referred to as 
fatty streaks.  They are the first grossly visible lesions, characterized by layers of macrophage 
foam cells and lipid−laden smooth muscle cells and minimal coarse−grained particles and 
heterogeneous droplets of extracellular lipid.  Type III (intermediate) lesions are the 
morphological and chemical bridge between type II and advanced lesions.  Their 
characteristic histological features are pools of extracellular lipids and particles formed 
among the layers of smooth muscle cells.  Thus, the lipid pools replace intercellular matrix 
proteoglycans and fibres and drive smooth muscle cells apart.  Types I, II, and III are 
successive stages in the development of atherosclerosis.  Each type is local, relatively small, 
and contains abnormal accumulations of lipoproteins, cholesterol esters, macrophages, and 
lipid droplets.   
Advanced lesions can be subdivided into three main histological characteristic types: IV, V 
and VI (Fig. 1.2).  Type IV lesions are characterized by the larger, confluent, and more 
disruptive core of extracellular lipid which causes the severe intimal disorganization.  Type V 
lesions contain, in addition to a lipid core, thick layers of fibrous connective tissue, these 
lesions are usually present around the fourth decade of life.  Type VI lesions (Fig. 1.2) are 
classified by features of fissure, haematoma or haemorrhage, and thrombus. These 
characteristics appear successively, as a potentially symptom−producing lesion forms.  
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Fig. 1.2.  Varying stages of atherosclerosis.  Drawings of cross-sections of identical, most 
proximal part of six left anterior descending coronary arteries.  The progression of 
atherosclerosis is depicted from the earliest stages (top left) to the most advanced (bottom 
right) culminating in the plaque rupture and associated thrombosis. Adapted from Stary et al 
(7). 
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1.3 Relationship between atherosclerosis and CVD 
CVD refers to arterial diseases that affect the cardiovascular system.  Cardiovascular events, 
such as stroke and heart attack, are secondary to atherosclerosis and represent the end result 
of the accumulation of atheromatous plaques within the walls of arteries (8).  Atherosclerosis 
is a leading cause of death and it has a substantial impact on the overall public−health burden 
in developed countries.  It is estimated that CVD will be the main cause of death globally 
within the next 10 years owing to its rapidly increasing prevalence in developing countries, 
and the rising incidence of obesity and diabetes (9).   
Atherosclerosis may not clinically manifest itself until lesions disrupt the blood flow.  After 
decades of progression, some atherosclerotic lesions may rupture and result in thrombosis and 
compromise oxygen supply to target organs.  For example, myocardial infarction occurs 
following the rupture of coronary plaques and ischemia.  Reduced blood flow to the heart and 
brain causes the loss of tissue functions and clinically manifests itself as heart attack and 
stroke, respectively.  They are also often referred to as coronary heart disease (CHD) and 
cerebrovascular disease, respectively.  Other clinical manifestations of CVD include angina, 
shortness of breath, heart failure, and even sudden death (1,10). 
1.3.1 Risk factors for coronary heart diseases  
With respect to the underlying pathology of atherosclerosis, there are a number of 
environmental and genetic risk factors.  Extensive clinical and statistical studies have 
identified several factors that increase the risk of CVD.  These include increasing age, male 
gender, heredity, tobacco smoking, high blood cholesterol level, hypertension, physical 
inactivity, obesity, and diabetes mellitus.  An elegant review by Stocker and Keaney (1) 
summaries risk factors of atherosclerosis which are strongly and consistently associated with 
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cardiovascular diseases.  It is noted that the more risk factors one has, the greater one’s 
chance of developing CVD.  Also, the greater the level of each risk factor, the greater the 
risk.  In a middle−aged white population, blood pressure, total cholesterol, and LDL 
cholesterol are recommended to effectively predict CVD risk (11).  Risk factors closely 
associated with CVD are briefly discussed in the following. 
INCREASING AGE  According to reports from American Heart Association, around 
82% of people who die of CHD are 65 years old or over.  In Australia, 16% of the indigenous 
population aged 35−44 years are reported to have long−term cardiovascular conditions, and 
the proportion increases to 31% for those aged 45 to 54 years, and to 47% for those aged 55 
years and over (12).  As mentioned previously, atherosclerotic lesions start appearing from a 
young age, though no symptoms are noted until middle age.  It is predicted that the average 
risk of developing cardiovascular disease for a 30 to 34−year−old male is about 3%, while 
this number rises to 21% for a comparable individual aged 60−64 years old (11). 
MALE GENDER  A number of clinical studies have suggested that males exhibit 
excess risk for CHD compared to age−matched females (1).  For example, according to the 
Australian Heart Foundation, the risk of developing CHD among males aged 25−74 years is 
two to three times greater than that in females (13).  The incidence of CHD in women lags 
behind that in men by 10 years for total CHD and by 20 years for more serious clinical events 
such as myocardial infarction and sudden death.  It is thought that estrogens may protect 
females (14).  However, up to date, there is no firm evidence supporting such speculation. 
OBESITY AND OVERWEIGHT  Obesity has become a major health issue with an 
increasing proportion of children and adolescents affected.  Excess weight increases the strain 
on the heart, raises blood pressure and blood cholesterol and triglyceride levels, and lowers 
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HDL cholesterol levels.  In fact, an elevated body mass index is related to several risk factors 
for CHD, such as hypertension and diabetes (15).  It is estimated that the prevalence of CHD 
will increase by a 5−16% by 2035 as a consequence of the increased obesity in adolescents 
(16). 
SMOKING  The relation between tobacco use and CVD was first reported in 1940 
(17).  Numerous subsequent observations and reports show that smoking substantially 
increases the risk of CVD.  Based on the statistics provided by the National Heart Foundation 
of Australia, it is estimated that in 2003 11.7% of deaths due to CVD were attributable to 
smoking (18).  Passive smoking (environmental smoke, secondhand smoke) also increases 
the risk for CVD compared to non−smokers (19).  The latest Surgeon General’s report 
indicates that non−smokers who are exposed to secondhand smoke increase their risk of 
developing CVD by 25−30%.  Apparently, levels of cotinine and other toxic chemicals in 
smoking are causally associated with CVD and make smokers about 50% more at risk of 
developing various forms of atherosclerotic diseases than non−smokers (20). 
HYPERTENSION  There is considerable support for the notion that high blood 
pressure is closely linked to CVD (1,21).  The latest Joint National Committee 7 report (22) 
suggests that in people who are older than 50, systolic blood pressure of greater than 140 
mmHg is a more important CVD risk factor than diastolic blood pressure, beginning at 
115/75 mmHg.  The CVD risk doubles for each increment of 20/10 mmHg (22).   
DIABETES MELLITUS  CVD commonly occurs in people with diabetes 
mellitus, a major risk factor (23).  The incidence of CVD is twice as high in diabetic males 
and three times as high in diabetic females compared to non−diabetic subjects (24).  The 
higher prevalence of CVD in people with diabetes is emphasized in a Multiple Risk Factor 
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Intervention Trial in which the age−adjusted incidence of CVD was found to be four times 
greater in diabetics than non−diabetics (25).  Additional studies and reports demonstrate the 
close relationship between diabetes and CVD.  It is noted that CVD causes almost 60% of 
deaths in people with diabetes.  Diabetic patients intend to have a two− to three−fold 
increased risk for CVD and two− to four−time greater CVD morbidity and mortality (26). 
SERUM CHOLESTEROL  It is now well established that a high level (>4.1 
mmol/L) of low−density lipoprotein (LDL) cholesterol is an important risk factor for CVD.  
The causative relationship between LDL and CVD is based on clinical intervention studies 
demonstrating that lowering LDL cholesterol levels greatly diminishes the clinical 
manifestations of atherosclerosis (1,27,28).  It is also supported by the fact that the 
development of fatty−streak lesions is characterized by the accumulation of foam cells.  The 
formation of foam cells is induced by the enhanced uptake of LDL by macrophages recruited 
to the vessel wall, possibly due to the presence of oxidatively modified LDL in arterial wall 
(29).  Furthermore, correcting high plasma levels of LDL by anti−hyperlipidemic drugs can 
reduce the risk of CVD (30).  Intensive lipid−lowering statins provide greater protection 
against death or major cardiovascular events than does a standard (non−intensive) regimen 
(31). 
In contrast to LDL cholesterol, high−density lipoprotein (HDL) cholesterol is inversely 
associated with atherosclerosis (32).  Considerable studies support that a low level of HDL 
cholesterol (1.03 mmol/L in men, 1.30 mmol/L in women) is an independent risk factor for 
future CVD (33).  Thereby, optimizing the level of HDL cholesterol has emerged as a 
potential therapeutic target for the treatment of CVD (34,35).  One of the protective effects of 
HDL against atherosclerosis is to promote reverse cholesterol transport via the ATP−binding 
cassette transporter A1 (ABCA1) pathway.  For example, Tangier disease, an autosomal 
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recessive genetic disorder, is characterized by mutations in the ABCA1 gene (36).  Tangier 
disease patients demonstrate a tissue cholesterol−loading syndrome and at least in some 
kindred this leads to increased CHD (37).  The role of HDL and oxidatively modified HDL 
are introduced in more detail (Section 1.7).   
OTHER RISK FACTORS  Other risk factors for CVD include heredity (people 
with a family history of CVD and related diseases), physical inactivity (i.e., lack of exercise), 
unhealthy diet and stress (38), as well as endothelial dysfunction (39).  The risk factors 
mentioned above show an accumulative effect on developing CVD.  The tendency of risk 
factors to cluster in single individuals is increasingly recognized (21) and the development of 
multiple risk factors is strongly contributing to the increasing incidence of CVD.   
1.4 Hypotheses of atherosclerosis 
Atherosclerosis is a complex and multi−factorial process.  Over the past years, there have 
been considerable efforts to explain the complex events associated with the development of 
atherosclerosis.  In a systematic review of atherosclerosis by Stocker and Keaney (1), three 
distinct hypotheses towards the development of atherosclerosis were presented: the 
response−to−injury, the response−to−retention, and the oxidative modification hypotheses.  
This review proposed “the oxidative response to inflammation” model as a means to 
reconcile the majors of existing evidence.  This modified model states inflammation as the 
primary process of atherosclerosis, and oxidative stress as a secondary event (1). 
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 1.4.1 The response−to−injury hypothesis 
The response−to−injury hypothesis has been proposed originally by Ross and Glomset (40).  
In this theory, atherosclerosis is an inflammatory disease beginning with endothelial injury 
and dysfunction characterized by enhanced endothelial permeability and LDL deposition in 
the arterial wall.  This is followed by fatty−streak formation, manifested as foam cell 
accumulation and an inflammatory response a leading to T−cell activation and the adherence 
and aggregation of platelets.  Advanced and complicated lesions of atherosclerosis are 
characterized by continued accumulation of macrophages, fibrous cap formation, and necrosis 
in the core of the lesion (41).   
1.4.2 The response−to−retention hypothesis 
According to the response−to−retention hypothesis of atherosclerosis (42), lipoprotein 
retention is the key pathogenic event that is necessary and sufficient to provoke the initiation 
of lesion formation in an otherwise−normal artery.  Other potential contributors to early 
atherosclerosis include hyperlipidemia, lipoprotein influx, lipoprotein modification, turbulent 
blood flow, and respective changes in cellular (i.e. endothelium, smooth muscle cells) and 
matrix elements that become dysfunctional.  Thus, many features of atherosclerosis can be 
attributed to an increase in the retention of lipoproteins within arterial wall, leading to 
atherosclerosis (42).   
1.4.3 The oxidative modification hypothesis 
The oxidative modification hypothesis was proposed by Steinberg et al. in 1989 (29).  The 
hypothesis is that LDL undergoes an oxidative modification within the artery wall that targets 
it for uptake by macrophages through the acetyl LDL or scavenger receptor (29).  This 
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hypothesis is based in part on the known inverse association between CAD and the intake of 
foods rich in antioxidants, such as vitamin E (Section 1.5) (43).  It implies that atherogenesis 
is reduced in subjects with LDL that is resistant to oxidation.   
1.5 Oxidative modification hypothesis in atherosclerosis 
According to the oxidative modification hypothesis of atherosclerosis, early events, such as 
the formation of fatty streaks, are attributed to effects of oxidized LDL (29).  Briefly, LDL 
initially accumulates in the extracellular sub−endothelial space of arteries, and becomes 
mildly oxidized through the action of resident vascular cells (Fig. 1.3).  The mildly oxidized 
LDL then stimulates monocytes recruitment and induces these monocytes to differentiate into 
macrophages in the arterial wall.  The activated monocytes and macrophages further promote 
the oxidation in LDL lipids and its protein, i.e. apolipoprotein B−100.  The oxidized LDL is 
recognized and taken up by scavenger receptors on the macrophages, leading to the formation 
of foam cells (44,45).  Oxidized forms of LDL can be taken up by macrophages more rapidly 
than native LDL.  All types of vascular cells (i.e., endothelial cells, smooth muscle cells and 
macrophages) can convert LDL to oxidized forms recognized by scavenger receptors and 
giving rise to uncontrolled uptake by macrophages (29).  Oxidized LDL also has direct 
chemotactic activity for monocytes and stimulates their binding to endothelial cells (43).  
Once monocytes become trapped in the sub−endothelial space, oxidized LDL inhibits their 
egress.  Furthermore, oxidized LDL is highly cytotoxic to arterial wall cells, leading to loss of 
endothelial integrity (46).  Such cytotoxicity of oxidized LDL can accelerate the release of 
lipids and lysosomal enzyme into the intimal extracellular space (47) and enhance the 
progression of atherosclerotic lesion formation (Fig. 1.3).   
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Fig. 1.3.  Oxidative modification hypothesis of atherosclerosis.  Native LDL becomes 
trapped in the sub−endothelial space, where it can be oxidized by resident vascular cells such 
as smooth muscle cells, endothelial cells, and macrophages.  Oxidized LDL stimulates (plus 
sign) monocyte chemotaxis (A) and inhibits (minus sign) monocyte egress from the vascular 
wall (B).  Monocytes differentiate into macrophages that internalize oxidized LDL, leading to 
foam-cells formation (C).  Oxidized LDL also causes endothelial dysfunction and injury (D), 
as well as foam-cell necrosis (E), resulting in the release of lysosomal enzymes and necrotic 
debris.  Broken arrows indicate adverse effects of oxidized LDL.  Obtained from Diaz et al 
(43). 
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Collectively, the oxidative modification hypothesis emphasizes the role of oxidative stress 
and redox reactions within the vasculature.  The oxidants considered to be involved in these 
processes may be categorized as free radical or non−radical oxidants (2).   
1.5.1 Oxidants and markers of oxidative events 
FREE RADICALS OR 1e−OXIDANTS  A free radical can be defined as any 
species capable of independent existence that contains one or more unpaired electrons (2).  
Table 1.1 lists selected free radicals generated in biological systems.  In most cases, radicals 
add to or abstract a hydrogen atom from a C−H, O−H or S−H bond of a non−radical 
molecule, such as antioxidants, lipids and proteins.  This results in the generation of another 
radical, such as a carbon−centered radical.  For instance, a hydroxyl radical (•OH) may 
abstract a hydrogen atom from lipid molecule containing a fatty acid chain (RH).  Under 
aerobic conditions, the resulting carbon−centered radical may then react with oxygen (rate 
constants often > 109M−1s−1) to give rise to a peroxyl radical (RO2•).  RO2• can set up and 
propagate a chain reaction.  Both peroxyl (RO2•) and alkoxyl (RO•) radicals are good 
oxidizing agents.  They can abstract H−atoms from other molecules.  In the case of a lipid 
containing bisallylic H−atoms (LH), the reaction may be initiated by an RO2• abstracting an 
H−atom from LH (reaction 1).  The resulting carbon−centered radical (L•) adds rapidly to O2 
to generate a lipid peroxyl radical (LOO•) (reaction 2).  The LOO• itself can propagate the 
process of lipid peroxidation by reacting with a neighboring lipid molecule to produce 
another L• and lipid hydroperoxide (LOOH) (reaction 3).  This reaction continues as a chain 
reaction.  In this fashion, many molecules of LOOH may be generated for each initiating 
radical (1).   
 LH + RO2•  L• + ROOH (reaction 1) 
 L• +O2   LOO•   (reaction 2) 
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 LOO• + LH   LOOH  (reaction 3) 
On the other hand, as a less reactive radical, LOO• preferentially reacts with α−tocopherol 
(α−TOH) by abstracting a H−atom from weak O−H bond and generate α−tocopheroxyl 
radical (α−TO•) and LOOH (reaction 4).  Ascorbate and other suitable reductants may reduce 
α−TO• to α−TOH and ascorbyl radical (reaction 5) (1).   
 LOO• + α−TOH   LOOH + α−TO•  (reaction 4) 
 H+ + ascorbate− + α−TO•   α−TOH  
      + ascorbyl radical (reaction 5) 
In the laboratory, azo initiators are often used to generate RO2• at controlled and known rates 
to study lipid peroxidation.  AAPH (Fig. 1.4B) is water−soluble and decomposes at a 
temperature−controlled rate to give carbon−centered radicals.  Some of these 
carbon−centered radicals react with oxygen to give RO2•.  These RO2• then induce the 
peroxidation of lipids, a process that itself can also damage proteins, such as proteins in 
lipoproteins.  For example, LOOH of lipoprotein phospholipids and cholesteryl esters can be 
reduced to the corresponding hydroxides when exposing isolated HDL and LDL to aqueous 
RO2• (48).  Methionine residues (Met) in apolipoprotein (apo) A−I and A−II (49,50) reduce 
lipoprotein LOOH, in exchange for hydroperoxide reduction.  Met residues are oxidized to 
methionine sulfoxide (MetO) (reaction 6)  
 
 LOOH + Met   LOH + MetO  (reaction 6) 
Reactive radicals, like •OH or RO• may abstract a hydrogen atom from the O−H bond of 
tyrosine to produce tyrosyl (TyrO•) radical.  TyrO• can give rise to cross−links like a 
bityrosin (Fig. 1.4A).  In the vasculature, the fast reaction between superoxide anion (O2−•) 
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and nitric oxide (•NO) to form peroxynitrite (ONOO−) (reaction 7) has drawn much attention 
because the reaction is biologically significant.   
 
•NO + O2−•  ONOO−   (reaction 7)    
First, •NO and O2−• may antagonize each other’s biological action.  It has been shown that in 
vivo, excess O2−• production within or near the vascular endothelium can cause 
vasoconstriction.  Indeed, excess endothelial O2−•  generation has been suggested to be one 
factor causing hypertension.  (2).  Second, ONOO− itself is a relatively weak oxidant, but 
likely generates more powerful oxidizing agents, such as ONOOH, and 
nitrosoperoxycardonate (ONOOCO2−), the latter formed by reaction with carbon dioxide (2).   
  
Chapter 1 General Introduction 
  19 
 
Table 1.1.  Examples of free radicals in biological systems.  Adapted from (1). 
Name    Formula Comments 
Carbon−centred radical         C•              These radicals with the unpaired electron residing  
on carbon, usually react rapidly with O2 to make 
peroxyl radicals 
Superoxide anion and O2 − •,  HO2 •       The ‘primary’ oxygen-centered radicals in its 
hydroperoxyl radical                                       anionic and protonated form 
Peroxyl and alkoxyl radical RO2 •,  RO•       Oxygen-centered radicals that can be formed from 
reaction of carbon-centered radicals with O2 
(RO2 •), or from the breakdown of organic  
peroxides, such as LOOH (RO2 •, RO•) 
Hydroxyl radical    •OH  Highly reactive, oxygen-centered radical that 
reacts with all biomolecules 
Nitric oxide (nitrogen •NO, •NO2       Nitric oxide is formed from L-arginine, and 
monoxide) and nitrogen nitrogen dioxide from reaction of •NO with O2 
dioxide 
Thiyl and perthiyl radical RS•, RSS•       A group of radicals with the unpaired electrons 
 residing on sulfur 
Transition-metal ions Fe, Cu, etc.     Ability to change oxidation numbers by one, 
allowing them to accept/donate single electrons;   
hence they can be catalysts of free-radical reactions 
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Fig. 1.4.  Reaction schemes and chemical structures.  A, Cross-linking of tyrosine 
residues.  Tyrosyl radical-radical recombination yields o,o’ dityrosine.  R is the amino acid 
back bone.  B, Chemical structure of the ‘azo initiator’ 2,2’-azobis(2-
amidinopropane)dihydrochloride (AAPH).  C, Hypocholorous acid (HOCl)−mediated 
oxidation of methionine to methionine sulfoxide.  D, HOCl converts tyrosine to 3-
chlorotyrosine.  E, Tyrosine nitration by peroxynitrite (ONOO−) produces 3-nitrotyrosine (2).   
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NON−RADICALS OR 2e−OXIDANTS  In addition to free radicals, several 
non−radical oxidants are considered important in oxidative events in vascular diseases (Table 
1.2) (1).  Hydrogen peroxide (H2O2) is produced in many tissues. For example, studies on 
perfused rat liver suggest steady−state concentrations of H2O2 of 10−7 to 10−8 M (2).  H2O2 
can be generated by the action of oxidases such as glucose and D−amino acid oxidases on O2, 
or by dismutation of O2−• (reaction 8).  H2O2 is a weak oxidant and poorly reactive.  
However, H2O2 can be cytotoxic at high concentrations (2).  Also, H2O2 can cross cell 
membranes avidly and act with transition metals to form much more damaging radicals.  
Thus, the •OH is thought to account for most H2O2−mediated damage.  H2O2 also reacts with 
certain heme proteins, such as myoglobin, hemoglobin and cyctochrome c.  In the 
vasculature, H2O2 is generally thought to be most active towards protein thiol (−SH) groups 
(1,2).   
HOCl is generated by the enzyme myeloperoxidase (MPO) by activated neutrophils or 
monocytes / macrophages (reaction 9) 
 2O2−• + 2H+  H2O2 + O2  (reaction 8) 
         MPO 
H2O2 + Cl−  HOCl + OH− (reaction 9) 
HOCl is a weak acid, but a powerful 2e−oxidant.  It has attracted much attention because of 
its high reactivity and ability to damage biomolecules both directly and by decomposing to 
form chlorine.  Products of MPO/H2O2 /Cl− system react readily with a wide variety of 
biological compounds, including heme, thiols, ascorbate, and NAD(P)H.  This can lead to 
chlorination of DNA bases, heme proteins, and amino acids in proteins (51).  In proteins, Met 
residues are a preferred target for HOCl (3.8 x107 M−1 s−1).  Following Met, the following 
protein moities are preferred targets for HOCl: Cys > cystine > His = α−amino > Trp > Lys 
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>Tyr > Arg (52,53).  Reaction of HOCl with a Met residue in proteins yields MetO (Fig. 
1.4C), while tyrosine residues are converted to 3−chlorotyrosine (Fig. 1.4D). 
An important feature of the reaction of non−radical oxidants is their predilection for proteins 
rather than lipids.  Non−radical reactive nitrogen species, including nitrous acid (HNO2), 
nitryl chloride (NO2Cl), dinitrogen trioxide (N2O3) and ONOOH, are good nitrating species 
(2).  ONOOH, the protonated form of ONOO− formed from the very fast reaction between 
O2−• and •NO (reaction 5) is a strong oxidizing species.  Addition of ONOO− to cells and 
tissues can lead to its protonation, followed by depletion of –SH groups and antioxidants, and 
it can oxidize lipids, cause DNA strand breakage, nitrate and deaminate DNA bases and 
aromatic amino acid residues in proteins (2).  A commonly studied example is the conversion 
of tyrosine to 3−nitrotyrosine (Fig. 1.4E).  This reaction may be mediated by 
nitrosoperoxycarbonate that is generated from the reaction of carbon dioxide with ONOO− 
(1,51). 
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Table 1.2.  Examples of non-radical oxidants of potential relevance to oxidative stress in 
the vasculature.  Adapted from (1).   
Name    Formula Comments 
Hydrogen peroxide H2O2                A diffusible oxidant that is only a weak oxidizing 
agent and is generally poorly reactive. It may 
participate in cellular signaling and, in the 
presence of available transition metals, can give 
rise to •OH. 
Hypochlorite,                           −OCl, HOCl   Weak acid (pKa ~7.5) but strong oxidant. Reacts 
hypochlorous acid                                           with Fe• S clusters, metal ions held in proteins by 
thiolate ligands, heme, amino acid residues 
(Met, Cys) of proteins and GSH. Can give rise 
to secondary, reactive species including 
chloramines and amino acid-derived aldehydes. 
Ozone O3                    Strong oxidant that attacks protein and lipids 
including cholesterol. Singlet oxygen 
may be formed as a by-product. 
Singlet oxygen 1∆gO2              Reacts with other molecules chemically or by  
                         transfer of its excitation energy. Reaction with 
            carbon-carbon double bonds is best known. The
                        relevance to the vasculature is unknown. 
Oxoperoxonitrate (1−) or 
peroxynitrite, 
peroxynitrous acid  
 
Alkylperoxynitrites, 
dinitrogen trioxide, nitryl 
chloride and nitronium 
(nitryl) ion 
ONOO− ,  
ONOOH 
ROONO, 
N2O3, 
NO2Cl and 
NO  
Can be formed via reaction of O2 −• with •NO with 
k ~1010 M-1 s-1 (54). The protonated form is  
highly reactive (55). 
 
Additional reactive nitrogen species 
 
Nitrosothiols RSNO             Formed via reaction of RS• with •NO, or thiols  
with higher oxides of nitrogen. Nitrosothiols 
are weak oxidants.  
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1.5.2 LDL oxidation 
1.5.2.1 LDL 
In general, LDL transports cholesterol and triglycerides from the liver to peripheral tissues.  
The average LDL particle contains 1 molecule of apolipoprotein B (apoB−100, a protein with 
4536 amino acid residues), cholesterol (600 molecules), cholesteryl esters (1600 molecules), 
phospholipids (700 molecules), triacylglycerols (180 molecules) and antioxidants including 
α−tocopherol (6−12 molecules) and ubiquinol−10 (0.5−1.0 molecules).  LDL has a highly 
hydrophobic core consisting of polyunsaturated fatty acid such as linoleate esterified to 
cholesterol.  The core is surrounded by a shell of phospholipids, cholesterol and apoB−100 
(56).  When subjected to oxidation, all of LDL’s components principally may become 
oxidized.  Like native LDL, oxidized LDL is thought to be retained within arteries by arterial 
proteoglycans (57) and by interaction with surface components of endothelial and vascular 
wall cells (58).  Retention of oxidized LDL is thought to contribute to the initiation and 
development of atherosclerosis (59,60) (Section 1.5). 
1.5.2.2 Evidence of LDL oxidation in atherosclerosis 
PROTEIN OXIDATION   It is known that an elevated plasma levels of LDL 
cholesterol is a major risk factor for CVD.  It is also evident that intimal accumulation of 
plasma LDL is the key event in the lesion development (61).  LDL isolated from human 
atherosclerotic lesions contains elevated levels of chlorotyrosine (62) and o,o’−dityrosine 
(63), which are the oxidation products for HOCl−mediated oxidation.  This finding has been 
reinforced by antibody−based studies that suggest the presence of HOCl−oxidized LDL in 
human atherosclerotic lesions (60,64).  Moreover, exposure of LDL to HOCl, produced by 
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the MPO/H2O2/Cl– system, results in the oxidation of Lys and Trp residues in apolipoprotein 
B−100 before aggregation of LDL particles (65).  
Radicals such as •OH and transition metals are also implicated in protein oxidation in human 
atherosclerotic plaques, evidenced by the detection of dopa, o−tyrosine, m−tyrosine, 
dityrosine, hydroxyleucine and hydroxyvaline (62,66).  Indeed, the types of protein oxidation 
detected in lesion LDL is expanding, and includes conversion of Met to MetO, Arg to 
5−hydroxy−2−aminovaleric acid, and Trp to 5−hydroxytryptophan (67).   
The oxidation of a protein may result in alteration of its secondary structure and it may also 
lead to cellular remodeling and cell growth.  For example, proteins oxidized by tyrosyl 
radical, reactive nitrogen species and HOCl, may be functionally inactive and implicated in 
the pathogenesis of atherosclerosis (67,68).  With emerging advanced mass spectrometry 
technology, oxidized LDL with specific modification to its protein’s amino acids has been 
identified.  These specific modifications include 3−cholorotyrosine, 3−nitrotyrosine and 
reveal associated pathways for their formation (69).  Together, the research efforts provide 
strong support for an important role of protein oxidation in atherogenesis.   
LIPID (PER)OXIDATION  The oxidative modification hypothesis of 
atherosclerosis has been based on the initial recognition of lipid oxidation and accompanied 
other modifications in LDL.  Many in vitro studies have shown that lipids can be oxidized 
into various oxidation products including fatty acid peroxides and hydroxides, oxysterols, 
core aldehydes and oxidation products of α−TOH (57). 
There are several different types of fatty acid oxidation products reported to be present in 
human atherosclerotic lesions.  Hydroxy products of linoleic acid (hydroxyoctadecaenoic 
acid, HODEs) and arachidonic acid (hydroxyeicosatetraenoic acids, HETEs) are the most 
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abundant types (1).  Most of these products are present as cholesteryl esters hydroperoxides 
(CE−OOH) or hydroxides (CE−OH), consisting of about 2−3% of the parent lipid in the most 
advanced lesions (70).  It is also indicated that lipoprotein lipid oxidation in atherosclerotic 
lesions is not only characterized by accumulation of CE−OOH and CE−OH, but also exhibits 
features of tocopherol−mediated peroxidation (71).  In fact, the model of 
tocopherol−mediated peroxidation describes the early stages of LDL lipid peroxidation under 
various oxidizing conditions and may help underpin the importance of lipid peroxidation in 
atherosclerosis (Section 1.5.2.3) (72).  Furthermore, secondary lipid oxidation products, such 
as malondialdehyde, have been reported to be present in human and animal atherosclerotic 
lesions, based on the immunohistochemical studies (56).   
POTENTIAL ATHEROGENIC ACTIVITY   Both in vitro and in vivo studies 
suggest a number of potentially atherogenic effects of oxidized LDL.  These include the 
support of foam cell formation, and the ability to stimulate endothelial cells and smooth 
muscle cells to synthesize and secrete monocytes chemotactic protein−1 thought to facilitate 
the recruitment of monocytes into the arterial wall (73).  Notable potential atherogenic 
activities of oxidized LDL also include its ability to alter inflammatory gene expression in 
vascular cells and to increase the expression of macrophage scavenger receptors.  
Furthermore, LDL−derived lipid oxidation products are cytotoxic and can induce cell 
apoptosis.  Oxidized LDL is immunogenic, elicits autoantibody formation, activates T cells 
and induces tissue factor expression and platelet aggregation (1,74).  It also has been reported 
that oxidized LDL impairs the biologic activity of endothelial cell−derived •NO, a process 
may exacerbate inflammatory cell entry into the arterial wall (75,76).   
Despite comprehensive evidence in support of a pathogenic role of oxidized LDL, a key 
unresolved issue remains, i.e., whether lipoprotein lipid (per)oxidation represents a response 
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to rather than a cause for lesion development.  For example, there is evidence that the 
accumulation of nonoxidized lipids precedes the accumulation of primary lipoprotein lipid 
oxidation products, and the later coexist with normal level of α−TOH (70).  In humans, direct 
evidence on the relationship between oxidized LDL and atherosclerosis is yet to be attained 
(1). 
1.5.2.3 α−TOH in LDL oxidation 
α−TOH is a most redox−active constituent carried by lipoproteins (56).  Traditionally, 
α−TOH is considered to be a classic chain−breaking antioxidant and it is thought to be 
beneficial to CVD (77).  However, placebo−controlled, prospective intervention studies 
examining the effect of α−TOH on CVD have overall not substantiated such benefit for 
supplemented with vitamin E (78-80).  In vitro, α−TOH can actually display a pro−oxidant 
activity (81-91), although the in vivo relevance of this remains unclear. 
α−TOH can act as an efficient antioxidant when LDL particles encounter a strong oxidant, or 
when they are exposed to and encounter radicals with high frequency.  This process is 
accompanied with little formation of LOOH.  In contrast, when LDL reacts with mild 
oxidants or encounters radicals with low frequency, large amount of LOOH are accumulated 
with little consumption of α−TOH.  Formation of the secondary lipid oxidation products, 
e.g., F2−isoprostanes, requires the essential depletion of LDL’s α−TOH (92).  In 
atherosclerotic lesions, such mild oxidants or low “fluxes” appear likely relevant because 
molecules other than LDL will react with oxidants and subsequently reduce the frequency of 
oxidant encounter by LDL.  Hence, under such conditions, the extent to which LDL lipids 
become oxidized is dependent primarily on the presence of α−TOH.  Thus, it suggests that 
α−TOH governs LDL lipid (per)oxidation under an environment of mild oxidants and this 
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persists as long as α−TOH remains present in LDL particles.  This particular process is 
described as tocopherol−mediated peroxidation (Fig. 1.5) (78,81-83,88,89).  
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Fig. 1.5.  Tocopherol-mediated peroxidation of LDL.  Adapted from Upston et al (1,89).  
According to the model, α-TOH acts as a phase-transfer agent reacting with aqueous radical 
oxidants (R•) that results in formation of α-TOH and hence “import” of radicals from the 
aqueous into the liquid phase.  The model predicts that there is only one radical (mostly α-
TO•) contained in an oxidizing LDL particle.  Suitable reductants or co-antioxidants (XH) 
react with this α-TO•.  Thereby regenerating α-TOH at the expense of formation of a co-
antioxidant-derived radical (X•) that “exports” the radical back into the aqueous phase (•Xaq) 
where it eventually gives rise to nonradical products (NRP).  In the absence of XH, α-TO• is 
forced to react with a lipid molecule containing bisallylic hydrogen atoms (LH), thereby 
initiating a chain reaction, in which α-TO•  is the chain-carrying radical (chain thansfer 
activity of vitamin E).  In this chain reaction many molecules of LOOH can be formed 
without consumption of α-TOH.  Tocopherol-mediated peroxidation is also inhibited under 
conditions of high flux, i.e., when LDL particles encounter radical oxidants at high 
frequency.  Under this condition (not shown), a second radical oxidant reacts with an 
oxidizing LDL particle before its α-TO• initiates lipid peroxidation via reaction with LH 
(1,89). 
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It is noteworthy, however, that oxidation in a developing atherosclerotic lesion is a complex 
process and Tocopherol-mediated peroxidation is only one process taking place.  Indeed, the 
overall role of vitamin E in atherosclerosis, if any, is yet to be determined.  What appears 
clear is that, α−TOH is a highly effective scavenger of 1e−oxidants, in the case of 
2e−oxidants, α−TOH fails to protect against oxidants, such as HOCl or ONOO−. 
α−Tocopherylquinone is formed as a major product when α−TOH is oxidized by 
2e−oxidants in human lesion (93).  Interestingly, α−Tocopherylquinone exists at comparable 
levels irrespective of the stages of diseases, suggesting that the 2e−oxidants may be involved 
in early lesion development (57,93).  Indeed, 2e−oxidants, such as HOCl and ONOO− are 
now generally considered to play an important role in oxidation pathways, some of which 
have been investigated in details (69,94,95).   
1.6 Established biomarkers of oxidative stress in atherosclerosis 
From a clinical perspective, biomarkers relevant to CVD have a variety of potential beneficial 
functions.  These include clarification of diseases stages, assistance in screening disease at 
the early stage and helping identify disease as a diagnosis and streamlining patient care.  
Therefore, in addition to existing classic risk factors, identification of biomarkers that predict 
CVD and /or its outcome has spurred on researchers.  As a result of decades of efforts, a long 
list of biomarkers for CVD is available (Table 1.3), including markers related to 
inflammation (C−reactive protein, interleukin−6 and lipoprotein−associated phospholipase 
A2), myocardial infarction (troponin I and troponin T), hemostasis/thrombosis (fibrinogen 
and plasmainogen−activator inhibitor 1), neurohormone activation (rennin and brain 
natriuretic peptide, [BNP]), insulin resistance (insulin and hemoglobin A1C) and endothelial 
dysfunction (homocysteine and urinary albumin) (96,97).  In general, biomarkers for 
oxidative stress in CVD are divided into those that indicate protein vs lipid oxidation, or 
antioxidant activities.   
 
Chapter 1 General Introduction 
  31 
1.6.1 Biomarkers of protein oxidation 
Markers of protein oxidation relevant to CVD usually refer to modifications of specific 
amino acids oxidation products.  Modification of proteins by either reactive oxygen species 
or reactive nitrogen species often results in structural alteration of individual amino acids.  
For example, nitration and chlorination of proteins can be detected by changes to Tyr, Phe 
and Trp residues (Section 1.5.1 and Fig. 1.4) (98-100). It is noted that the modification of 
Phe residues appear to be a minor oxidation product (101).  Oxidation of HDL mediated by 
peroxyl radicals (Section 1.7.4.2) causing the formation of MetO in apolipoprotein(apo) A−I 
and A−II are determined by HPLC (102).  Furthermore, the oxidized apoA−I containing 
MetO has been detected in subjects with increased risk of developing atherosclerosis (103) 
and subjects with type 1 diabetes (104). 
MPO−catalyzed oxidative damage can transform human apoA−I and HDL into dysfunctional 
forms, characterized by a diminished ability to promote cholesterol efflux.  Mass 
spectrometric techniques provide detailed identification of specifically modified amino acids 
that might contribute to the impaired cholesterol efflux ability of apoA−I.  From this point, 
Tyr residues in HDL are perhaps the best studied amino acid from various in vitro and in vivo 
explorations (105-110).  Plasma levels of 3−nitrotyrosine and 3−cholortyrosine are elevated 
in and indicators for established CVD (107,108).  
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Table 1.3.  Established biomarkers for CVD.   
Markers in CVD in association with  Ref. 
C-Reactive protein Inflammation 
Endothelial dysfunction 
(96,111,112) 
Tumor necrosis factor α  Inflammation (112) 
Interleukins 1 and 18 Inflammation (112,113) 
Fas (APO-1) Heart failure (112) 
Lipoprotein-associated 
phospholipase A2  
Inflammation (111,114) 
Troponin I  
Troponin T 
Myocardial damage, cardiac 
abnormalities 
(97,111,115) 
Matrix 
metalloproteinases  
Ventricles remodeling  (112,116,117) 
N-terminal pro-brain 
natriuretic peptide  
Left ventricular dysfunction, 
myocyte stress 
(111,115) 
Brain natriuretic peptide  Neurohormones activation 
(stress), Myocyte stress,dyspnea 
(112) 
Cystatin C Renal failure (111,115) 
Plasmainogen-activator 
inhibitor 1 
Hemostasis/thrombosis (97) 
Fibrinogen Hemostasis/thrombosis (97) 
Insulin Insulin resistance (97) 
Hemoglobin A1c Insulin resistance (97) 
Homocysteine Endothelial dysfunction (97) 
Urinary albumin Endothelial dysfunction (97) 
Oxidized LDL Oxidative stress (112) 
MPO, MPO derived 
HOCl 
Oxidative stress (112,118) 
3-cholortyrosine, 3-
nitrotyrosine 
Oxidative stress (106,107) 
Malondialdehyde  Oxidative stress (112) 
Isoprostanes Oxidative stress (112) 
Renin Neurohormones activation  (112) 
Endothelin-1 and big 
endothelin-1 
Neurohormones activation, 
Pulmonary artery pressure 
(119) 
Norepinephrine 
 
Neurohormones activation, (120) 
Growth differentiation 
factor-15  
Non-ST-elevation acute 
coronary syndrome and ST-
elevation, myocardial infarction 
(121) 
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Furthermore, serum MPO levels have been indicated to predict human endothelial 
dysfunction independent of classic biomarkers, such as C−reactive protein (122).  Endothelial 
dysfunction has been implicated as a key event in the pathogenesis of CVD, i.e., coronary 
vasoconstriction and, probably, myocardial ischemia (123), and as a main event in increasing 
known risk of CVD, such as smoking (124) 
The analysis of oxidative protein modification includes features that are more complex than 
the analysis of lipid oxidation.  A major limitation for the application of protein oxidation 
products to blood samples is their low abundance.  Aside albumin and immunoglobulins, the 
22 most abundant proteins in human plasma together contribute 99% of the total proteome 
mass (125).  Many of the biologically more interesting proteins relevant to CVD (i.e., 
troponin), and other human diseases (e.g., insulin and tumor necrosis factor) are of 
low−abundance.  For instance, apoA−I in HDL only corresponds to 1% of human plasma 
proteins (125).  This represents a challenge for analytical methods.  Fortunately, advanced 
technologies such as mass spectrometry make detailed plasma proteomics profiling, including 
post−translational modifications, increasingly possible.  Mass spectrometry requires little 
sample preparation, is non−destructive, and can be used to characterize biological fluids in 
either a targeted or a pattern−discovery (fingerprint) manner (97).  Once new biomarkers are 
discovered, a subsequent plausible clinical testing method is needed, such as ELISA. 
1.6.2 Biomarkers of lipid (per)oxidation 
F2−Isoprostanes are considered to be the gold standard of available biomarkers for in vivo 
lipid peroxidation (126,127).  F2−Isoprostanes are secondary lipid oxidation products arising 
from arachidonic acid.  They can be measured in plasma and urine by GC−MS or HPLC−MS 
techniques.  Increased levels of F2−isoprostanes in human plasma and/or urine are observed 
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in several conditions associated with oxidative stress, e.g., aging and Alzheimer’s disease, 
and in conditions of elevated risk to develop CVD including hypertension and smoking 
(126,128-130).   
Malondialdehyde is derived largely from the peroxidation of polyunsaturated fatty acids with 
more than two double bonds, including linolenic, arachidonic and docosahexaenoic acids.  
4−Hydroxynonenal is formed during the peroxidation of n−6 polyunsaturated fatty acids, 
such as linoleic and arachidonic acid.  Both Malondialdehyde and 4−Hydroxynonenal formed 
in esterified lipids can degrade further and oxidize apoB in LDL, and leading to increased 
uptake of the particle by macrophages (57).  For example, Malondialdehyde modified LDL is 
increased in patients with familial combined hyperlipidemia indicating a direct relationship 
with atherogenesis (131).  Familial combined hyperlipidemia is a genetic disorder of lipid 
metabolism resulting in the increased risk of premature CHD (132).  Available methods for 
detection of these Malondialdehyde associated products are HPLC− or GC−based.  However, 
as pointed out by Halliwell and Gutteridge, the value of Malondialdehyde and 
4−Hydroxynonenal should be interpreted with caution as considerations of “free” aldehydes 
in vivo are often low, because they readily conjugate to proteins (2).  Furthermore, lipid 
(per)oxidation products including CE−OOH, CE−OH and 27−hydroxycholesterol (70) as 
well as 7−oxygenated sterols (133) have been found in human atherosclerotic lesions and to 
have a strong association with CVD.  In human lesions, the presence of 
p−hydroxyphenylacetaldehyde (134) and p−hydroxyphenylacetaldehyde−ethanolamine (135) 
are indicators of MPO activity during atherosclerosis.   
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1.6.3 Other parameters 
Endothelial dysfunction has been observed in patients with established CVD and CVD risk 
factors (136).  Assessment of endothelial dysfunction can predict the risk of the CVD events 
(137).  Brachial artery flow−mediated dilation inversely correlates with endothelial function 
and has been used for more than a decade as a biomarker for endothelial function (138).  A 
recent study involving a large population of young adults (139), combined brachial artery 
flow−mediated dilation with asymmetrical dimethylarginine (ADMA), a methylated arginine 
derivative thought to interfere with •NO metabolism, and hence endothelial function 
(140,141).  Elevated plasma ADMA was associated with decreased brachial artery 
flow−mediated dilation, providing evidence that levels of ADMA correlated with endothelial 
function (139).  However, mass spectrometric analysis is the gold standard for determination 
of ADMA which challenges its application into routine clinical testing. 
Glutathione peroxidase 1, a cellular antioxidant enzyme, has been suggested to have 
prognostic value in addition to that of traditional risk factors.  A medium−sized prospective 
study has demonstrated low levels of glutathione peroxidase 1 activity (less than 45 Units/g 
Hb) to be independently associated with increased risk of CVD (142).  Another biomarker, 
lectin−like oxidized LDL receptor−1, has been reported to be strongly associated with acute 
coronary syndromes (143).   
The list of biomarkers is expanding.  It has been noted that probably none of the individual 
biomarkers available to date is ideal (2), and that combining several biomarkers into a 
“multimarker” score may be more useful to predict the individual’s risk of CVD (97).  
Indeed, a recent investigation shows that several biomarkers including C−reactive protein, 
brain natriuretic peptide, urinary albumin, rennin 
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associated with CVD or death (144).  Therefore, the ultimate test for a new biomarker 
depends on whether it is consistent with existing risk factors or biomarkers, or whether it 
improves the prediction of risk in individuals and hence contribution to personalized 
medicine.  Only then can it be added to the list as a solid biomarker in CVD (97).   
1.6.4 Potential biomarker directions 
As mentioned previously, atherosclerosis is characterized by heightened oxidative damage to 
all classes of lipoproteins in the arterial wall.  While the association of LDL with 
atherosclerosis has been studied extensively, attention has shifted recently to HDL, its 
oxidative modification and their functional consequences.  A substantial increase in 
understanding the mechanisms of HDL oxidation in atherosclerosis has yielded useful 
information for the discovery of new biomarkers for oxidative stress in CVD.  On the basis of 
rigorous chemical identification, indicators of HDL protein oxidation have emerged as new in 
vivo oxidation pathways illuminating disease mechanisms (110).  Oxidation of sensitive Met 
residues in apolipoprotein (apo) A−I represents one of these novel oxidation pathways. 
1.7 High−density lipoproteins 
1.7.1 Compositions and structure of HDL  
COMPOSITIONS OF HDL   HDL are the smallest (7.0−12 nm diameter) and densest 
(1.063 < d < 1.25 g/mL) of plasma lipoproteins.  They consist of a hydrophobic core 
surrounded by a surface monolayer of phospholipids, cholesterol and apolipoproteins.  The 
hydrophobic core is composed mainly of cholesteryl esters and a small amount of 
triacylglycerol and cholesterol (145).  ApoA−I is the most abundant protein comprising 
roughly 70% of the HDL protein mass.  The other major protein is apoA−II accounting for 
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15−20%.  The reminder is made up of minor apolipoproteins including apoA−IV, apoA−V, 
apoCs, apoD, and apoE (146).  A recent proteomics study has identified more than 40 
proteins associated with HDL (147). 
HDL are isolated traditionally from human plasma by ultracentrifugation and their density 
typically ranges from 1.063 to 1.21 g/mL (148).  HDL are heterogeneous, differing in 
density, size, shape, electrophoretic mobility, and apolipoprotein content.  HDL can be 
fractionated into sub−populations (sub−classes) as HDL2 (1.063−1.125 g/mL) and HDL3 
(1.125−1.21 g/mL) according to density ranges.  Based on particle sizes, HDL2 and HDL3 can 
be divided further into five distinct subclasses by gradient gel electrophoresis.  These are 
named HDL2b (≈ 10.6 nm), HDL2a (≈ 9.2 nm), HDL3a (8.4 nm), HDL3b (8.0 nm) and 
HDL3c (7.6 nm) (149).  HDL also can be divided into two sub−fractions on the basis of 
apolipoprotein composition.  One sub−fraction comprises HDL that contain predominantly 
apoA−I with small amounts of phospholipids and cholesterol.  The other sub−fraction 
contains both apoA−I and apoA−II, and are mostly found in the HDL3 fraction, whereas 
apoA−I is a prominent protein in both HDL2 and HDL3 fractions (150,151).  HDL can also 
differ in shape (discoidal and spherical).  Using electrophoretic mobility (surface charge) as a 
criteria, HDL can be classified into pre−β HDL and α−HDL, migrating similarly to pre−β 
and α−globulins, respectively (145).  Most of the HDL particles in plasma isolated by 
ultracentrifuge are spherical α−HDL include HDL2 and HDL3 sub-populations.  Pre−β HDL 
is discoidal and its density is usually higher than 1.21 g/mL containing only 2−14% apoA−I, 
also known as lipid−poor apoA−I (152,153).   
HDL STRUCTURE   The HDL structure is complex because of the existence of 
sub−classes of particles and due to its remodeling induced by interactions with various 
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proteins and HDL receptors on cell surfaces (154).  Early models proposed HDL as 
“icebergs”, where the protein “icebergs” are embedded in a “sea” of lipid (155).  Nuclear 
magnetic resonance spectroscopy techniques subsequently considered HDL to be micellar 
particles with essentially all polar groups of molecules oriented into the surrounding aqueous 
environment (156).  However, the precise nature of the structural foldings that give rise to the 
complex structure and function of HDL remained unknown.  Until the 1980’s, pre−β HDL 
was recognized and more detailed structure and function relationships were resolved (157).  
More importantly, apoA−I, the principal protein in HDL, has been identified as a 
conformationally flexible molecule that binds to different sizes of HDL.  The key structural 
motif in the apoA−I molecule that mediates lipid binding is the amphipathic α−helix (145).  
This finding has enabled further research into structure elucidations for lipid−bound apoA−I 
at different stages (Section 1.7.3.1).  In general, α−HDL is mature and spherical with a 
hydrophobic core of cholesteryl ester and triacylglycerol encapsulated by a surface of 
amphipathic α−helical apolipoproteins, phospholipids and cholesterol (Fig. 1.6). 
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Fig. 1.6.  The “oil drop” model of spherical HDL.  The structure is an approximately 10 
nm-diameter sphere with a non-polar core of cholesteryl ester (CE) and trigacylglycerol (TG) 
molecules encapsulated by a surface monolayer of amphipathic alpha-helical apolipoprotein 
and phospholipid (PL) molecules. Adapted from (145). 
Chapter 1 General Introduction 
  40 
1.7.2 Properties of HDL 
1.7.2.1 Reverse cholesterol transport 
Numerous clinical and epidemiological studies have demonstrated the inverse relationship 
between HDL cholesterol and the risk of CVD.  Subjects with low levels of HDL cholesterol 
(< 1.03 mmol/L in men and < 1.30 mmol/L in women) are at increased risk of CVD (35).  
Conversely, several lines of evidence support the concept that increasing HDL cholesterol 
levels may provide protection against development of CVD (34,158-161).  This 
anti−atherogenic activity is believed to depend largely on the function of HDL as a carrier of 
excessive cholesterol from peripheral tissues to the liver in a process referred to as reverse 
cholesterol transport.  The mechanism of reverse cholesterol transport and HDL metabolism 
are illustrated in Fig. 1.7 (162).   
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Fig. 1.7.  Overview of reverse cholesterol transport and HDL metabolism.  Adapted from 
(162).  Direct and indirect pathways are indicated. 
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In general, excessive cholesterol in peripheral tissues (e.g., lipid laden macrophages in the 
vessel wall) is removed and transported to the liver by HDL.  In the liver, cholesterol is 
subsequently catabolised or excreted into bile.  During this process, the adenosine 
triphosphate−binding cassette transporter A1 (ABCA1), located on arterial macrophages, 
promotes the transport of cholesterol to the extracellular, lipid−poor apoA−I or a nascent 
pre−β HDL.  Subsequently, lecithin−cholesterol acyltransferase (LCAT) esterifies cholesterol 
within nascent HDL to produce cholesteryl esters, thereby maturing α−HDL.  Mature 
α−HDL can take up further cholesterol via the macrophage adenosine triphosphate−binding 
cassette transporter G1 (ABCG1) (162).  There are at least two pathways to transport 
cholesterol to liver.  The first pathway is directly to the liver through interaction of HDL with 
the scavenger receptor, class B, type I (SR−BI).  The second, indirect pathway involves 
cholesterol ester transfer protein (CETP) that transfers cholesteryl esters from HDL to VLDL 
and LDL that then bind to the liver through LDL receptor.  HDL cholesterol taken up by the 
liver is then excreted in the form of bile acids and cholesterol, thus completing the process of 
reverse cholesterol transport (163).  With regards to HDL−mediated cholesterol efflux from 
macrophages to HDL, it is believed the process can occur by passive diffusion, by interaction 
with the SR−BI receptor, or by binding to the ABCA1 transporter pathways (Fig. 1.8) 
(34,164).  Passive diffusion is likely also involved in the exchange of cholesterol between 
mature spherical α−HDL and cellular membranes.  Oxysterols in cells can modulate reverse 
cholesterol transport through regulation of the liver X receptors pathway and via expression 
of the SR−BI and ABCA1 transporter genes (34). 
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Fig. 1.8.  Three major pathways of cholesterol efflux by HDL.  HDL may mediate 
cholesterol efflux from cholesterol-loaded macrophages to HDL (left).  Passive diffusion 
involves exchange of non-esterified cholesterol (FC) between mature spherical α-HDL and 
the cellular membrane.  Net cholesterol efflux occurs after the conversion of FC to 
cholesteryl esters (CE) by LCAT.  In the SR-B1 pathway, FC is transported to mature 
spherical α-HDL.  In the ABCA1 transporter pathway, lipid poor apoA-I binds to the 
ABCA1 transporter and facilitates the efflux of cellular cholesterol from the late endocytic 
compartment, thereby decreasing the cholesterol content of the cell.  Nascent preβ-HDL is 
ultimately converted to mature spherical α-HDL after the esterification of FC to CE by 
LCAT.  Right, both the SR-B1 and ABCA1 transporter pathways are regulated by the 
oxycholesterol content of the cell.  Excess cellular cholesterol is converted at least in part to 
27-hydroxycholesterol by 27-hydroxylase.  27-Hydroxycholesterol binds to the ligand-
stimulated transcription factor liver X receptors, which, after dimerization with retinoid X 
receptors, binds to the liver X receptor response element promoter element and increases the 
expression of SR-B1 and the ABCA1 transporter genes.  Thus, both α and pre-β HDL 
facilitate the efflux of cellular cholesterol and participate in reverse cholesterol transport to 
the liver (159).   
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Table. 1.4.  Characteristics of pivotal proteins involved in reverse cholesterol transport.  
Adapted from (165).   
Protein         Number of          
structure         amino acids 
Function in reverse cholesterol 
transport 
Major sites of 
synthesis 
Apolipoproteins 
 
apoA-I                          243 
 
 
 
Major protein component of HDL 
activation of LCAT, stimulation of 
cholesterol efflux, ligand of HDL binding 
sites (i.e.  SR-B1, ABCA1) 
 
 
Liver, small intestine 
apoA-II                         77 Major protein component of HDL ligand 
of HDL binding site, inhibition of hepatic 
lipase 
liver 
apoA-IV                       376 Activation of LCAT, modulation of LPL, 
stimulation of cholesterol efflux 
Small intestine 
apoC-I                          57 Activation of LCAT, inhibition of hepatic 
TGRL uptake 
Liver 
apoC-II                        79 Activation of LPL, inhibition of hepatic 
TGRL uptake 
Liver 
apoC-III                       79 Inhibition of LPL, inhibition of hepatic 
TGRL uptake 
Liver 
apoD                            169 Formation of pre-β3-LpA-I Liver, spleen, CNS, 
small intestine, 
adrenals, placenta 
apoE                             299 Ligand of apoE receptors, mobilization of 
cellular cholesterol in macrophages and 
cholesterol efflux 
Liver, macrophages, 
CNS 
Enzymes and lipid transfer 
protein 
LCAT                           440 
 
 
Cholesterol esterification, maturation of 
HDL 
 
 
Liver, tests, CNS 
CETP                            476 Exchange of cholesterol esters and 
triglycerides between HDL and LpB, 
conversion of HDL, generation of lipid-
free apoA-I 
Liver, small intestine, 
spleen, macrophages 
PLTP                             493 Transfer of phospholipid from TGRL 
onto HDL, fusion small HDL, generation 
of lipid-free apoA-I 
Liver, endothelium 
Cellular receptors and 
transporters 
ABCA1                        2201 
 
 
Mediation of cholesterol and 
phospholipid efflux, maturation of HDL 
 
 
Liver, macrophages, 
intestine, fetal tissues   
SR-B1                          509 Mediation of selective uptake and 
cholesterol efflux 
Liver, adrenals, testes, 
ovary, macrophages 
Abbreviations: TGRL, triglyceride−rich lipoproteins; LPL, lipoprotein lipase; CNS, central nervous system. 
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Overall, a number of apolipoproteins, enzymes and lipid transfer proteins and cellular 
receptors and transporters are involved in RCT (Table 1.4) (165).   
1.7.2.2 Anti−atherogenic activity of HDL independent of reverse cholesterol transport 
ANTIOXIDANT PROPERTY  HDL possesses many features that are 
anti−atherogenic.  The best recognized mechanism is its key role in reverse cholesterol 
transport.  In addition, HDL is thought to be an effective antioxidant.  It protects against LDL 
oxidation by preventing LDL oxidation and/or inactivating newly formed lipid oxidation 
products (146).  This antioxidant activity may be due to the removal/detoxification of lipid 
(per)oxidation products from oxidized lipoproteins or cellular membranes.  In human blood 
HDL has been identified as the major carrier of lipid hydroperoxides (166) and 
F2−isoprostanes (167).  The former are transported to the liver for detoxification (168).  In 
addition, HDL−associated enzymes such as paraoxonase, LCAT and platelet−activating 
factor acetylhydrolase may contribute to the antioxidant function of HDL (169).   
CYTOPROTECTIVE PROPERTY  There are also lines of evidence to support a 
cytoprotective property of HDL.  HDL protects vascular cells against certain pro−atherogenic 
agents, such as chylomicron remnants and tumor necrosis factor α (169).  The mechanism of 
this protective effect is yet to be fully understood, but HDL− associated enzymes, lipids and 
antioxidants are believed to be implicated in this effect.  Endothelial dysfunction is a key 
variable in the pathogenesis of atherosclerosis (170).  HDL helps to maintain endothelial 
integrity, facilitate vascular relaxation, inhibit the adhesion of leukocytes to the vascular 
endothelium, reduce platelet aggregation and it may favor fibrinolysis (171).  HDL prevents 
endothelial cell apoptosis by preserving mitochondrial integrity, thereby inhibiting 
cytochrome c release and caspase cascade activation (172).  Furthermore, HDL inhibits 
activation and proliferation of cells mediated by oxidized LDL.  This activity may be 
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attributed partly to sphingosine−1 phosphate associated with HDL that modulates the 
migration of smooth muscle cells (169).   
ANTI−INFLAMMATORY PROPERTY  The importance of chronic inflammation 
in atherosclerosis is now well accepted.  It is reflected, in part, by the accumulation of 
macrophages, and macrophage foam cells and T lymphocytes in the arterial intima (41).  The 
expression of adhesion molecules, such as vascular cell adhesion molecule−1, intercellular 
adhesion molecule−1 and E−selectin on endothelial cells, is upregulated during the early 
inflammatory stages of atherogenesis (173).  Adhesion molecules expression occurs 
preferentially at sites where atherosclerotic lesions develop (174).  HDL inhibits endothelial 
cell adhesion molecule expression (175) as well as suppresses the production of monocyte 
chemotactic protein−1, a chemokine important in the recruitment and activation of leukocytes 
during inflammation (175).  By reducing the infiltration of monocytes into the artery wall, 
HDL suppresses the inflammatory response (173).   
As a consequence of the multiple anti−atherogenic properties of HDL, there are continuous 
efforts in the development of new therapies designed to raise HDL cholesterol levels to 
enhance the magnitude and clinical importance of such effect (34).  In addition, much 
research has focused on HDL’s most abundant protein, apoA−I and its roles in HDL function.   
1.7.3 Apolipoproteins in HDL 
ApoA−I and apoA−II are the two major apolipoproteins in HDL contributing ≈70% and 
15−20% of the HDL mass, respectively.  ApoA−I is a 243−amino acid, single polypeptide of 
28−KDa molecular weight that lacks glycosylation and disulfide linkages.  A majority of 
HDL’s functions is attributed to the ability of apoA−I to sequester phospholipids and 
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cholesterol and to interact with plasma enzymes and cellular receptors.  During reverse 
cholesterol transport, apoA−I is mainly responsible for interaction with cellular receptors 
including ABCA1 and SR−B1 and for activation of LCAT (176).  As a result, the plasma 
concentration of apoA−I is one of the strongest risk factors to predict susceptibility to CVD.  
Mature apoA−II is present as a dimer of two 77−amino acid chains joined by a disulfide 
bridge.  In contrast to the extensively studied apoA−I, limited information is available 
regarding its role in CVD, although it is known to be involved in the regulation of HDL 
metabolism (177,178).  The latest findings suggest that apoA−II is involved in the 
modulation of very−low−density lipoproteins lipolysis and hence it is implicated in 
hyperlipidemia and insulin resistance (179). 
1.7.3.1 Structure of apoA−I 
It is estimated that 5−10% of human apoA−I is present in a lipid−free or lipid−poor state 
(180).  Lipid−free apoA−I may derive from the direct secretion by the liver and intestine, or 
by dissociation from nascent pre−β HDL present in discoidal shape.  As mentioned earlier, 
most apoA−I exists in lipid−associated forms found in mature, spherical HDL (α−HDL) that 
can be divided, based on difference in density, into HDL2 (1.063< d <1.25 g/mL) and HDL3 
(1.125< d <1.21 g/mL) (181). 
ApoA−I in discoidal HDL is of interest to researchers because of the absence of lipid.  
However, such apoA−I is not easy to isolate as it is short lived and only small amounts can be 
separated from peripheral lymph (145).  Therefore, in vitro reconstituted discoidal HDL 
(rHDL) is used commonly for the study of apoA−I structure (182).  The analysis of the 
primary structure of apoA−I has identified eight α−helical segments of 22 amino acid 
residues and two 11−residue repeats that are usually separated by a proline−containing 
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segment  These helices are amphipathic with a hydrophobic face that likely interacts with 
lipid (i.e., phospholipids) and a polar face that interacts with the aqueous phase (183).   
LIPID−BOUND APOA−I STRUCTURE  To date, three models of apoA−I 
structure in discoidal HDL have been proposed.  The “picket fence” model is the most 
commonly presented.  In this model, the 22 amino acid repeats amphipathic α−helices are 
aligned parallel to the phospholipids acyl chains in the bilayer discs and are connected by 
hairpin loops, (Fig. 1.9A) (184).  In the “double belt” model (Fig. 1.9B), each of two 
ring−shaped apoA−I molecules are oriented in anti−parallel formation and comprise a small 
segment of phospholipids, each in its own leaflet (185).  The helical “hairpin” model (Fig. 
1.9C) (186) pairs two apoA−I molecules with each other via a “head−to−head” or 
“head−to−tail” orientation (145).  This model has been extended to a “looped belt” 
conformation, composed of apoA−I belts aligned anti−parallel with a central loop−like 
structure, centered at position 139 and bordered by residues 133 and 146 (184).   
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Fig. 1.9.  Models of lipid-bound apoA-I on discoidal rHDL.  Three models that describe 
the structure of apoA-I on discoidal rHDL under evaluation are the picket fence (A), belt (B), 
and hairpin model (C). Obtained from (184). 
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ApoA−I is known to self−associate in aqueous solution, a process that stabilizes the protein 
(187) and may represent a putative lipid−binding structure when bound to HDL.  Such a 
conformationally flexible molecule appears to be responsible for the complex structure of 
HDL (145,187).  Borhani et al published the crystal structure of a truncated form of human 
apoA−I (residues 44−243).  They reported lipid−free apo ∆ (1−43) A−I to both bind, lipid 
similarly to intact apoA−I, and to retain the lipid−bound conformation even in the absence of 
lipid (188).  As a result, a model of apoA−I bound to spherical HDL has been presented 
which contains four molecules of apoA−I (Fig. 1.10).  HDL particles are believed to usually 
contain two or four molecules of apoA−I that present as anti−parallel dimers.  Because of the 
unique conformation of apoA−I, the apoA−I monomer is thought to consist primarily of 
amphipathic α−helices punctuated by kinks at regularly−spaced proline residues.  In this 
conformation, the α−helices at the C−terminus is separated from the rest of the molecule by 
220−227 residues that adopt an extended, non−helical conformation (188).  The apoA−I 
dimer is described as two molecules of apoA−I tightly associated in an anti−parallel 
conformation.  The tetramer structure of apoA−I requires two dimers in anti−parallel fashion 
to form an elliptical tetrameric ring.  For the lipid−bound structure, apoA−I tetramer is 
believed to be irrelevant because of its hydrophilic surface (188).   
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Fig. 1.10.  Hypothetical model of apoA-I bound to spherical HDL.  Obtained from (188).  
The model comprises four molecules of apoA-I (A-D) in spherical HDL.  The lipid head 
groups are represented by blue balls, apoA-I molecule A is gold, molecule B purple, 
molecule C red, and molecule D green. 
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LIPID−FREE STRUCTURE OF APOA-I  Recently, full length, lipid−free apoA−I 
has been studied intensively.  This revealed apoA−I to comprise four N−terminal helical 
anti−parallel bundles and two C−terminal helices (Fig. 1.11A) (189).  It was observed that 
the N−terminal domain plays a prominent role in maintaining the lipid−free conformation of 
apoA−I.  Fig. 1.11B illustrates the homology model of full length, lipid−free apoA−I, as 
determined by cross−linking and sequence techniques (190).  The model appears to be 
consistent with the crystal structure.  Based on the crystal structure, a modified structure with 
the alternate N−terminal conformation has been proposed (Fig. 1.11C) (191).  
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Fig. 1.11.  Structure of full length, lipid-free apoA-I.  Obtained from (185).  A, x-ray 
crystal structure of lipid-free apoA-I (189).  B.  Independently generated homology model of 
full-length, lipid-free apoA-I (190).  C.  Modified Ajees crystal structure, with the secondary 
structure of the N-terminal 98 residues modelled according to the EPR data of Lagersted et al 
(191).  For all models, the N-terminal 44 residues are colored red, the C-terminal 50 residues 
are colored yellow, and the extreme terminal amino acids are shown space-filled.  The insets 
show the elements of the secondary structure as if they had been laid flat with no tertiary 
relationships.  A short run of the β-sheet in the N-terminus of the Lagerstedt model is shown 
as an undulating sheet. 
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1.7.3.2 Properties of apoA−I 
LIPID BINDING VIA ABCA1  ApoA−I plays a critical role in reverse 
cholesterol transport.  Lipid−poor apoA−I in discoidal HDL is an excellent acceptor of 
cholesterol, phospholipids, and other metabolites molecules from cells (e.g., macrophages) 
through an active process mediated by ABCA1 (153).  ABCA1 is a membrane protein that 
can translocate lipids to the cell surface to form lipid domains for interaction with the 
α−helical amphipathic parts of apoA−I.  Lipid−poor apoA−I stimulates ABCA1−mediated 
cholesterol efflux from macrophages and thereby contributes to reverse cholesterol transport 
(192,193).  Furthermore, α−TOH of which approximately half is located in HDL is 
co−transported with lipids in plasma lipoproteins and accumulates in cell membranes 
throughout the body (194).  Lipid−free ApoA−I promotes α−TOH efflux from macrophages 
and appears to be the major transporter of α−TOH between tissues (100).  This transportation 
has been found to be mediated by both ABCA1−dependent and −independent processes 
(195). 
ACTIVATION OF LCAT  ApoA−I is known to activate LCAT, an enzyme that 
hydrolyzes the sn−2 fatty acid of from phosphatidylcholine and esterifies it to cholesterol to 
generate lyso−phosphatidylcholine and cholesterol ester.  This process is crucial in the 
conversion of a nascent pre−β HDL particle into a mature, spherical α−HDL with a core of 
neutral cholesterol esters (154,158).  The mechanism underlying the activation of LCAT by 
apoA−I is yet to be fully established.  However, it is suspected that a specific domain of 
apoA−I, i.e., residues 144−165, may be responsible for the activation (154).  This region 
contains three Arg residues that appear critical for LCAT activation (196). 
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SR−BI BINDING  SR−BI is a class B type I scavenger receptor present in cell 
plasma membranes that interacts with apoA−I (197).  Such binding of apoA−I facilitates 
cellular cholesterol efflux.  SR−BI is expressed primarily in liver and non−placental 
steroidogenic tissues (198).  SR−BI−mediated cholesterol efflux is one of three pathways of 
cholesterol efflux, and the binding of apoA−I to SR−BI is centrally important for reverse 
cholesterol transport (34,164). 
INTERACTION WITH CETP  CETP is a hydrophobic glycoprotein that is 
secreted mainly by the liver and that transfers cholesterol esters from HDL to apolipoprotein 
B (apoB)−containing lipoproteins, including VLDL, VLDL remnants, IDL and LDL, in 
exchange for triacylglycerol (199).  CETP is bound primarily to HDL and it is involved 
indirectly in reverse cholesterol transport.  The interaction of CETP with HDL is largely 
depended on the presence of apoA−I (158).   
OTHER PROPERTIES OF APOA−I   As apoA−I plays key structural and 
functional roles in HDL, there is no doubt that the properties of HDL are largely dependent 
on apoA−I.  However, when HDL (apoA−I) is subjected to oxidation, its structure and 
functions may change (200).  Indeed, oxidative modifications affect the secondary structure 
of apoA−I and hence its lipid affinity and activities (177).  Consequently, the protective effect 
of HDL and / or apoA−I against atherogenesis may be impaired. 
1.7.4 Oxidized HDL in atherosclerosis  
Atherosclerosis represents a state of heightened oxidative stress characterized by lipid and 
protein oxidation in the affected arterial wall.  The extent of this oxidative damage, at least 
with regards to lipid oxidation, appears to be comparable for all classes of lipoproteins 
present in affected vessels (i.e., LDL & HDL) (1).  While oxidized LDL has received much 
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attention (29), there is increasing evidence that atherosclerosis is also associated with 
dysfunctional HDL, and that oxidation of HDL−associated proteins (apolipoproteins) 
contributes to the lipoprotein becoming dysfunctional. 
Oxidized HDL may be dysfunctional due to altered chemical/physical properties.  Oxidants 
such as HOCl, peroxyl radicals, metal ions, and peroxynitrite can affect both surface and core 
components of HDL.  Products derived from lipid (per)oxidation, such as LOOH and 
aldehydes, are associated with the changes to the physical properties of HDL (201,202).  The 
formation of chlorotyrosine, nitrotyrosine and MetO are the result of oxidation of HDL 
apolipoproteins (106).  Such changes in the physical property may give rise to dysfunctional 
HDL because of the close relationship between HDL structure and function.  In certain 
circumstances, HDL might contribute to the development of atherosclerosis.  For instance, 
HDL can become pro−inflammatory as apoA−I undergoes oxidative modification(s) (203).  
Therefore, numerous recent studies have addressed the functional consequences of oxidation 
of HDL. 
1.7.4.1 Lipid (per)oxidation and protein oxidation in HDL 
Oxidation of HDL is a complex process, the outcome of which depends on several factors, 
including the oxidant involved and the extent to which the oxidation process proceeds.  In 
general, oxidation mediated by 1e− (or radical) oxidants initially results in lipid peroxidation, 
defined as the formation of LOOH (Section 1.5.1), whereas 2e− oxidants (such as HOCl) 
initially react with apolipoproteins associated with lipoproteins (1).  LOOH may degrade 
and/or become further oxidized to secondary lipid oxidation products, such as 
F2−isoprostanes and fragmented lipid containing reactive groups (204), and these secondary 
processes commonly lead to protein oxidation (205,206).  In addition, LOOH may be reduced 
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by apolipoprotein−associated amino acid residues, particularly Met (50).  Furthermore, 
primary protein oxidation products, such as those generated during lipoprotein oxidation 
mediated by HOCl, can also degrade giving rise to radical species that themselves then may 
initiate lipoprotein lipid (per)oxidation (207).  Given this complexity, it is not surprising that 
there is considerable diversity in the methods used to evaluate lipoprotein oxidation 
(208,209).  In the following sections, HDL lipid and protein oxidation mediated by 1e− and 
2e−oxidants is discussed. 
1.7.4.2 Free radical (1e−oxidant) mediated oxidation 
Transition metals, such as copper, are thought to be one of the common inducers for lipid 
(per)oxidation in atherosclerosis.  There is evidence that HDL is more susceptible to 
copper−mediated lipid (per)oxidation than LDL (210,211).  In vitro experiments have 
demonstrated that lipids in HDL become oxidized before those in LDL when isolated plasma 
is exposed to peroxyl radicals, and HDL is the major carrier of endogenous lipid 
hydroperoxides, such as hydroperoxides of cholesteryl esters, (CE−OOH, the first and major 
products formed during oxidation) in human plasma (168).  CE−OOH and their 
corresponding CE−OH are removed rapidly from HDL through selective uptake in vitro 
(48,212) and in vivo (168). 
In the case of HDL, the LOOH formed during lipid (per)oxidation can be reduced by Met 
residues of apoA−I or apoA−II and generate specifically oxidized forms of apoA−I and 
apoA−II containing MetO, respectively.  All three Met residues in apoA−I, located at 
positions of 86, 112 and 148, can be converted to MetO as a result of oxidation of HDL (Fig. 
1.12) (50,102,103).  Interestingly, specifically oxidized apoA−I containing MetO at positions 
86 plus 112 has been shown to possess an enhanced ability to promote cholesterol efflux 
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from lipid−laden human monocytes−derived macrophages (100).  A similar phenomenon has 
been observed for tyrosyl radical−oxidized HDL (213).  However, other types of oxidative 
modifications have been reported to decrease the ability of apoA−I to stimulate cholesterol 
efflux from cells (106,109).   
In addition, oxidative modifications of HDL have been found to be accompanied with altered 
biological activities of associated enzymes, such as paraoxonase, CETP and LCAT (214).  
For example, peroxyl radical−oxidized HDL has decreased activity of LCAT (215) and it has 
also been reported that HDL could become pro−oxidant due to altered CETP and LCAT 
activities (216).  HDL oxidized by copper or peroxyl radicals shows compromised ability to 
promote release of paraoxonase−1 and stabilize the enzyme activity (217) 
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Fig. 1.12.  The full length structure of lipid-free apoA-I.  The structure, determined by 
Ajees et al (189), has two major domains:  a four-helix bundle generated by the three-quarters 
of apoA-I nearest to the N-terminus, and a two-helix bundle formed by the C-terminus.  The 
positions of Met residues that can undergo oxidation to MetO are indicated.  Obtained from 
(118). 
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1.7.4.3 Oxidation mediated by non−radical, 2e−oxidants 
There is strong evidence for 2e−oxidant−induced oxidative damage occurring to HDL within 
the human artery wall as atherosclerosis develops (118).  HOCl, a powerful and principal 
oxidant derived from MPO, has been found to modify HDL−associated amino acids, 
unsaturated fatty acids and cholesterol in vitro.  This commonly results in an impaired ability 
of the particle to promote cholesterol efflux, at least when high molar ratios of 
oxidant−to−lipoprotein (60:1) are used (98).  At relatively lower molar ratios of 
oxidant−to−lipoprotein (e.g., 5:1), Met residues in apoA−I are the major oxidation target (99).  
It is also noted that other substrates, such as bromide, iodide, thiocyanate, nitrite and 
numerous other phenolic and related materials can be oxidized when mediated by MPO 
(218). 
ApoA−I in the arterial wall appears to be a selective target for oxidation mediated by 
MPO/HOCl.  Such oxidation decreases the ability of apoA−I to facilitate cholesterol efflux 
via the ABCA1 pathway (107,219,220).  Specifically, 3−chlorotyrosine, a specific oxidation 
product of the MPO/H2O2/Cl− system, has been found to be present at relatively high levels in 
HDL isolated from vascular lesions (220) and plasma samples (107).  Similarly, 
3−nitrotyrosine is found in circulating HDL isolated from patients with CVD (107,108).  
3−Nitrotyrosine is usually generated from Tyr by ONOO− (221), but it also can be produced 
via the MPO/H2O2/NO2− system (107).  Subsequent studies identified Tyr192 (Fig. 1.12) of 
apoA−I is as a major site of nitration and chlorination by MPO, as well as the nitration by 
ONOO−.  It has been reported that chlorination by MPO, but not nitration, markedly reduces 
apoA−I’s cholesterol efflux activities (222,223).  H2O2, a relatively weak 2e−oxidant causes 
HDL oxidation which essentially is limited to Met residues (Section 1.7.5).  In vivo, one of 
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the sources for H2O2 and superoxide radicals is from NADPH oxidase, and MPO can convert 
it into more powerful oxidants including HOCl.  Similarly, •NO, produced by cells of the 
artery wall can give rise to nitrating species such as ONOO−, in the presence of superoxide 
generated from NADPH oxidase (224).  Thus, MPO is potentially involved in pathways 
promoting protein oxidation in the arterial wall and the generation of dysfunctional HDL.     
Collectively, both 1e− and 2e−oxidants can transform human apoA−I and HDL into 
dysfunctional forms characterized by a diminished ability to promote cholesterol efflux 
through ABCA1 pathway, and a reduced LCAT activity.  However, the precise mechanisms 
underlying the functional changes associated with HDL and apoA−I oxidation need to be 
investigated further, especially the type of oxidation that leads to functional consequences 
manifested in the clinical setting. 
1.7.5 Oxidized apoA−I containing MetO 
As mentioned above, LOOH are the first and primary products of lipid peroxidation formed 
during HDL oxidation induced by different radicals. Therefore, the oxidation of 
apolipoproteins in HDL by LOOH may be biologically important.  Furthermore, since HDL 
isolated from human atherosclerotic lesions contains relatively normal amounts of α−TOH, 
oxidative changes to apoA−I occurring while α−TOH remains intact may be pathologically 
important.   
An in vitro condition that may mimic these conditions is exposure of HDL to a controlled and 
low rate of peroxyl radicals.  Peroxyl radicals are generated conveniently and in a controlled 
manner by thermo−labile azo-initiators (R−N=N−R), such as AAPH (225).  AAPH is a 
water−soluble initiator that temperature-dependently generates aqueous alkylperoxyl radicals 
(ROO•) at known and constant rates (reaction 10).  Under aerobic conditions, and in the 
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presence of lipoproteins that contain fatty acids with bisallylic hydrogen atoms (LH), ROO• 
initiates lipid peroxidation by generating a carbon−centered lipid radical (L•) (reaction 11), to 
which molecular oxygen adds, resulting in the formation of a lipid peroxyl radical (LOO•) 
(reaction 2).  Lipid peroxidation is then propagated by LOO• abstracting an hydrogen atom 
from another LH, resulting in the formation of LOOH (reaction 3). 
 R – N = N – R  2R•   2ROO•  (reaction 10) 
 ROO•   +   LH  ROOH   +   L•   (reaction 11) 
In the case of HDL, most LOOH are in the form of hydroperoxides of phospholipids and 
cholesteryl esters.  These LOOH can then become reduced to the corresponding LOH via 
direct two−electron transfer from the sulfur of thioethers of Met residues of apolipoproteins 
(reaction 6, Fig. 1.13), resulting in specifically oxidized apoA−I and apoA−II (102).   
Met residues in apoA−I are the major amino acids that react with LOOH, giving rise to the 
corresponding MetO and lipid hydroxides, respectively (48-50,102).  ApoA−I contains three 
Met residues at positions 86, 112 and 148 (Fig. 1.12), whereas apoA−II contains of a single 
Met residue at position 26.  Specifically oxidized forms of apoA−I have been assigned as 
apoA−I+16 (MetO86 or MetO112), apoA−I+32 (MetO86 plus MetO112) and oxidized apoA−II 
named as apoA−II+16 (apoA−II dimer containing a single MetO26) (103).  Under the oxidation 
conditions specified above, apoA−I+32 is formed later and becomes a relatively stable 
oxidation product.  And interestingly, Met148 does not appear to become oxidized at this 
conditions (50,102,103).  This might be due to microenviroment alterations within apoA−I 
molecule caused by different oxidants (226,227). 
N2 
2O2 heat 
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Fig. 1.13.  Proposed mechanism for the reduction of HDL-associated LOOH by human 
apoA-I and apoA-II.  HDL’s LOOH are reduced to the corresponding lipid hydroperoxides 
(LOH) via direct two-electron transfer from the sulfur of thioethers of the oxidation–prone 
Met86 and Met112 residues of apoA-I and Met26 of apoA-II, resulting in formation of their 
respective MetO. Obtained from (50). 
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In addition to peroxyl radicals, H2O2 causes MetO formation in lipid-free or HDL−associated 
apoA−I (226).  Such MetO formation appears to involve all three Met residues in apoA−I 
(Met86, Met112 and Met148) (110).  However, oxidation by H2O2 alone has no effect on 
apoA−I/HDL−mediated cholesterol efflux (220).  In contrast, oxidation by HOCl resulting in 
the formation of MetO of apoA−I has impaired ability to promote cholesterol efflux through 
the ABCA1−dependent pathway (106,228).  Furthermore, the recent research shows that 
MetO−containing apoA−I impairs reverse cholesterol transport by impaired ability to activate 
LCAT (229).  It is also reported the formation of MetO affects the structure and stability of 
lipid−bound apoA−I (230), suggesting that MetO can alter the structure and functions of 
apoA−I, hence HDL.  Together, it will be important to extend the study to investigate the role 
of oxidized apoA−I containing MetO in atherosclerosis and assess its suitability as a 
surrogate biomarker for CVD.   
1.8 Potential marker for atherosclerosis 
Given the post−translational modifications apoA−I may undergo in an oxidative environment 
such as that present in an atherosclerotic lesion, specific forms of oxidized apoA−I/HDL may 
be useful marker(s) for the diagnosis of atherosclerosis.  It is noteworthy in this context that 
HDL is more susceptible to oxidative modification than LDL, at least under some conditions 
(168,211,231).  As mentioned previously, it is possible that mildly oxidized HDL could be 
present in plasma of subjects with CVD (227).  Specifically oxidized HDL and 
HDL−associated apolipoproteins that reflect early changes occurring during lipoprotein 
oxidation may therefore be important markers of atherosclerosis. 
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There are other considerations potentially favouring the utility of oxidized HDL and/or 
HDL−associated apolipoproteins as a marker of atherosclerosis.  For example, compared to 
LDL, oxidized HDL formed in the arterial wall may be more readily able to re−enter the 
circulation, as HDL is substantially smaller than LDL (232).  Also, apolipoproteins dissociate 
more easily from HDL than LDL (176).  Finally, and of practical importance, HDL and 
apoA−I are simpler to work with in terms of their characterizations, compared to LDL and 
apoB−100, respectively (227).   
Given that Met residues in apoA−I are susceptible to direct (e.g., H2O2, HOCl) and indirect 
oxidation mediated by lipid peroxidation, oxidized apoA−I may also be a potential marker of 
lipoprotein oxidation, encompassing both protein and lipid oxidation.  This is distinct to 
“F2−isoprostanes”, a general marker of lipid oxidation (204).  Together, these considerations 
indicate that it is worthwhile to investigate the potential role of oxidized apoA−I containing 
MetO residues in atherosclerosis and its potential use as a marker of lipoprotein oxidation 
and/or atherosclerosis.  Notably, there is evidence that HDL−associated, apoA−I+32 is present 
in circulation of subjects with increasing risk of CVD (Fig. 1.14) (103) and subjects with type 
1 diabetes (104).  This observation suggests a potential relationship between 
MetO−containing apoA−I and an increased risk of atherosclerosis. 
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Fig. 1.14.  Relationship between apoA-I+32 and eNOS genotype and exposure to cigarette 
smoking.  The concentration of apoA-I+32 measured by HPLC, was determined in HDL 
isolated from serum of cord blood in subjects of eNOSa/b (n=4) and eNOSb/b (n=8), and of 
cord blood samples with (n=5) and without (n=12) exposure to smoking during pregnancy.  
Both eNOSa allele carriers and cigarette smokers are associated with increased risk for CVD.  
Results are expressed as a percentage of total apoA-I concentration and represent mean ±SD.  
Abbreviation: eNOS, endothelial nitric oxide synthesis.  Obtained from ref (103). 
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1.9 Aims and scope of the current work 
The overall aim in the present study was to test the usefulness of MetO−containing, oxidized 
apoA−I as a marker for atherosclerosis and to establish suitable novel tools to investigate this 
question.   
Development of atherosclerosis is a chronic and complex process, yet many atherosclerotic 
lesions do not have a clinical manifestation until a late stage.  Despite considerable advances 
in its treatment, CVD remains the leading cause of death in developed countries.  Thus, there 
is a need for preventing atherosclerosis development at an early stage, and this requires the 
discovery of biomarkers useful to detect the early stages of CVD.   
Oxidized apoA−I containing MetO is an indicator of the early stages of HDL oxidation and 
hence, possibly of early atherosclerotic lesions.  To assess its potential diagnostic value and 
its involvement in atherogenesis, a prospective, cohort, nested case control study in a general 
population was conducted.  This study assessed the presence of MetO−containing, oxidized 
apoA−I in HDL isolated from human plasma and correlated the data obtained with further 
CVD events and an established biomarker of lipid oxidation, i.e., F2−isoprostanes.   
At present, the potential use of specifically oxidized HDL as a diagnostic tool is limited by 
the need for time consuming and expensive methodology and technology, such as HDL 
isolation and HPLC, or MS equipment.  In addition, limitation of sensitivity is a major 
obstacle for its application to clinical samples.  To improve the methodology for the detection 
of oxidized apoA−I, a new and sensitive ELISA was developed.  Both lipid−free and 
lipid−associated forms (i.e., HDL, plasma) of oxidized apoA−I were tested in the ELISA.  
The specificity was examined by testing apoA−I and HDL oxidized in vitro.  The specificity 
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of the monoclonal antibody (mAb) used was also characterized using various Met residue 
mutants and Biacore’ surface plasmon resonance technology.  Finally, the ELISA was 
applied to human plasma samples to evaluate its clinical applicability.  Throughout, the 
existing HPLC method was used to validate the development and application of the ELISA. 
In summary, the present study aims to: 
1) Examine the usefulness of MetO−containing oxidized apoA−I, determined by HPLC, 
as a biomarker for CHD in a prospective, cohort, nested case control study in a 
general population. 
2) Develop a sensitive ELISA for the detection of oxidized apoA−I in HDL and in 
human plasma. 
3) Validate the ELISA with the existing HPLC method and characterize the specific 
reactivity of the monoclonal antibody. 
4) Apply the ELISA to different clinical plasma samples. 
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2.1 Materials 
2.1.1 Animals 
Balb/c mice were used for immunization with HPLC−purified human apoA−I+32 to produce 
the monoclonal antibody (Section 2.6.2). 
2.1.2 Medium  
Cell culture media including Dulbecco's modified eagle's medium (DMEM), and hybridoma-
Serum Free Medium (SFM) were purchased from Invitrogen (Carlsbad, CA, USA).   
2.1.3 Antibodies 
The sources of the various antibodies used are listed in Table 2.1.   
Chapter 2 
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Table 2.1.  Sources of the various antibodies used in the present study. 
Antibody Company Cat # 
Goat anti−human apoA−I polycolonal Ab  Biodesign A95120H 
Goat anti−human apoA−I polycolonal Ab  Rockland 600−101−109 
Goat anti−human apoA−I polycolonal Ab  Chemicon AB740 
Mouse anti−human apoA−I monoclonal Ab  Chemicon MAB010−A/11 
Streptavidin HRP Ab Dako P0397 
Anti−goat IgG peroxidase conjugate Sigma A4174 
Anti−mouse IgG peroxidase conjugate Sigma A9917 
Polycolonal rabbit anti−mouse immnoglobulins 
/HRP 
Dako P0260 
Mouse immunoglobulin screening/isotyping kit Zymed 97−6550 
Mouse myeloma IgG1 Zymed 02−6100 
Mouse anti-human smooth muscle actin 
monoclonal Ab 
Dako N1584 
 
 
 
 
 
Chapter 2 General Methods 
  72 
2.1.4 Reagents and solvents  
2,2’−Azobis(2−amidinopropane) dihydrochloride (AAPH) was purchased from Wako Pure 
Chemical Ind.  (Osaka, Japan).  3,3’,5,5’−Tetramethylbenzidine (TMB), diethylene triamine 
pentaacetic acid (DTPA), ascorbic acid, hydrogen peroxide (H2O2), sydnonimine-1 (SIN−1), 
bovine serum albumin (fraction V), potassium bromide (KBr), myoglobin, fibrinogen and 
ferritin were obtained from Sigma (St. Louis, MO, USA).  Lipoprotein precipitation reagents 
including α-cyclodextrin (α−CD), dextran sulfate (DS), polyethylene glycol (Mr. 8000) 
(PEG) and sodium phosphotungstate (SPG) were also obtained from Sigma.  Sodium 
hypochloride (4% solution) was obtained from Septone (Hemmant, QLD, Australia), while 
phosphate buffered saline (PBS, pH 7.4, 10 mM) was prepared from tablets (Oxoid, 
Basingstoke, England).  Bicinchoninic acid protein reagent A and EZ-Link 
Sulfo−NHS−LC−Biotin were obtained from Pierce (Rockford, IL, USA).  Trifluoroacetic 
acid (TFA) and HPLC-grade water were obtained from British Drug House (Poole, England).  
Other HPLC−grade solvents were obtained from Merck (Darmstadt, Germany).  All other 
reagents used were of analytical grade.  Water was purified by a Milli−Q Ultrapure water 
system (Millipore, Sydney, NSW, Australia). 
2.2 Isolation of lipoproteins from human plasma 
2.2.1 Plasma separation 
Blood (10−200 mL) from healthy overnight fasted subjects was collected into heparin 
vacutainers (Becton, Dickinson and Company, Singapore).  Plasma was obtained after 
centrifugation of the blood (AllegraTM 6R centrifuge, Beckman, USA) at 1,430 x g for 20 
min at 4 ℃.  Relevant ethics approval was obtained from the University of Sydney. 
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2.2.2 Small scale isolation of HDL 
For small scale preparation, HDL was isolated from fresh human plasma (maximum volume:  
15 mL) by density gradient ultracentrifugation based on the method of Sattler et al. (233).  
Specifically, the density of plasma (0.4−1.9 mL) was adjusted to 1.24 g/mL by adding 381.6 
mg KBr per mL plasma, and the KBr was dissolved and the density−adjusted plasma then 
ultracentrifuged at 356,000 x g and 15 ℃ for 3 h using a Beckman bench top ultracentrifuge 
(Beckman Optima TLX).  The ultracentrifuge was equipped with either a TLA 100.2 rotor for 
0.4 mL plasma in 1.9 mL quick seal tubes (Beckman, Fullerton, CA, USA), or a TLA 100.4 
rotor for 1.9 mL plasma in 5.1 mL quick seal tubes (Beckman) ultracentrifugation.  The 
resulting HDL band, consisting of HDL2 and HDL3 (Fig. 2.1 A), (volume of HDL obtained: 
≈0.3 mL for 0.4 mL plasma, ≈1.5 mL for 1.9 mL plasma) was aspirated using a 21G 1½ 
needle attached in a 1 mL syringe.  Low molecular weight compounds present in the HDL 
fraction were then removed by gel-filtration using a NAP−10 column (GE Healthcare, 
Uppsala, Sweden) and the purified HDL eluted with 1.5 mL of ice−cold PBS containing 1 
mM EDTA.  All procedures were carried out on ice to prevent autoxidation of 
HDL−associated compounds. 
The protein concentration of an aliquot of the HDL prepared was determined by the 
bicinchoninic acid assay (Pierce), and the remaining lipoprotein was subjected to HPLC for 
immediate analysis (Section 2.4.1) or stored at 4°C for use within 24 h.  
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Fig. 2.1.  Lipoprotein fractions after density ultracentrifugation.  A: VLDL, LDL and 
HDL after 3 h ultracentrifugation.  Such distributions were observed with either small or 
large quick seal tubes.  Location of HDL (B) and (C) LDL after the second 
ultracentrifugation step using large quick seal tubes. 
Chapter 2 General Methods 
  75 
2.2.3 HDL isolation after lipoprotein precipitation  
Supernates (1 mL) obtained from plasma samples after applying various lipoprotein 
precipitating methods (Section 2.9) were adjusted to the density of 1.24 g/mL with KBr, 
followed by density ultracentrifugation (Section 2.2.2).  The resulting HDL was collected for 
HPLC analysis (Section 2.4.1). 
2.2.4 Large scale preparation of HDL and LDL 
Large quantities of HDL were isolated from the plasma of subjects fasted overnight by 
sequential ultracentrifugation (233).  Briefly, pooled plasma (100 – 200 mL) was adjusted to 
1.24 g/mL density with KBr (381.6 mg per mL plasma), placed in Beckman quick seal tubes 
(40 mL capacity) centrifuged at 206,360 x g and 10 ℃ for 3 h in a Beckman Optima L-90K 
ultracentrifuge equipped with a VTi50 Beckman rotor.  The resulting HDL and LDL bands 
(Fig. 2.1A) (≈ 40 mL for each) were collected separately and then distributed into two quick 
seal tubes (≈ 20 mL of either HDL or LDL for each tube).  The tubes were filled with 20 mL 
of either 1.24 g/mL density solution for HDL or 1.063 g/mL density solution for LDL.  The 
tubes were then re-centrifuged in a Ti70 Beckman rotor at 206,360 x g and 10 ℃ overnight 
(16−24 h).  The resulting top band of HDL (Fig. 2.1B for HDL) or LDL (Fig. 2.1C for LDL) 
was removed and dialyzed at 4 ℃ and in the dark for 24 h against 10 mM PBS containing 
0.1% EDTA and 0.01% chloramphenicol, with 5−6 times buffer change.  The dialysis tubing 
used was obtained from Viscase (MEMBRA−CEL, MD10-14 x 100 Clr, Chicago, IL, USA).  
The tubing was boiled in distilled water for 3 min and rinsed with water three times prior to 
use.  To prevent autoxidation, all procedures were carried out on ice.  The protein content of 
HDL and LDL was determined using the bicinchoninic acid protein assay (Pierce). 
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2.2.5 HDL isolation for Fletcher−Challenge study and pilot study 
Frozen aliquots of plasma samples (0.4 mL) were thawed at room temperature and adjusted 
to a density of 1.24 g/mL with 152.6 mg of KBr, followed by density gradient 
ultracentrifugation, as described in Section 2.2.2.  The isolated HDL was gel−filtered through 
a NAP−10 column (Section 2.2.2) and then subjected to HPLC analysis (Section 2.4.2).  All 
operations were carried out on ice. 
2.3. In vitro oxidation of HDL with peroxyl radicals 
Native HDL (1-1.5 mgp/mL) was oxidized in 10 mM PBS containing 1 mM EDTA by 
incubation with the peroxyl radical generator, AAPH (1−2 mM) at 37 ℃ under air for 3 h 
(102).  The oxidation was terminated by gel−filtration of the reaction mixture using a 
NAP−10 column (GE Healthcare, Uppsala, Sweden), and eluting HDL with 1.5 mL of 10 
mM ice−cold PBS.  The protein concentration of oxidized HDL was determined by the 
bicinchoninic acid protein assay (Pierce).  The oxidized HDL was analyzed immediately to 
determine specifically oxidized apolipoproteins, or stored at 4°C for use within 24 h. 
The oxidation of HDL by other oxidants including H2O2 and HOCl, is detailed in Section 
2.12.3.3. 
2.4 HPLC−based analysis 
2.4.1 HPLC analysis of native HDL and oxidized HDL 
Gradient HPLC was performed on a Waters Alliance 2690 separation module equipped with 
a Waters 2487 dual absorbance detector (Waters, Milford, MA, USA).  Specifically, 1.5 mL 
of freshly isolated native or oxidized HDL was transferred into a 2 mL HPLC vial and then 
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subjected to HPLC analysis, consisting of a Vydac guard column (5 µm, 4.6 ID) (Grace, 
Chicago, IL, USA)) connected to a Vydac RP C18 column (250 x 4.6 mm, 5 µm, Grace) 
eluted at 0.5 mL/min and 50 °C and monitored at 214 nm.  The analysis conditions were 
modified based on the previous method (103).  Mobile phase A contained 0.1% TFA in 
acetonitrile (vol : vol) and mobile phase B contained 0.1% TFA in water (vol : vol).  Native 
and oxidized HDL samples were analyzed using the following gradient:  
a. Linear increase in Solvent A from 25% to 45% over 5 min 
b. Linear increase in Solvent A to 55% over 32 min 
c. Linear increase in Solvent A to 95% over 10 min 
d. Increase in Solvent A to 100% in 1 min 
e. Linear decrease in Solvent A to 25% over 10 min 
f. Maintenance of Solvent A at 25% for 10 min for column re-equilibration 
and before injection of next sample 
To determine apolipoproteins in native and oxidized HDL, the peak area of each native 
apolipoprotein and its oxidized forms was quantified using the Millennium software.  The 
percentage of apolipoprotein oxidation was assessed by peak area comparison between 
oxidized apolipoprotein and total apolipoproteins (oxidized forms plus native form of 
apolipoproteins).  The amount of apoA−I+32 contained in oxidized HDL was determined 
using apoA−I+32 HPLC standard curve (Section 2.4.3).  
2.4.2 HPLC analysis of clinical samples 
To analyze HDL isolated from plasma samples of the Fletcher−Challenge study, the obtained 
HDL samples (1 mL) was subjected immediately to HPLC (Section 2.4.1) to determine its 
major apolipoproteins, i.e., apoA−I and apoA−II, and their respective oxidized forms.  In 
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pilot clinical study, the isolated HDL (300 µL) was applied to HPLC for apolipoprotein 
analysis.  The peak area of each native apolipoprotein and its oxidized form was quantified 
using the Millennium software.  The proportion of apoA−I oxidation was determined by area 
comparison between oxidized apoA−I and total apoA−I (oxidized apoA−I plus apoA−I).   
2.4.3 Preparation of apolipoproteins and their oxidized forms 
For the purpose of collection of HPLC−purified apolipoprotein standards and their 
corresponding oxidized forms, a semi-preparative RP C18 column (250 x 10 mm, 10 µm, 
Vydac) was used to allow injection of large amounts (≤ 5 mg protein) of native and oxidized 
HDL.  The flow rate was increased to 2 mL/min and the respective native and oxidized forms 
of apolipoproteins were collected. 
Under the conditions used, apoA−I and apoA−II eluted from the semi−preparative RP C18 
column at ~25 min and ~34 min, respectively.  Several oxidized forms of apoA−I and 
apoA−II were separated and collected from AAPH−oxidized HDL: apoA−I+32 eluting at ~16 
min; apoA−I+16 (MetO112) eluting at ~17 min; apoA−I+16 (Met86) eluting at ~24 min; and 
apoA−II+16 eluting at ~28 min.  The collected apolipoproteins were dried under vacuum using 
an AES1010 speedvac system (Thermo Savant, Medford, MA, USA) operated in vapornet 
cryopumping Mode, and then reconstituted in PBS (2 mL).  Reconstituted native apoA-I and 
apoA-II, and oxidized forms of apoA-I were overlaid with argon and stored at −80 ℃ prior to 
use.  These HPLC−purified apolipoproteins are referred to subsequently as lipid−free 
apolipoproteins.  The protein concentration in each sample was determined using the 
bicinchoninic acid protein assay (Pierce).  Then, these HPLC−purified, lipid−free 
apolipoproteins were subjected to HPLC in serial concentrations, and peak areas of the 
apolipoproteins were plotted as apolipoprotein standard curve. 
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2.4.4 Other HPLC measurements 
Levels of plasma cholesterol were measured by an HPLC system employing variable 
wavelength UV/VIS detection (234,235).  Briefly, plasma (200 µL) or plasma after albumin 
removal (150 µL) was extracted with 4 vol of methanol and 20 vol of hexane.  The hexane 
layer was removed, dried, and re-dissolved in 200 µL mobile phase (methanol/iso-
propylalcohol/acetonitrile/water, 30/60/15/2 (vol/vol/vol/vol) containing 20 mM LiClO3.  
H2O).  Redissolved lipids (100 µL) were subjected to a Supelcosil (Supelco, Bellefonte, PA, 
USA) LC−18 (25 x 0.46 cm, 5 µm) column, eluted at 1 mL/min with the mobile phase and 
monitored at UV210 nm for cholesterol analysis.   
2.5 Mass spectrometric (MS) analysis 
2.5.1 MS confirmation of apolipoproteins 
HPLC−purified apolipoprotein standards were subjected to mass spectrometry to verify their 
chemical identity.  In general, masses of apolipoproteins were determined by electrospray 
ionization mass spectrometry (ESI-MS), using an API QStar Pulsar I hybrid tandem mass 
spectrometer (TOF) (Applied Biosystems, Foster City, CA, USA).  Samples were dissolved 
in water/acetonitrile (1:1, vol/vol) containing 0.1% formic acid and an aliquot (1 µL) loaded 
into nanospray needles (Proxeon, Odense, Denmark) and the tip positioned ~10 mm from the 
orifice.  Nitrogen was used as the curtain gas, and a potential of 900 V was applied to the 
needle.  TOF−MS scans were acquired (m/z 550−2000, 1 s) and accumulated for ~1 min into 
a single file.  The obtained spectra were de−convoluted using the Bayesian reconstruct 
method contained within the Analyst QS software (Applied Biosystems). 
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HPLC traces of HDL showed native apoA-I eluted as a single species, while apoA-II (dimer) 
eluted as three distinct species (103), hereafter referred to as apoA-II−1, apoA-II−2 and 
apoA-II−3.  Each of these apoA-II species was purified further by preparative HPLC and 
characterized as dimers, monomers and trypsin peptides by TOF mass spectrometry (MS), 
with scans acquired for m/z 250−2000.  Precursor ions corresponding to the expected N− or 
C−terminal peptide ions were selected by Q1 for subsequent MS−MS analysis.  TOF spectra 
were analyzed and individual protein or peptide masses calculated using Bayesian reconstruct 
algorithms (Applied Biosystems).  Tandem mass spectra were compared and interpreted 
manually. 
2.5.2 GC−MS analysis of F2-isoprostanes 
F2-Isoprostanes were measured in the Kevin Croft laboratory in Perth using a method 
previously published (236) with minor modification.  In brief, deuterated 8-isoprostaglandin 
F2α (8-F2t-IsoP-d4, 5 ng) and 15-isoprostaglandin F2α (15-F2t-IsoP-d4, 5 ng) were added as 
internal standards to plasma (250 µL).  After base hydrolysis with KOH (1 M) samples were 
diluted with 2 mL 0.1 M sodium acetate solution (pH 4.6) and purified by solid phase 
extraction on a mixed reverse phase/anion exchange column (Bond Elut-Certify II, Varian, 
Harbor city, CA, USA).  F2-Isoprostanes were eluted with ethyl acetate/methanol (9:1 
vol/vol), dried under vacuum and derivatized to the trimethylsilyl, pentafluorobenzylesters 
and analyzed by GC-MS on an Agilent 6890 gas chromatograph coupled to an Agilent 5973 
mass selective detector (Agilent Technologies, Santa Clara, CA, USA) using electron capture 
negative ionization.  Chromatographic separations were performed in splitless mode using 
HP-5MS capillilary columns (30 m x 0.25 mm i.d, with 0.25 µm stationary-phase film 
thickness) and helium as the carrier gas at a flow rate of 0.68 mL/min.  Methane was used as 
the reagent gas at an ion source pressure of 1.8 torr.  The GC-MS injector, transfer line, ion 
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source and quadrupole temperatures were maintained at 250, 280, 200 and 100℃, 
respectively.  The initial column temperature of 160°C was held for 1 min and then 
programmed from 160 to 300°C at 20°C/min and maintained at 300°C for 17 min, giving a 
total run time of 25 min.  F2-Isoprostanes were detected by selected ion monitoring using m/z 
569 and m/z 573 for 15-F2-isoprostanes, and 15-F2t-IsoP-d4 and 8-F2t-IsoP-d4, respectively. 
2.6 Production of the monoclonal anti-human apoA-I+32 antibody  
In general, monoclonal antibodies are typically made by fusing spleen cells of a mouse that 
has been immunized with the desired antigen with myeloma cells.  The resulting successfully 
fused cells (referred to as hybridomas cells) producing the antibody specific to the desired 
antigen are selected and grown in culture (Fig. 2.2.).   
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Fig. 2.2.  General procedures to produce mouse monoclonal antibodies.  
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2.6.1 Generation of hybridoma cells 
Generation of hybridomas cells was performed by the Centre for Animal Biotechnology 
(University of Melbourne, Melbourne, Australia) with approval from the local animal ethics 
committee.  Briefly, six Balb/c mice were immunized three times, four weeks apart by both 
subcutaneous and intravenous injection of 10 µg apoA-I+32 in Freund’s adjuvant.  The 
strongest responding mice, as determined by serum Ig levels on ELISA, were chosen for 
subsequent fusion.  Five days before the fusion and at least four weeks after the previous 
boost immunization, a final boost apoA-I+32 (10 µg in saline) was administered by 
intravenous injection.  On the day of fusion, spleen cells (2 x 108) in 10 mL taken from the 
immunized mice were added to NS-1 cells (4 x 107) in 10 mL in serum−free DMEM and the 
fusion done by stirring with 50% polyethyleneglycol.  The fused cells were plated over eight 
96 well plates with rat thymocyte feeder cells.  Seven to ten days after the fusion, hybridoma 
supernates were screened for antibodies using solid-phase ELISA and apoA−I+32 as the 
immunogen coated.  Hybridomas from high producing cell pools were cloned by limited 
dilution.  Three rounds of clonal isolation were performed to obtain stable cell lines 
producing monoclonal antibodies.  Two hybridoma cell lines (6.4.4.26 and 6.4.4.17.2.2) were 
expanded, followed by freezing and storage in liquid nitrogen.   
2.6.2 Production and characterization of monoclonal antibodies (mAb) 
Hybridoma cell lines 6.4.4.26 and 6.4.4.17.2.2 producing anti-human apoA-I+32 mouse mAbs, 
designated mAb26 and mAb17 respectively, were cultured initially in DMEM containing 
10% FBS, and were adapted subsequently to serum-free medium (Hybridoma-SFM, 
Invitrogen).  After serum-free culture of hybridomas, supernates were harvested followed by 
the addition of 0.05 % sodium azide and storage at 4 ℃.The supernates were filtered through 
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a 0.22 µm filter (Millipore, Milford, MA, USA) prior to mAb purification.  The antibody 
concentration was determined by measuring the absorbance at 280 nm using a U-3210 
spectrophotometer (HITACHI).  The antibody solution (1 mL) was placed in a quartz cuvette 
and the concentration of IgG (mg/mL) was calculated as OD 280 nm / 1.35.   
To determine the immunoglobulin isotype, the mouse immunoglobulin screening/isotyping 
kit (Zymed Laboratories Inc, San Francisco, CA, USA) was used and the standard protocol 
was followed. 
2.6.3 Purification of mAbs 
The mAb17 and 26 were purified from hybridoma supernates using a Hitrap protein G HP 
affinity column (GE Healthcare, Uppsala, Sweden) installed on a Bio-Rad Biologic Duo 
Flow liquid chromatography system (Bio-Rad, USA).  The column was equilibrated with 20 
mM PBS pH 7.0.  Cell culture supernates was loaded at a flow rate of 5 mL/min, the column 
washed with 20 mM PBS pH 7.0 and the mAb eluted with 0.1 M glycine-HCl, pH 2.7.  The 
mAb was collected in a tube containing 1 M Tris-HCl, pH 9.0 to neutralize the pH of the 
purified antibody.   
The neutralized antibody solution was dialyzed against 10 mM PBS pH 8.0 at 4 ℃ for two 
days with regular buffer changes (5−6 times).  Alternatively, the neutralized antibody 
solution (1 mL) was gel-filtered using three consecutive NAP-10 columns (GE Healthcare) 
eluted with 1.5 mL of 10 mM PBS to remove glycine and Tris. 
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2.6.4 Purity confirmation by SDS−PAGE 
The purity of the mAb was assessed by SDS-PAGE.  Mouse myeloma IgG1 (1 µg) (Zymed 
Laboratories Inc.) and the purified monoclonal antibodies were loaded into 10% NuPAGE 
Bis-Tris Gel (1.5 mm x 15 well, Invitrogen).  SeeBlue Plus2 (Invitrogen) was used as the 
molecular weight marker.  The antibody preparation was electrophoresed for 50 min at a 
constant current of 100 mA, voltage 200 V in MOPS−SDS buffer (Invitrogen).  The proteins 
were then stained with Coomassie Blue. 
To achieve the desired concentration of antibody, Centriplus YM-10 (Millipore) was used for 
concentration by centrifuging (AllegraTM 6R centrifuge, Beckman) at 4000 x g and 4℃ until 
the desired concentration was attained (> 1mg/mL). 
2.6.5 Production of biotinylated mAb (B−mAb) 
The pH of mAb17 and 26 solutions was adjusted to 8.0 and the protein concentration was 
adjusted to >1 mg/mL using Centriplus YM-10 (Millipore). The final protein concentration of 
antibodies was measured by spectrophotometry at 280 nm.  The mAb was biotinylated by 
addition of a 20−fold molar excess of Sulfo-NHS-LC-Biotin (Pierce, Rockford, IL, USA.  
Fig. 2.3).  Following mixing, the reaction mixture was incubated for > 30 min in the dark at 
room temperature.  The reaction was stopped by adding 100 µL of 1 M Tris (pH 8-9.0).  The 
biotinylated mAb was dialyzed extensively against PBS at 4 ℃ for two days to remove 
unreacted biotin reagent and byproducts.  Alternatively, three consecutive NAP−10 columns 
(GE Healthcare) were used and the B−mAb eluted with 1.5 mL of PBS.  The concentration of 
the B−mAb was then determined by measuring the absorbance at 280 nm (A280nm) and the 
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final concentration was calculated.  Sodium azide (0.05 %) was added to the B−mAb 
preparation, and the preparation was subsequently stored at −20 ℃ in aliquots until use. 
The binding of B−mAbs was tested by coating the microplate with B−mAb17 or B−mAb26 
in a range of concentrations (0−500 ng) and incubating at 37 ℃ for 1 h.  A non−biotinylated 
antibody (mAb26) was used as a control.  The plate was washed three times with 0.1% 
Tween 20 in PBS (PBST), followed by the addition of streptavidin HRP (1: 2500) and 
incubation at 37 ℃ for 1 h.  TMB (100 µL/well) was added and the absorbance read at 450 
nm in a Titertek Multiskan MCC/340 MK II microplate reader (Labsystems, Finland). 
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Fig. 2.3.  Biotinylation of proteins.  Sulfo-NHS-LC-Biotin reacts with Lys residues of 
proteins to produce biotin−labelled proteins and by products, including non-reacted biotin 
reagents that can be removed through gel-filtration. 
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2.7 ELISA development for the detection of MetO−containing apoA−I 
2.7.1 General ELISA set−up 
The 96-well plate (Maxisorp Nunc-immuno, Roskilde, Denmark) was coated with the capture 
antibody (various antibodies detailed in the Results Sections) in PBS at appropriate dilutions 
and incubated at 4 ℃ overnight.  The plate was then washed with 0.1% Tween 20 in PBS 
using a plate washer (Denley, MI, USA) and incubated at 37 ℃ in an oven (Axyos 
Technologies, Australia) for 1 h with 2% BSA in PBS as blocking buffer.  The plate was 
washed and various amounts of samples (lipid-free forms of apolipoproteins, lipid-associated 
forms of apoA-I including oxidized HDL and plasma) were added and incubated at 37 ℃ for 
1 h.  Following washing, the detection antibody (mAb or B−mAb) was added and the plate 
incubated further for 1 h at 37 ℃.  The plate was washed again and appropriate 
HRP−conjugated antibodies (specific HRP conjugate detailed in the text) added and 
incubated for another 1 h at 37 ℃.  Finally, the plate was washed four times with PBST 
before TMB substrate (100 µL/well) was added for color development.  The reaction was 
stopped by addition of 20% H2SO4 (100 µL/well).  The absorbance was read at 450 nm in a 
plate reader. 
2.7.2 Optimized ELISA set−up 
In the optimized ELISA, the mouse anti-human apoA-I monoclonal antibody (mAb010-A/11, 
Chemicon) was chosen as the capture antibody at 1:500 dilution in PBS (100 µL/well).  The 
detection antibody was B-mAb26 (hereafter referred to as B−MOA−1) at 1: 400 dilution in 
2% BSA in PBS (100 µL/well), and Streptavidin HRP (Dako) at 1:2,500 dilution in PBS 
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containing 2% BSA.  The remainder of the procedures was as described in Section 2.7.1.  
The optimized ELISA conditions are also referred to as the standard ELISA (Fig. 2.5). 
2.7.3 Competition assay 
In the competition assay, polyclonal goat anti-human apoA-I Ab (Rockland) was used as 
capture antibody (1: 10,000 dilution in PBS) and incubated at 4 ℃ overnight.  After standard 
washes and blocking steps, the same amount of apoA-I+32 (400 ng/mL) was applied to each 
well.  After incubation and washes, B−mAb17 (600 ng/mL) was added to each well as 
detection antibody, followed by competing antibodies at increasing molar ratio to mAb17 
(0−5 molar excess) and incubation for 1 h at 37 ℃.  All subsequent steps were performed as 
described in Section 2.7.1.   
2.7.4 Detection of lipid-free forms of MetO−containing apolipoproteins 
HPLC−purified, lipid-free apolipoproteins (apoA-I, apoA-II) and their oxidized forms (apoA-
I+32, apoA-I+16 (MetO86 or MetO112) were added in serial dilutions ranging from 0 - 500 
ng/mL in PBS containing 2% BSA.  The remaining procedures were as described in Section 
2.7.2.  The sensitivity of detection was compared with that of the HPLC−based method by 
subjecting 0 − 200 µg/mL lipid−free apoA−I+32 to HPLC as described in Section 2.4.1.   
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Fig. 2.4.  The ELISA set−up.  The standard ELISA consists of anti-apoA-I mAb 
(MAB010−A/11) as the capture Ab and B−MOA−1 as the detection Ab, followed by Ab 
conjugates (streptavidin HRP) and substrate (TMB) for colour formation. 
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2.7.5 Detection of lipid-associated, MetO−containing apoA-I 
2.7.5.1 HDL−associated, MetO−containing apoA−I (HDLox) 
Native HDL and LDL, and AAPH−oxidized HDL and LDL were added in serial dilutions (0–
15 µgp/mL) either in PBS containing 2% BSA, or in acetonitrile at a final concentration of 
40% (protein: 50% acetonitrile; 1: 4, vol:vol).   
2.7.5.2 MetO−containing apoA−I in plasma 
The filtered and diluted plasma sample was supplemented with increasing amounts of 
AAPH−oxidized HDL (0−15 µg protein) and passed through a hydrated SwellGel column 
(SwellGel Blue albumin removal kit, Pierce) with details described in Section 2.10.  The 
column was then washed with 400 µL optimized buffer (25 mM Tris, 300 mM NaCl, pH 
7.4).  After centrifugation, the washes were collected and combined with the flow−throughs 
and 50 µL/well of resulting samples applied to the ELISA.  To compare with an HDLox 
standard curve, increasing amounts of HDLox (0−1.5 µg/well) were added to the ELISA 
plate. 
In pilot clinical studies, filtered and diluted (1:10, vol:vol) plasma samples were processed by 
the SwellGel Blue method before application to ELISA as described above.  As the parallel 
experiment, HDL was isolated after ultracentrifugation (Section 2.2.5) and analyzed by 
HPLC (Section 2.4.2). 
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2.7.6 Detection of apoA−I mutants and their H2O2−oxidized forms 
Mutant apoA−I (0−500 ng/mL) in which one, two or all three of its Met residue(s) were 
replaced with Leu residue(s), or H2O2−oxidized mutant apoA−I (0−500 ng/mL) were added 
to the ELISA plate.  Wild type apoA−I was used as a negative and H2O2−oxidized, wild type 
apoA−I was used as a positive control, respectively.  The remaining procedures were as 
described in Section 2.7.2 for the standard ELISA. 
In the HPLC−based analysis, mutant apoA−Is and their H2O2−oxidized forms (5 µg) were 
applied to HPLC (Section 2.4.1). 
2.7.7 Detection of differently oxidized apoA−I, HDL or LDL 
Lipid−free apoA−I (0−500 ng/mL) oxidized with either 1e− or 2e−oxidants (Section 2.12.3) 
was applied to the standard ELISA (Section 2.7.2).  Alternatively, HDL (0−15 µgp/mL) 
oxidized by H2O2 or HOCl (Section 2.12.3) was added to the ELISA plate.  For comparison, 
LDL (0−15 µgp/mL) oxidized by H2O2 or HOCl (Section 2.12.3) was added to the ELISA.  
The rest of the ELISA procedures were as described in Section 2.7.2.   
In parallel experiments, different 1e− or 2e−oxidant oxidized apoA−I (5 µg) and HDL (0.5 
mg) were subjected to HPLC after gel-filtration using NAP-10 column for analysis of apoA−I 
and its oxidized forms (Section 2.4.1).   
2.7.8 Detection of Met−containing proteins oxidized with 2e−oxidants 
Other proteins containing Met residues including BSA, myoglobin, ferritin, and fibrinogen (1 
mg/mL each) were oxidized with H2O2 or HOCl (Section 2.12.5) and applied at 0−10 
µgp/mL to the ELISA.  For comparison, apoA−I (5 µM) oxidized with either H2O2 or HOCl 
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(Section 2.12.5) was applied at (0−500 ng/mL) to the ELISA.  All remaining steps were as 
described in Section 2.7.2. 
2.7.9 Application of samples after lipoprotein precipitation 
Samples obtained after lipoprotein precipitation (Section 2.9) were applied to the ELISA in 
serial dilutions (0−10 µg), with the remaining of the procedures as described for the standard 
ELISA (Section 2.7.2).  
The supernates obtained from various lipoprotein precipitation methods were subjected to 
HPLC (Section 2.4.1) after ultracentrifugation (Section 2.2.2) to determine the efficacy of 
lipoprotein precipitation.   
2.8 Other ELISAs 
Measurements of other variables in the Fletcher−Challenge study, including fibrinogen and 
high-sensitivity C-reactive protein, were assayed using automated immunonephelometric 
assays (Dade Behring, Oxford, UK) (237).  Interleukin-6 was assayed using a high–
sensitivity ELISA (R & D Systems, Oxford, UK) (237).  The standard protocols were 
followed.  C−reactive protein in human plasma samples in the pilot study were measured 
using particle−enhanced immunoturbidimetric assay (Roche Tina−quant CRP) in the Routine 
Biochemistry Laboratory (Royal prince Alfred Hospital, Sydney, NSW, Australia).  
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2.9 Lipoprotein precipitations 
2.9.1 α-Cyclodextrin 
It is documented that α-cyclodextrin is used to precipitate all plasma lipoproteins, i.e., 
chylomicrons, VLDL, LDL and HDL (238).  In the present study, 1 mL of 20% α-
cyclodextrin solution, 1 mL of PBS or nothing (control) was added to human plasma (2 mL) 
was added either.  The sample was mixed briefly before being centrifuged at 2,000 x g at 4 ℃ 
for 10 min.  The resulting supernate was examined for remaining HDL using 
ultracentrifugation followed by HPLC (Sections 2.2.4 and 2.4.1).  The pellet was washed 
with PBS two or three times, then dialyzed extensively at 4 ℃ against PBS, and finally 
applied to the ELISA for detection of apoA−I (Section 2.7.9). 
2.9.2 Dextran sulfate−MnCl2 
A modified method was used for the stepwise isolation of lipoproteins (239).  Briefly, 5 µL 
of 10% dextran sulfate and 50 µL of 1 M MnCl2 were added to 1 mL of plasma.  For 
controls, 55 µL PBS or nothing was added.  The mixture was centrifuged at 20,000 x g for 30 
min.  The supernate was removed and placed into a different tube to which 10 % dextran 
sulfate (60 µL) and 1 M MnCl2 (150 µL) were added.  After incubation at room temperature 
for 2 h, the mixture was centrifuged again at 20,000 x g for 30 min.  The subsequent 
precipitates were washed with Tris-HCl-NaCl buffer containing 20 mM Tris, 1% NaCl, 0.1% 
dextran sulfate and 0.1 M MnCl2 pH 7.5) and recovered by centrifuging at 6,000 x g for 10 
min.  The precipitate was re-suspended in 160 µL of 2% sodium citrate containing 1% NaCl 
and mixed until solubilized, with the pH being adjusted to 8.0 with NaOH.  The resulting 
turbid mixture was centrifuged again at 6,000 x g for 10 min and the supernate applied to 
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HPLC after ultracentrifugation (Sections 2.2.4 and 2.4.1) or ELISA (Section 2.7.10) for 
further evaluation.  In addition, the supernates obtained from each centrifugation were also 
analyzed separately by HPLC for the un-precipitated HDL after ultracentrifugation (Sections 
2.2.4 and 2.4.1). 
2.9.3 Sodium phosphotungstate-MgCl2  
According to the precipitation method of Burstein et al (239), 100 µL of 4% sodium 
phosphotungstate and 25 µL of 2 M MgCl2 were added to 1 mL plasma.  Control samples 
received 125 µL PBS.  The mixtures were centrifuged immediately at room temperature at 
6,000 x g for 10 min, and the supernate removed to a different tube to which 900 µL of 4% 
sodium phosphotungstate was added.  The mixture was re−centrifuged to remove gamma 
globulins, and the resulting supernate was added to 175 µL of 2 M MgCl2 and incubated at 
room temperature for 2 h before centrifuged at 20,000 x g for 30 min.  The resulting 
precipitate was washed with washing buffer (1% NaCl, 0.4% sodium phosphotungstate, and 
0.1 M MgCl2) and centrifuged at 6,000 x g for 10 min.  The resulting precipitate was 
solubilized in 1% NaCl (70 µL), and followed by the dropwise addition of 10 % sodium 
carbonate.  This mixture was centrifuged again at 6000 x g for 10 min and the supernate, that 
contained HDL and other serum proteins, was collected.  This final supernate was subjected 
to the ELISA (Section 2.7.10).  The first two supernates were also analyzed for any 
remaining HDL by HPLC after the ultracentrifugation (Sections 2.2.4 and 2.4.1).   
2.9.4 Polyethylene glycol 
Briefly, 20% of polyethylene glycol (pH 10) was added to plasma (1:1, vol:vol) and 
centrifuged at 9,500 x g for 5 min (240).  The resulting supernate (containing HDL and other 
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serum proteins) was analyzed by HPLC after the ultracentrifugation (Sections 2.2.4 and 
2.4.1) and ELISA (Section 2.7.10). 
2.9.5 HDL determination kit 
To separate HDL from plasma, the HDL and LDL/VLDL cholesterol quantification kit 
(Biovision, Mountain view, CA, USA) was also used.  Standard protocols for the separation 
of HDL from LDL/VLDL were followed according to the manufacture’s instructions.  In 
brief, 100 µL of plasma was mixed with 100 µL of 2 x Precipitation Buffer and incubated for 
10 min at room temperature before centrifuging at 2,000 x g for 10 min.  The resulting 
supernate containing HDL was subjected to HPLC (Sections 2.2.4 and 2.4.1) and ELISA 
(Section 2.7.10). 
In addition, the supernate obtained from the above precipitation method was also applied to 
SwellGel Blue procedure (Section 2.10) to remove serum albumin prior to subsequent 
assessment by ELISA.   
2.10 Albumin removal using SwellGel Blue column 
SwellGel (SwellGel Blue albumin removal kit, Pierce) was chosen to remove albumin from 
human plasma prior to its application to ELISA.  All human plasma samples were diluted 
(1/10, vol/vol) and then filtered through 0.22 µm filter (Millipore) on ice before loaded onto 
the SwellGel column.  The specific procedures were as follows: One SwellGel column was 
formed by hydrating one SwellGel disc with 380 µL water and briefly mixing, followed by 
centrifugation at 12,000 x g for 1 min to remove excess liquid.  Filtered plasma samples (total 
volume of 100 µL with different dilutions) were loaded onto the column, incubated for 1−2 
min and followed by centrifuging at 12,000 x g for 1 min.  The flow−through was re−applied 
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to the column, the incubation and centrifugation repeated to ensure maximal albumin binding 
to the column.  The resulting (2nd) flow−through was retained.  The column was washed by 
adding different buffers and incubation for another 1-2 min, followed by centrifugation at 
12,000 x g for 1 min.  The washing step was repeated three to four additional times, as 
indicated.  Finally, the eluate (wash) was collected for further use.   
2.10.1 Efficacy of albumin removal 
The efficacy of albumin removal was assessed by applying filtered fresh plasma (10 µL) in a 
total volume of 100 µL SwellGel buffer (Tris 25 mM, NaCl 25 mM, pH 7.4) to the SwellGel 
column.  The flow−through was collected, the column washed with SwellGel buffer (300 
µL).  Subsequently, samples before and after passing through the SwellGel column were 
loaded on SDS−PAGE for assessment of remaining albumin as an indicator of efficacy of 
albumin removal (Section 2.11.3). 
2.10.2 The recovery of apoA−I after albumin removal 
The filtered plasma (10 µL) was added with increasing amount of oxidized HDL (HDLox) 
ranging from 0−15 µg protein, the volume adjusted to 100 µL with SwellGel buffer, and the 
mixture then subjected to a hydrated SwellGel column.  After 2 min incubation at room 
temperature, the columns were centrifuged at 12,000 x g for 1 min and the flow−through 
re−applied to the column to ensure maximal albumin binding.  The columns were centrifuged 
again and the flow−through retained, followed by the column wash with SwellGel buffer 
(300 µL).  Alternatively, the SwellGel column was washed with 100 µL of SwellGel buffer, a 
process repeated five times.  The eluate obtained from each wash was collected into different 
tubes for further assessment by SDS−PAGE/western blot (Section 2.11.4). 
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The recovery of apoA-I from the SwellGel process was optimized by using 400 µL of 
different buffers that varied in ionic strengths for the washing steps, following the initial 
sample loading and centrifugation.  The buffers were 25 mM Tris, pH 7.4 containing 10, 30, 
75, 125, 200 or 300 mM NaCl.  In addition, PBS (pH 7.4) and 1: 10 diluted PBS were also 
used to wash the column.  The resulting second flow−through was collected and combined 
with the 400 µL wash to assess the recovery of apoA−I by SDS−PAGE and Western blot 
(Section 2.11.4).   
2.11 SDS−PAGE and Western blotting 
2.11.1 Confirmation of mAb26 purity 
The purity of mAb26 (MOA−1) collected from FPLC was confirmed by SDS−PAGE 
(Section 2.6.4). 
2.11.2 Immuno−reactivity of MOA−1  
The immno−reactivity of MOA−1 towards different apolipoproteins and their oxidized forms 
was assessed by Western blotting as described in Section 2.12.1. 
2.11.3 Quantification of albumin after SwellGel process   
SDS−PAGE was performed using NuPAGE Novex 10% Bis−Tris gels (Invitrogen) under 
reducing conditions.  Samples before (1 µL) and after (4 µL) albumin removal by the 
SwellGel process were loaded on the gel, and human serum albumin (1 µg) that was not 
passed through the SwellGel process loaded as control.  After electrophoresis (200 V, 400 
mA, 1 h) using MOPS−SDS running buffer (Invitrogen), proteins were stained with 
Coomassie Blue.  The albumin was quantified by comparison of albumin before and after the 
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SwellGel process using Quantity One 1D−analysis software in Gel Doc XR documentation 
system (Bio−Rad). 
2.11.4 Determination of recovery of apoA−I after albumin removal 
SDS−PAGE was performed on NuPAGE Novex using either 10% or 4-12% Bis−Tris gels 
(Invitrogen) under reducing conditions according to the manufacture’s instructions.  Samples 
loaded onto the gel consisted of 1 µL of 10 x diluted plasma with an aliquot (15 − 0 µg 
protein) of the oxidized HDL.  For comparison, 4 µL of combined eluate obtained after the 
SwellGel Blue process, was used (Section 2.10.2). 
To assess the recovery of apoA−I after the SwellGel process with different buffers, 1 µL of 
HDLox−spiked plasma and 5 µL of eluate with different buffers (Section 2.10.2) obtained 
after the SwellGel process, was loaded onto the gel. 
SeeBlue Plus2 (3 µL, Invitrogen) protein standard was loaded onto the gels as 
molecular−weight markers.  After electrophoresis (200 V, 400 mA, 1 h), proteins were either 
stained with Coomassie Blue, or transferred to nitrocellulose membranes (Hybond ECL, 
Amersham Biosciences), and immunoblotted using polyclonal goat anti-human apoA-I 
antibody (Rockland, Gilbertsville, PA, USA) as the primary antibody (1: 4,000 dilution).  
And anti-goat horseradish peroxidase (Sigma, 1: 5,000 dilution) was the secondary antibody.  
Quantification was obtained using Quantity One 1D−analysis software in Gel Doc XR 
documentation system (Bio−Rad). 
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2.12 Characterization of reactivity of MOA−1 
2.12.1 Immuno−reactivity of MOA−1 determined by Western blotting 
Apolipoproteins (20 ng, apoA-I and apoA-II) and their oxidized forms (20 ng, apoA-I+32, 
apoA-I+16 (Met86 or Met112, and apoA-II+16) were loaded onto NuPAGE Novex 4-12% 
Bis−Tris gel (Invitrogen) and the gel electrophoresed (200 V, 400 mA, 1 h) under reducing or 
non−reducing conditions using MOPS−SDS, or MES−SDS (Invitrogen) running buffer, 
respectively.  SeeBlue Plus2 (3 µL, Invitrogen) protein standard was loaded as 
molecular−weight markers.  Following electrophoresis, proteins were transferred to 
nitrocellulose membranes (Hybond ECL, Amersham Biosciences), and immnoblotted using 
either MOA−1 (1: 500 dilution) or goat anti−human apoA−I polyclonal antibody (Rockland, 
1: 4,000 dilution) as the primary antibody.  The secondary antibodies were anti-mouse HRP 
(Sigma, 1: 5,000 dilution) and anti-goat HRP (Sigma, 1:5,000 dilution), respectively.   
2.12.2 Surface Plasmon Resonance 
The surface plasmon resonance is a label-free technology that determines the binding 
specificity between two molecules, quantifies the concentration of a given molecule is active 
and defines both the kinetics and affinity of binding (241).  An array of protein-binding 
samples is immobilized onto a gold-coated glass chip which provides the physical conditions 
necessary for the surface plasmon resonance reaction (Fig. 2.5).  Sample binding is detected 
as mass concentration−dependent changes in refractive-index at that spot, which makes it 
possible to monitor binding in real time (242).  When molecules in the test solution bind to a 
target molecule the mass increases, when they dissociate the mass falls.  This principle forms 
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the basis of the sensorgram (Fig. 2.6).  The rise and fall of refractive index reflects the 
molecule in the test solution binding to, and dissociate from the immobolized protein. 
 
 
 
 
 
Fig. 2.5.  Surface plasmon resonance−based biosensors.  The sensor chip provides a 
gold−coated surface through which minute changes in biomolecule concentration, due to 
molecular binding, are detected in real time.  These changes lead to changes in the reflected 
light that are captured by the optical detection unit and converted to a resonance signal 
(Biacore International AB). 
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Fig. 2.6.  Surface plasmon resonance sensorgram.  As molecules bind to and dissociate 
from the sensor chip surface, the resulting changes in the resonance signal create a 
sensorgram.  The shape and amplitude of the measurements can then be used to determine in 
real-time on specificity of binding, active concentration of molecule in a sample, kinetics and 
affinity (Biacore International AB).   
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The binding of MOA−1 to apolipoproteins was investigated by Biacore’s surface plasmon 
resonance technology performed at 25 ℃ with HBS-N (Biacore AB, Uppsala, Sweden) or 
PBS (filtered through 0.22 µm filter and degassed prior to use) as running buffer using a 
Biacore 2000 instrument (Biacore AB).  HBS-N contains 10 mM N-(2-hydroxyethyl) 
piperazine-N’-(2-ethanesulfonic acid), pH 7.4 and 250 mM NaCl, 3.5 mM EDTA, and 0.05% 
Biacore surfactant P20).  MOA−1 was immobilized onto a CM5 or a SA sensor chip 
(Research grade, Biacore AB), followed by injection of various amounts (10 – 1000 nM) of 
apolipoproteins over the sensor chip.  All apolipoprotein samples were filtered through 0.22 
µm filter (Millipore) prior to injection and each sample was injected over the sensor chip for 
1−2 min before the next injection.  The flow rate was maintained at 20 µL/mL.  Regeneration 
of the sensor surface between assays was performed by the injection of 10 mL of 10 mM 
glycine-HCl pH 3.0. 
To test the effect of HBS−N on MOA−1’s reactivity in the ELISA, HPLC−purified apoA−I, 
apoA−I+32 and apoA−II were dried under vacuum and reconstituted in HBS−N.  
Subsequently, these reconstituted apolipoproteins (0−500 ng/mL) were analyzed by ELISA 
(Section 2.7.2). 
2.12.3 Oxidation of apoA−I, HDL and other Met−containing proteins 
2.12.3.1 Preparation of differently oxidized lipid-free apoA-I 
Lipid-free apoA-I (5 µM) was oxidized at 37 ℃ for 1-24 hours with various oxidants in 20 
mM PBS containing 100 µM DTPA.  Specifically, for the Fenton reaction either FeCl3 (10 
µM) plus H2O2 (5 mM) with 2 h incubation, or FeSO4 (10 µM) plus ascorbic acid (1 mM) 
with 1 h incubation, were used.  The reactions were terminated by addition of 5 mM EDTA.  
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Copper− and iron− induced oxidation was achieved by addition of CuSO4.5H2O (5 µM) or 
FeCl3 (10 µM), respectively, with 2 h incubations and termination of the reaction by addition 
of 5 mM EDTA (5 mM). 
For 2e−oxidants, apoA-I (5 µM) was exposed to either H2O2 (5 mM, 24 h incubation, 
reaction stopped with 200 nM catalase) or HOCl (50 µM, 1 h incubation, reaction stopped 
with 2.5 mM methionine).  Alternatively, apoA−I (5 µM) was incubated with HOCl (50 µM) 
and H2O2 (5 mM) for 1 hour and the reaction stopped with methionine (2.5 mM) and catalase 
(200 nM).  In yet other conditions, apoA−I was incubated with sydnonimine−1 (SIN-1, 1 
mM) for 2 h, and the reaction stopped by addition of 100 µM butylated hydroxytoluene.  
SIN−1 decays spontaneously to generate O2−• and •NO that combine to ONOO− (2).  For 
controls, the reactions were carried out in the absence of oxidants.  Subsequently, aliquots of 
the reaction mixtures were subjected to HPLC (Section 2.4.1) and ELISA (Section 2.7.7). 
2.12.3.2 Preparation of apoA−I mutants and their oxidized forms 
Wild type apoA-I and mutants with one, two or three of the Met residues replaced with Leu 
residues were expressed in E. coli as described.  Individual substitution mutations within 
human apoA-I cDNA were introduced by primer-directed PCR mutagenesis or mega-primer 
PCR.  All mutations were verified by dideoxy automated fluorescent sequencing of cDNA, 
and confirmed by MS analysis of the protein (106,243).  These mutants (5 µM) were then 
exposed to 20 mM phosphate buffer pH 7.4 containing 100 µM DTPA without (control) or 
with H2O2 (50 mM) at 37°C for 24 hours to convert the remaining Met residue(s) to the 
corresponding MetO.  The reaction was terminated by addition of 200 nM catalase (to 
scavenge remaining H2O2) and 10 mM methionine (to inhibit further oxidation).  Mutated 
native and oxidized forms of apoA-I were then subjected to HPLC and ELISA as described 
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above.  The formation of MetO was confirmed by LC-ESI-MS/MS analysis of tryptic or Glu-
C digests of oxidized apoA-I protein and the product yield of individual MetO residues was 
determined with reconstructed ion chromatograms of product and precursor peptides as 
described (244).  These native and oxidized wild type and mutant apoA−Is were prepared in 
the laboratories of Professor Heinecke (University of Washington, Seattle, WA, USA) and Dr 
Oda (Children’s Hospital Oakland Research Institute, Oakland, CA, USA) and then were 
shipped to Sydney for ELISA (Section 2.7.6) and HPLC analyses (Section 2.4.1). 
2.12.3.3 Oxidation of HDL, LDL and other Met-containing proteins with 2e− oxidants 
Native HDL (1 mg protein /mL) or 1 mg protein /mL of LDL, BSA, myoglobin, ferritin or 
fibrinogen were oxidized at 37°C in 20 mM PBS containing 100 µM DTPA with either H2O2 
(100 mM) or HOCl (500 µM).  The mixtures were incubated for 24 h (H2O2) or 1 h (HOCl) 
and the reactions terminated by addition of catalase (200 nM, for H2O2) or methionine (2.5 
mM, for HOCl), respectively.  Controls for each protein oxidation were carried out in the 
absence of the respective oxidant. 
For ELISA, serial dilutions of each reaction mixture were added in appropriate wells in PBS 
containing 2% BSA (Section 2.7.9).  For HPLC analysis, reaction mixtures were subjected to 
HPLC after gel filtration using NAP-10 columns (Section 2.4.1).   
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2.13 Clinical samples  
2.13.1 Fletcher−Challenge Study 
The parent study for the nested study was the Fletcher−Challenge cohort study of New 
Zealand (245).  Samples of EDTA plasma (2 mL) were taken at baseline and stored at –70 °C 
in the presence of butylated hydroxytoluene (22 µg/mL).  Prospective follow-up of the 
10,529 subjects used national record linkage systems.  For the nested study, cases were all 
members of the study who had CHD, defined as a fatal coronary event or non–fatal hospital-
diagnosed myocardial infarction, during the follow-up period (median 5.6 y).  In total, 227 
cases were identified.  For each case, between 1 and 3 (mean 1.9) matched controls were 
randomly sampled; anyone who became a case after the date of the index case’s coronary 
event was eligible for selection as a matched control, and controls could be matched with 
more than one case (246).  Matching variables were age, sex and study (occupational or 
general population).  In total, 420 unique subjects without CHD (“unique controls”) were 
identified.  Age was matched, to the index case, within one year for all but 3 controls, these 
being matched within five years.  Patients provided informed consent and ethics approval was 
provided by the University of Sydney. 
2.13.2 Pilot clinical study 
Fresh blood (10 mL) was collected into heparin vacutainers from 15 adult patients aged over 
20 referred for coronary angiography or angioplasty at the Eastern Heart Clinic, Prince of 
Wales Hospital (Sydney, NSW, Australia).  This procedure was performed via a 6−French 
catheter sheath inserted into either the right or left femoral artery.  Blood (10 mL) was 
withdrawn from this femoral arterial sheath at the start (before) and again at the end (after) of 
the procedure.  The blood samples were then centrifuged at 1,430 x g for 20 min at 4 ℃, 
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aliquot (1 mL), and stored at –80 ℃ for subsequent analysis.  Patient demographic and 
clinical data, as well as angiographic findings to determine the presence and absence of CAD 
were collected.  From this angiographic findings, three group of subjects (n=15) including 
control (n=5), CAD patients without angioplasty (n=5), and CAD patients post angioplasty 
(n=5) were chosen.  
Control subjects had coronary arteries that appear completely normal, i.e., no stenos is, nor 
any obvious luminal irregularities that may have reflected early atherosclerosis.  CAD 
patients were defined as those with aerodynamically significant stenosis (diameter of arterial 
lumen narrowed by > 70%) affecting at least one of three main epicardial coronary arteries.  
These patients were divided into those that underwent just diagnostic angiography (CAD) or 
those that received therapeutic angioplasty (CAD+PCI).  
This study was approved by the local human ethics committee.  Patients were given an 
information sheet explaining the study, and consented by an authorized member of the 
research team prior to the procedure.  All analytical procedures were carried out in a blinded 
manner. 
2.14 Statistical analyses 
Results are shown as mean ± standard deviation unless stated otherwise.  Inter−assay and 
intra−assay variation were determined during the development of the ELISA.  For this, 
samples were analyzed on at least four separate occasions, each in triplicate.  The Wilcoxon 
rank sum test was selected for statistical analysis of clinical data.  A p− value of <0.05 was 
considered statistically significant. 
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For the Fletcher−Challenger study, the cases and unique controls were compared.  For 
continuous variables, t-tests after transformations to better approximate normal distributions 
were used.  Spearman rank correlations were calculated after adjustment for age and sex, to 
compare markers of antioxidant stress with each other and with coronary risk factors.  Odds 
ratios for CHD were estimated from conditional logistic regression models (246), using the 
matched sets as units of observation.  As sensitivity analyses, odds ratios were obtained 
separately for subjects without CHD at baseline. 
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Summary 
The role of oxidative damage in the etiology of coronary disease remains controversial; 
clinical trials investigating the effect of antioxidants have not generally been positive.  In the 
present study, 227 coronary cases, identified during follow-up of a cohort study, were 
matched, by age and sex, with 420 controls in a nested case-control design.  Stored plasma 
samples were analyzed for F2-isoprostanes by stable isotope dilution MS, and specifically 
oxidized forms of apoA-I containing MetO by HPLC analysis of HDL.  Median values of 
F2-isoprostanes were higher in plasma samples that contained oxidized MetO−containing 
apoA-I compared to samples with undetectable oxidized apoA-I (1542 v 1165 pmol/L; 
p=0.003).  F2-Isoprostanes were significantly correlated with variants of non-oxidized 
apoA-II (r=−0.15) and HDL cholesterol (r=0.21).  F2-isoprostanes in cases (median, 1146 
pmol/L) were not significantly different (p=0.75) from controls (1250 pmol/L).  The odds 
ratio (95% confidence interval) for a one standard deviation increase in F2-isoprostanes was 
1.08 (0.91-1.29).  Similarly, there was no independent association between the presence of 
3 Chapter 
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MetO−containing apoA-I, detected in ~20% of the samples, and coronary risk.  In conclusion, 
elevated levels of F2-isoprostanes in plasma sample contain MetO−containing apoA-I.  
Markers of lipid (F2-isoprostanes) and protein (MetO−containing apoA-I) oxidation are not 
associated with CHD risk in a general population. 
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3.1 Introduction 
HDL is thought to protect against CHD by promoting reverse cholesterol transport and by 
antioxidant, anti-inflammatory, and anti-thrombotic effects (173).  HDL may aid the 
detoxification of pro-atherogenic oxidized lipids (168).  CETP transfers oxidized lipids from 
LDL to HDL (247), and HDL’s apolipoproteins reduce LOOH to the corresponding alcohols 
(48), thereby decreasing the likelihood of additional oxidation reactions.  In addition, 
oxidized lipids associated with circulating HDL are rapidly removed by the liver (166,248). 
HDL is also subject to oxidation.  In vitro, HDL lipids are oxidized in preference to those of 
LDL (168).  In human atherosclerotic lesions, HDL lipids are oxidized to an extent 
comparable to that of LDL (70,91).  Such oxidized HDL could conceivably re-enter 
circulation, as HDL is smaller than LDL and is comparatively less retained via interaction 
with extra-cellular matrix in the vessel wall.  Indeed, there is evidence for the presence of 
oxidized HDL in the circulation of subjects with atherosclerotic disease (108,220,227).  
ApoA-I and apoA-II are the major proteins of HDL.  HDL can chemically reduce LOOH in a 
reaction accompanied by the conversion of specific Met residues of apoA-I and apoA-II to 
MetO (50,102).  Similarly, and independent of the nature of the oxidant involved, apoA-I+16 
(apoA-I containing MetO86 or MetO112), apoA-I+32 (containing MetO86 and MetO112) and 
apoA-II+16 accumulate as HDL lipids become peroxidized (103).  Therefore, these specific 
forms of oxidized apoA-I and apoA-II containing MetO may be useful markers of in vivo 
HDL oxidation and hence, possibly, atherosclerosis (103). 
F2-Isoprostanes are stable secondary oxidation products of arachidonic acid commonly used 
as markers of in vivo lipid oxidation (126).  There is good evidence from animal models of 
free radical injury and human conditions associated with increased oxidative stress that when 
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determined in plasma or urine by suitable mass spectrometric methods, F2-isoprostanes 
provide a reliable measure of in vivo oxidative stress. 
To date, few prospective epidemiological studies of CHD have considered the diagnostic 
value of markers of oxidative damage.  The present study was to test the usefulness of 
MetO−containing apoA−I as a marker for oxidative damage and CHD.  Samples from a 
nested case-control study were analyzed by HPLC and GC−MS to also investigate the 
association between CHD and markers of protein (apoA-I+16, apoA-II+16 and apoA-I+32) and 
lipid oxidation (F2-isoprostanes) in a general population.   
3.2 Materials and Methods 
Samples of EDTA plasma were taken from subjects in Fletcher−Challenge cohort study in 
New Zealand with the average follow−up of 5.6 years.  The subjects’ information, sample 
collection and storage details are described in Section 2.13.1. 
All plasma samples were thawed once only with all reagents details are as described in 
Section 2.1.4.  HDL was isolated from plasma of subjects using density gradient 
ultracentrifugation as described in Section 2.2.5, followed immediately by HPLC analysis of 
apolipoproteins as described in Section 2.4.2.  All apolipoproteins were quantified by peak 
area comparison with HPLC−purified apolipoprotein standards.  The preparation of these 
standards is detailed in Section 2.4.3.  The identity of these apolipoprotein standards, 
including characterization of three distinct species of apoA−II, were verified by electrospray 
ionization MS as described in Section 2.5.1.  The proportion of MetO−containing apoA−I 
and apoA−II was expressed as percentage of the corresponding total apolipoprotein.  Intra- 
and inter-assay variations for all oxidized apolipoproteins were comparable and, e.g., were 
5.2 and 9.3% for apoA-I+32, respectively. 
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Plasma levels of F2-isoprostanes were determined as described in Section 2.5.2. 
The measurements of other variables including fibrinogen, high-sensitivity C-reactive protein 
and interleukin-6 are mentioned in Section 2.8.  Respective statistical methods are described 
in Section 2.14. 
3.3 Results 
Due to limited plasma, some results were incomplete.  Apolipoprotein variables and 
F2-isoprostanes were measured, respectively, on 205 and 227 of the 227 cases and on 334 and 
417 of the 420 unique controls.   
3.3.1 Confirmation of native forms of apoA-I and apoA-II in HDL 
Native and oxidized forms of the major apolipoproteins were determined by applying HDL 
isolated from plasma of healthy subjects to gradient HPLC, collecting the corresponding 
fractions and subjecting them to mass spectrometry analysis.  Native apoA-I and apoA-II 
were well separated with retention times of ~31 and ∼40 min for apoA-I and apoA-II, 
respectively (Fig. 3.1A).  The mass determined by ESI-MS were 28,079 Da for apoA-I (Fig. 
3.2A) and 17,379, 17,251 and 17,123 Da for the three distinct variants of apoA-II, i.e., 
apoA-II-1, apoA-II-2 and apoA-II-3, respectively (Fig. 3.2B).  ApoA-II exists as a disulfide-
linked homodimer, and several distinct variants have been reported recently (249).  The 
variant with the largest molecular mass was previously assigned to apoA-II homodimer with 
both N-terminal Glu residues cyclized (predicted mass 17,381.8 Da)(250).  Based on the mass 
changes, the two variants with lower molecular mass were assigned previously to apoA-II 
with one or both of the C-terminal Glu residues removed (predicted masses 17,253.6 and 
17,125.4 Da, respectively) (103). 
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Fig. 3.1.  Typical HPLC traces of native and peroxyl radical-oxidized HDL.  HDL was 
isolated and then subjected to HPLC analysis without and with prior oxidation with AAPH (1 
mM, 37 °C, 3 h) as described in Section 2.3.  A, native HDL (0.06 mg protein injected) 
contains apoA-I and apoA-II as major proteins.  B, oxidized HDL (1 mg protein injected) 
contains oxidized forms of apoA-I and apoA-II in addition to apoA-I and apoA-II.  The 
oxidized forms detected include (in order of elution) apoA-I+32 (containing MetO86 and 
MetO112), apoA-I+16 (MetO112), apoA-I+16 (MetO86), and apoA-II+16 (containing one of the 
two Met26 of apoA-II dimer as MetO).  For assignment of the different peaks see references 
(50,102,103,251). 
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Fig. 3.2.  Mass spectra of native apoA-I and apoA-II.  An applied Biosystems mass 
spectrometer (API Q Star hybrid TOF) was used for the analyses.  The mass determined by 
ESI-MS was 28,079 Da for apoA-I (A) and 17,379, 17,251 and 17,123 Da for the three 
distinct variants of apoA-II, i.e., apoA-II-1, apoA-II-2 and apoA-II-3, respectively (B). 
 
B 
A 
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For the present study, mass spectrometric analyses of freshly and rapidly HPLC-isolated 
apoA-II-1 and apoA-II-2 variants were also carried out; there was insufficient material 
available to characterize apoA-II-3.  These analyses showed that in freshly isolated apoA-II 
variants, cyclyzation of Glu was not a major process (Table 3.1), indicating that cyclization 
of the C-terminal Glu residue of apoA-II is an in vitro artifact that occurs during prolonged 
storage of the protein.  The masses of the major components contained in apoA-II-1 and 
apoA-II-2 were 17411, 17283, 17155 and 17054 Da, corresponding to the expected masses of 
full-length dimeric apoA-II, dimeric apoA-II with one (apoA-II-Q) or two Glu residue(s) lost 
(apoA-II-2Q), and dimeric apoA-II with two Glu and one Thr residue(s) lost (apoA-II-2Q & 
T), respectively.  Chemical reduction of apoA-II-1 and apoA-II-2 produced monomers with 
masses of 8706, 8758 and 8477 Da (Table 3.1).  These masses also correspond to monomeric 
apoA-II, apoA-II-Q, and apoA-II-Q & T, respectively.  The chemical nature of the 
modifications were confirmed after partial tryptic digestion, comparison of experimental with 
theoretical masses and tandem MS.  In all experiments, ions from the partial tryptic peptide 
apoA-II1-28 (m/z 3235.5) were observed, whereas loss of Glu from the N-terminus would have 
produced an ion with an m/z of 3107.5.  Consistent with the C-terminal Glu being lost, the 
m/z of the full-length C-terminal apoA-II56-77 peptide derived from apoA-II-1 was 2385.1 
whereas that of the apoA-II56-76 peptide was 2257.0.  Similarly, peptides with masses 
corresponding to apoA-II56-77 (m/z 2385.2), apoA-II56-76 (m/z 2257.6) and apoA-II56-75 (m/z 
2155.6) were detected after digestion of fraction 2.2 (Table 3.1).  The sequences of these 
peptides were confirmed after tandem mass spectrometry of selected precursor ions (not 
shown).  Together, these results unambiguously identify apoA-II-1 and apoA-II-2 as apoA-II 
isomers with the C-terminal Glu and Glu plus Thr residues lost, respectively. 
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Table 3.1.  Mass spectrometric analysis of apoA-II isomers 
Compound ApoA-II-1 ApoA-II-2 Theoretical Mass 
ApoA-II dimer 17411 - 17414 
ApoA-II dimer-Q 17283 17283 17286 
ApoA-II dimer-2Q - 17155 17158 
ApoA-II monomer 8706 8707 8708 
ApoA-II monomer-Q 8578 8578 8580 
ApoA-II monomer-Q&T - 8477 8479 
ApoA-II1-28 3235.8 3235.6 3235.5 
ApoA-II56-77 2385.1* 2385.2* 2382.2 
ApoA-II56-76 2257.0* 2257.6* 2257.1 
ApoA-II56-75 - 2155.6* 2156.1 
 
ApoA-II-Q, apoA-II-2Q and apoA-II-Q&T respectively refer to apoA-II with 1 Glu, 2 Glu 
and 1 Glu plus Thr residue lost.  *Fragmentation spectra of [M+3H]3+ precursor ions were 
consistent with sequences.   
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3.3.2 Confirmation of oxidized forms of apoA-I and apoA-II in HDL 
A typical chromatogram obtained from AAPH-oxidized HDL is shown in Fig. 3.1.  ApoA-I 
contains three Met residues of which Met86 and Met112 become oxidized to MetO during the 
early stages of oxidation of HDL (102,103).  Three new apoA-I-derived peaks eluted before 
apoA-I and corresponded to oxidized apoA-I, two of them with an increase in mass of 16 Da 
(designated as apoA-I+16) and the third with a mass of 32 Da heavier than apoA-I (referred to 
as apoA-I+32).  ESI and MALDI-TOF analysis of native and selectively oxidized apoA-I and 
Met-containing peptides derived from them (103) revealed that the mass increases were due 
to the oxidation of one or both Met residues 86 and 112 to MetO.  ApoA-I+32 (Met86 and 
Met112) was detected only in samples that also contained apoA-I+16 (Met112, eluting at 
~24 min) (Fig. 3.1B).  ApoA-II dimer contains two Met residues (Met26 in each apoA-II 
monomer) and oxidation of HDL leads to the formation of apoA-II+16 and apoA-II+32 (Fig. 
3.1B).  As the latter co-elutes with non-oxidized apoA-I (50,102), apoA-II+16 was only 
quantified.  Overall, the results obtained with native and oxidized HDL were consistent with 
previous reports (50,102,103). 
3.3.3 Presence of oxidized apolipoproteins in plasma 
HDL, isolated from a total of 534 samples, was analyzed by HPLC.  Similar to HDL of 
freshly prepared plasma obtained from healthy volunteers, HDL of all Fletcher−Challenge 
plasma samples contained native apoA-I and apoA-II as the two major proteins (Fig. 3.3A).  
In addition, 116 (22 %) of the samples also contained apoA-I+16 (Fig. 3.3B), with the 
percentage of apoA-I present as apoA-I+16 ranging from 3 to 45 %.  This apoA-I+16 was 
present exclusively as MetO86, whereas apoA-I+16 (MetO112) was not seen.  Only 9 (1.7 %) of 
the samples contained apoA-I+32 and in only three of these apoA-I+32 co-existed with 
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apoA-I+16 (Fig. 3.3C).  In the samples that contained apoA-I+32, the proportion of apoA-I 
present as apoA-I+32 ranged from 22 to 77 %.  As was the case for apoA-I+16 (MetO112), 
apoA-II+16 was not detected in any of the samples analyzed.   
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Fig. 3.3.  Typical HPLC traces of HDL samples isolated from plasma.  A, sample 
containing no oxidized apoA-I; B, sample containing apoA-I and apoA-I+16; and C, sample 
containing apoA-I and apoA-I+32. 
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3.3.4 Epidemiological analyses 
Of the biochemical markers, only F2-isoprostanes, apoA-II-1 and apoA-II-2 had a continuous 
distribution; the remaining variables had few non-zero percentages and were thus analyzed as 
dichotomous variables (zero/non-zero percentage).  There were significant differences 
between the cases and controls in coronary risk factors, with total cholesterol, triglycerides, 
fibrinogen, body mass index, percentage smoking, interleukin-6 and CRP all being 
significantly higher, and HDL significantly lower, in the cases (Table 3.2).  In contrast, there 
was no evidence of any difference (P>0.05) between cases and controls for any of the 
oxidative stress variables. 
Average values of F2-isoprostanes, after transformation, were significantly higher in samples 
with non-zero values for apoA-I+16 compared to those with zero values (medians: 1576 v 
1178 pmol/L; P=0.02); similarly for apoA-I+16 + apoA-I+32 (1542 v 1165 pmol/L; P=0.003).  
The comparison for apoA-I+32 was not significant (P=0.14), but this was likely due to the 
small number (9) of non-zeros, since mean F2-isoprostanes were higher in the non-zeros than 
the zeros (1484 v 1226 pmol/L).  Unexpectedly, F2-isoprostanes were significantly positively 
related to apoA-II-1 (r=0.09; P=0.03) and negatively related, with virtually identical strength, 
to apoA-II-2 (r=-0.10; P=0.02).  There was no evidence of an association between 
F2-isoprostanes and apoA-II-3 (P=0.89). 
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 Table 3.2.  Summary measures for unique controls and cases 
Note: age and sex were matched 
 
Variable Controls Cases 
Continuous variables n min median max  n min median max 
Age (years) 420 19 57 85  227 20 58 85 
Systolic blood pressure (mmHg) 420 91 132 200  227 82 135 198 
Total cholesterol (mmol/L) 419 3.1 5.5 8.9  226 2.9 5.9 11.5 
HDL cholesterol (mmol/L) 409 0.47 0.94 2.31  211 0.41 0.83 2.33 
Triglycerides (mmol/L) 409 0.30 1.49 6.48  211 0.39 1.68 18.18 
Body mass index (kg/m2) 420 16.8 26.0 45.9  226 17.0 26.7 44.1 
Fibrinogen (g/L) 411 1.56 3.20 5.10  223 1.37 3.45 7.19 
Interleukin-6 (pg/mL) 372 0.12 1.29 20.00  204 0.25 1.78 20.00 
CRP (mg/L) 360 0.16 1.10 39.00  200 0.16 1.87 123.00 
F2-Isoprostanes (pmol/L) 417 255 1250 65287  227 332 1146 49666 
Apo-II-1 (%) 334 0.0 33.6 100.0  205 0.0 34.7 100.0 
Apo-II-2 (%) 334 0.0 60.9 84.9  205 0.0 62.0 96.8 
Categorical variables n %    n %   
Male sex 325 77    175 77   
Current smokers 74 18    55 24   
Ex-smokers 169 40    105 46   
ApoA-I+16 (positive) 67 20    49 24   
ApoA-I+32 (positive) 7 2    2 1   
ApoA-I+16+apoA-I+32 (positive) 71 21    51 25   
ApoA-II-3 (positive) 43 13    20 10   
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There were few significant correlations between coronary risk factors and the continuous 
biochemical markers (Table 3.3), except for HDL which was correlated with F2-isoprostanes 
(positively) and apoA-II-1 (negatively).  The only other significant correlations were positive 
ones between F2-isoprostanes and body mass index (P=0.03) and total serum cholesterol 
(P=0.02).  The only significant coronary odds ratio was for apoA-II-1 (Table 3.4): the odds 
of CHD rose by 9% (95% confidence interval: 1 to 17%) for every extra 10-percentage 
points.  This significance was lost after adjustment for other coronary risk factors; indeed, it 
became non-significant (P=0.08) after adjustment for fibrinogen alone, indicating that 
apoA-II-1 was not an independent predictor of CHD.   
At baseline, 19% of the cases, but none of the controls, had already experienced a heart 
attack.  Removing these 43 cases, and their matched controls, made no appreciable changes 
to the odds ratios, before or after adjustments for potential confounding factors (Table 3.4). 
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Table 3.3. Age and sex-adjusted linear regressions between continuous markers of oxidative stress and coronary risk factors.  Results 
shown are the slope of the fitted line (after transforming the dependent variable, as indicated) the p value (in parentheses) for the adjusted 
significance of the risk factor and R2, the percentage of variation in the dependent variable explained by the regression. 
 
Dependent variable 
(transformation) 
Systolic 
BP            
Total 
cholesterol 
HDL 
cholesterol 
Triglycerides Body mass  
index 
Fibrinogen IL-6 C-reactive  
protein 
F2-Isoprostanes -0.0019 0.0666 0.4389 0.0075 0.0240 0.0330 0.0116 -0.0016 
(log, base e) (0.23) (0.01) (<0.0001) (0.73) (0.002) (0.44) (0.25) (0.71) 
 19% 20% 21% 18% 21% 20% 19% 20% 
ApoA-II-1 -0.0002 -0.0198 A* -0.0092 0.0067 0.0552 0.0118 0.0028 
(raised to power 1/3) (0.87) (0.39)  (0.63) (0.32) (0.13) (0.18) (0.46) 
 2.2% 2.4%  2.2% 2.4% 3.0% 2.6% 2.8% 
ApoA-II-2 201 4450 29541 2543 -686 -1032 -473 B* 
(raised to power 3) (0.56) (0.43) (0.19) (0.59) (0.68) (0.91) (0.83)  
 2.2% 2.3% 2.5% 2.3% 2.2% 2.3% 2.3%  
 
BP= blood pressure.  *Blanks appear where there was a significant interaction with case/control status.  Values, by case/control status were then: 
A - controls: -0.2791, (0.01), 3.1%, cases: -0.6735, (<0.0001), 13%; B – controls: -6786, (0.01), 3.7%, cases: 562, (0.60), 2.8%.  All other results 
are for all participants taken together. 
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Table 3.4.  Odds ratios (95% confidence intervals) for CHD 
 All subjects  Subjects free of CHD1 
Variable Unadjusted2 Adjusted3  Unadjusted2 Adjusted3 
F2-Isoprostanes (pmol/L)     
1st third (254-954) 1 1  1 1 
2nd third (955-1538) 1.31 (0.87-1.97) 1.35 (0.73-2.52)  1.41 (0.88-2.26) 1.36 (0.66-2.76) 
3rd third (1539-65288) 1.04 (0.64-1.71) 0.88 (0.40-1.95)  1.16 (0.67-2.00) 0.93 (0.39-2.24) 
Continuous4 1.02 (0.98-1.06) 1.04 (0.93-1.15)  1.02 (0.98-1.06) 1.04 (0.93-1.16) 
      
ApoA-I+16 (+ve v –ve) 1.24 (0.81-1.89) 1.08 (0.57-2.02)  1.31 (0.83-2.08) 1.15 (0.57-2.34) 
ApoA-I+32 (+ve v –ve) 0.57 (0.12-2.75) 0.41 (0.03-6.16)  0.67 (0.14-3.30) 0.32 (0.01-7.36) 
ApoA-I+16 + apoA-I+32  
(+ve v –ve) 
1.24 (0.81-1.89) 1.05 (0.56-1.95)  1.30 (0.82-2.06) 1.10 (0.55-2.22) 
ApoA-II-3 (+ve v –ve) 0.68 (0.38-1.20) 0.76 (0.31-1.84)  0.57 (0.29-1.10) 0.51 (0.18-1.44) 
      
ApoA-II-1 (%)      
1st third (0-29.13) 1 1  1 1 
2nd third (29.14-40.10) 1.28 (0.83-1.98) 1.09 (0.58-2.05)  1.38 (0.85-2.24) 0.98 (0.49-1.94) 
3rd third (40.11-100) 1.42 (0.93-2.17) 1.12 (0.58-2.18)  1.46 (0.91-2.37) 1.11 (0.50-2.46) 
Continuous5 1.09 (1.01-1.17) 1.03 (0.91-1.15)  1.09 (1.00-1.19) 1.01 (0.88-1.16) 
      
ApoA-II-2 (%)      
1st third (0-52.10) 1 1  1 1 
2nd third (52.11-67.23) 1.10 (0.72-1.68) 1.32 (0.72-2.42)  1.20 (0.76-1.91) 1.55 (0.77-3.11) 
3rd third (67.24-96.79) 0.95 (0.61-1.48) 1.21 (0.66-2.20)  1.05 (0.64-1.73) 1.39 (0.68-2.84) 
Continuous5 0.96 (0.89-1.03) 1.02 (0.91-1.14)  0.98 (0.90-1.07) 1.06 (0.92-1.21) 
1Without CHD at baseline.  2Matched for age and sex.  3Adjusted for smoking status 
(current/ex/never), systolic blood pressure, body mass index, total cholesterol, HDL-
cholesterol, triglycerides, fibrinogen, interleukin-6 and C-reactive protein, as well as for age 
and sex by matching.   4For an increase of one inter-quartile range in unique controls (1013 
pmol/L).  5For an increase of ten percentage points.   
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3.4 Discussion 
This prospective study shows the expected relationships between CHD and several 
established coronary risk factors, including body mass index, cholesterol, CRP, HDL and 
smoking.  However, it was not able to demonstrate any association between CHD and plasma 
markers of lipid or protein oxidation, namely F2-isoprostanes and HDL-associated, 
selectively oxidized apoA-I and apoA-II, respectively.  This is the first study examining the 
relationship between markers of oxidative damage and CHD outcome in a prospective study 
in a healthy population.  The present study shows that the parameters used to assess oxidative 
stress do not predict CHD.  Therefore, oxidants that generate these particular markers in high 
yield do not significantly contribute to CHD outcome.  However, the results demonstrate the 
correlation between F2-isoprostanes and oxidized apoA−I, indicating potential usefulness of 
oxidized apoA−I as a marker for oxidative stress and/or CHD. 
F2-Isoprostanes are considered the ‘gold standard’ marker of oxidative stress (204).  The 
plasma levels of F2-isoprostanes in this study were similar to plasma isoprostanes measured 
in freshly collected plasma from recent human studies (252), indicating that samples were 
well preserved during storage and free from artifactually high levels of lipid peroxidation 
products.  A previous matched case-control study suggested that urinary F2-isoprostanes may 
be a risk marker for CHD (253).  However, samples were collected after the development of 
disease so that it is impossible from that study to determine if F2-isoprostanes are a predictor, 
or a result, of CHD.  In a cohort of healthy young adults, coronary artery calcium was more 
likely in subjects with high rather than low plasma F2-isoprostanes (254).  However, only 
10% of the cohort had detectable disease, and the data do not support the proposal that 
plasma F2-isoprostanes are predictive of future severe CHD.  Finally, in a study of 298 
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healthy adults, sex was the strongest predictor of plasma F2-isoprostanes, followed by 
smoking and CRP (255).  In this study, cases and controls were matched for age and sex, and 
no significant relationship with CRP was seen. 
The relative and independent contribution of coronary risk factors to systemic oxidative stress 
in a general population has been assessed previously (256).  Smoking, diabetes and body 
mass index were highly associated with oxidative stress, determined by urinary 8-epi-
prostaglandin F2α.  In agreement with that study, the present study showed a positive 
relationship between body mass index and F2-isoprostanes.  Interestingly, there was a strong 
positive association of plasma F2-isoprostanes with HDL, in keeping with the positive 
correlation between plasma F2-isoprostanes and HDL-cholesterol as well as oxidized HDL 
apolipoproteins.  It is also consistent with the finding that in healthy subjects the majority of 
LOOH (168) and F2-isoprostanes (167) reside in HDL. 
Importantly, the relationship, if any, between F2-isoprostanes and protein oxidation is not 
known, yet protein oxidation could be important because it occurs during atherogenesis (67), 
and there is mounting evidence that HDL oxidation contributes to disease outcome (108,257).  
Therefore, a measure of protein oxidation that reflects HDL lipid oxidation independent of 
the oxidant species involved was employed (50,102).  The latter is an important consideration 
as the oxidant(s) responsible for protein oxidation in human atherosclerosis remain poorly 
characterized (1).  However, the data showed that, similar to plasma F2-isoprostanes, the type 
of protein oxidation assessed does not predict CHD.  Additional studies are required to 
determine whether this extends to other markers of HDL protein oxidation, such as 
chlorinated and/or nitrated species of apoA-I, of which several different types have been 
characterized and reported to be present in atherosclerotic lesions or circulation (109,110). 
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Unfortunately, a ‘gold standard’ for in vivo protein oxidation is presently not available.  The 
method used here is complex, although in vitro artifacts occurring during HDL isolation are 
not likely to explain the absence of association between CHD and oxidized HDL proteins.  
This is because the good internal correlation between markers of plasma lipid and HDL 
protein oxidation observed in the study: plasma F2-isoprostanes were significantly higher in 
samples that contained oxidized HDL proteins, whereas such correlation would not be 
expected if substantial oxidation of HDL occurred during its isolation.  Also, the samples 
used here were stored in the presence of an antioxidant that associates with and prevents 
HDL lipid oxidation and hence formation of apoA-I+16 and apoA-I+32 (50,102).  In addition, 
the pattern of oxidized forms of apoA-I detected in the study samples differed greatly from 
that seen with in vitro oxidized HDL.  Specifically, in in vitro oxidized HDL apoA-I+32 
always co-exists with apoA-I+16, independent of whether apolipoprotein oxidation is induced 
indirectly via LOOH (compare Fig. 3.1B with Fig. 3.2) or directly via a 2-electron oxidant.  
Therefore, the findings suggest, for the first time, that apoA-I+16 and apoA-I+32 are potential 
useful general markers for in vivo protein oxidation.  A limitation of this study is that only 
22% of the 534 HDL samples analyzed contained apoA-I+16 and/or apoA-I+32.  There might 
be more of samples have apoA−I containing MetO, but these are merely below the detection 
limit of the method employed.  In following Chapter 4, the detection limit of HPLC assay 
for apoA−I containing MetO is found about 1 µg protein/mL.  To explore the usefulness of 
oxidized apoA−I as a marker for in vivo protein oxidation, and hence, atherosclerosis, a more 
sensitive detection method for oxidized apoA−I is needed.   
An unexpected finding of the present study was that increases in apoA-II-1 were associated 
with significantly elevated risk of CHD.  Little is known about the function of apoA-II, 
although in vitro apoA-II can affect hepatic lipase, LCAT and CETP, and there is evidence 
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suggesting an association between apoA-II and insulin hypersensitivity (258).  Even less is 
known about the potential role of apoA-II variants, although it is increasingly appreciated that 
circulating apoA-II exists in different forms.  This study is the first to document a potential 
negative association between CHD and circulating apoA-II without its C-terminal Glu 
residue.  There is no explanation for this putative association at this stage.  In its simplest 
interpretation it may suggest a relationship between CHD and carboxypeptidases.  The 
inverse relationship between CHD and apoA-II-I disappeared after controlling for established 
coronary risk factors, and even after controlling for fibrinogen alone.  This indicates that 
apoA-II-I is not an independent risk factor for CHD, and that there could be a relationship 
between apoA-II-I and thrombosis. 
In conclusion, the markers of lipid and protein oxidative stress investigated, F2-isoprostanes 
and oxidized apoA-I and apoA-II containing MetO, are not associated with an increased risk 
of CHD in a general population.  Importantly, high levels of F2-isoprostanes in plasma 
sample contain oxidized apoA-I indicating the potential usefulness of oxidized apoA−I 
(containing MetO) as a marker for oxidative stress and/or CHD.   
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Summary 
Oxidized HDL has been proposed to play a key role in atherogenesis.  A wide range of 
reactive intermediates oxidizes Met residues to MetO in apoA-I, the major HDL protein.  
These reactive species include those produced by MPO, an enzyme implicated in 
atherogenesis.  The aim of the present study was to develop a sensitive and specific ELISA 
for detecting MetO residues in HDL.  Therefore, mice were immunized with HPLC-purified 
human apoA−I containing MetO86 and MetO112 (termed apoA−I+32), to generate a 
monoclonal antibody termed MOA−I.  An ELISA using MOA−I detected lipid-free 
apoA−I+32, apoA−I modified by 2e−oxidants (H2O2, HOCl, ONOO−), and HDL oxidized by 
1e− or 2e−oxidants and present in buffer or human plasma.  Detection was concentration-
dependent, reproducible, and exhibited a linear response over a physiologically plausible 
range of concentrations of oxidized HDL.  In contrast, MOA−I failed to recognize native 
apoA−I, native apoA−II, apoA−I modified by hydroxyl radical or metal ions, or LDL 
modified by 2e−oxidants.  Because the ELISA developed in this study specifically detects 
 
4 Chapter 
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apoA−I containing MetO in HDL and plasma, it may provide a useful tool for investigating 
the relationship between oxidized HDL and CAD. 
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4.1 Introduction 
Atherosclerosis is characterized by heightened oxidative damage to lipids and proteins in the 
affected arterial wall (1), and the extent of this damage is comparable for different classes of 
lipoproteins including LDL and HDL (91).  Recent interest has focused on the functional 
consequences of HDL oxidation.  Oxidation could conceivably contribute to the formation of 
dysfunctional HDL, proposed to be present in humans with CVD (173).   
One potentially important pathway for generating dysfunctional HDL via oxidation involves 
MPO, an enzyme that converts H2O2 and chloride ion to HOCl.  MPO is expressed in human 
atherosclerotic tissue (94), and HOCl-modified proteins are present in such lesions (60).  
HOCl converts protein Tyr residues to 3-chlorotyrosine, and Met residues to MetO.  In 
addition, MetO can also be formed from exposure of HDL’s major protein, apoA−I to H2O2 
(177) or LOOH (50,102), the latter generated during the oxidation of HDL lipids.   
Oxidation of Tyr and Met residues can have dramatic consequences on the functions of 
apoA−I/HDL, including reverse cholesterol transport, wherein HDL accepts cholesterol from 
macrophage foam cells in the artery wall and transports it back to the liver for excretion 
(193).  Specifically, apoA−I containing 3−chlorotyrosine and MetO has an impaired ability to 
promote cholesterol efflux by the ABCA1 pathway (106,107,220).  Similarly, oxidation of 
Met148 impairs apoA-I’s ability to activate LCAT (229).   
There is evidence that oxidized apoA−I is present in human blood plasma.  Thus, levels of 
3−chlorotyrosine are higher in circulating HDL isolated from patients with CVD than in HDL 
isolated from controls (107,108,220), suggesting that MPO may target HDL for oxidation in 
humans during atherogenesis.  Similarly, apoA−I containing Met residues 86 and 112 as 
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MetO (hereafter referred to as apoA−I+32) has been detected in circulating HDL, and is 
present at increased concentrations in subjects with a genotype associated with increased 
coronary artery disease (103).  Moreover, it was recently shown that the MetO content of 
apoA−I is elevated in human type 1 diabetes (104), a disorder commonly associated with 
increased oxidative stress (259).   
The above findings suggest that oxidized forms of apoA−I containing 3−chlorotyrosine 
and/or MetO could be clinically relevant.  However, testing this possibility is limited by 
current methods for oxidized apoA−I detection that require time−consuming HDL isolation 
and HPLC− or mass spectroscopy-based detection steps.  Therefore, this study was sought to 
develop a simple method for the specific detection of apoA−I containing MetO.  Here is 
described a sensitive and specific ELISA that detects MetO−containing apoA−I in HDL and 
plasma.   
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4.2 Materials and Methods 
Native HDL was isolated from plasma of healthy subjects with detailed isolation procedures 
described in Section 2.2.5.  Oxidized HDL was prepared by incubating HDL with AAPH as 
described in Section 2.3.  Preparation of standards of HPLC−purified apolipoproteins and 
their respective oxidized forms containing MetO is described in Section 2.4.3.  The identity 
of HPLC−purified lipid−free apolipoproteins and MetO−containing apolipoproteins was 
confirmed by mass spectrometry as described in Section 2.5.1. 
Procedures involved in the production, purification and biotinylation of MOA−1 are 
described in Section 2.6.  The ELISA consisted of a commercial anti−human apoA−I 
monoclonal (or polyclonal) antibody as capture and MOA−1 (or biotinylated) as detection 
antibody.  The specific ELISA set−up used in the experiments is described in Sections 2.7.1 
and 2.7.2.  Competition assay was carried out to choose an optimal pair of capture and 
detection antibodies that recognize different epitopes on apoA−I+32, with relevant details 
described in Section 2.7.3. 
Recognition of apoA−I for HPLC−purified lipid−free MetO−containing apoA−I as well as 
native forms of apolipoproteins is referred to Section 2.7.4.  To test MOA−1’s ability to 
detect MetO−containing apoA−I in HDL, peroxyl radical oxidized HDL was used as 
described in Section 2.7.5.1.  
Lipoproteins precipitation from human plasma is described in Section 2.9.  SwellGel Blue 
albumin removal kit (Pierce) was used to remove albumin from human plasma and the 
efficacy of albumin removal by the SwellGel approach was assessed with the details 
described in Sections 2.10.1 and 2.11.3.  Level of HDL cholesterols remained in plasma after 
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albumin removal was measured by HPLC as described in Section 2.4.3.  Recovery of apoA−I 
from the SwellGel column was optimized by using different washing buffer and evaluated by 
SDS−PAGE/Western blotting with the details described in Sections 2.10.2 and 2.11.4. 
Finally, the ability of MOA−1 to detect MetO−containing apoA−I in human plasma was 
tested and human plasma containing oxidized HDL was applied to ELISA with detailed 
procedures in Section 2.7.5.2. 
Preparation for differently oxidized apoA−I is stated in Section 2.12.3.1, followed by the 
detection for these differently oxidized apoA−I with details described in Section 2.7.7.  
Preparation of apoA−I mutants and their H2O2−oxidized forms is described in Section 2.7.6.  
Reactivity characterization on these H2O2−oxidized apoA−I mutants is referred to Section 
2.12.3.2. 
HDL and LDL were oxidized with different 2e−oxidants as described in Sections 2.12.3.3 
and 2.12.3.4, respectively, followed by MOA−1’s detection (Section 2.7.7).    
Other Met−containing proteins than apoA−I oxidized with 2e−oxidants are described in 
Section 2.12.3.3, followed by MOA−1’s detection for these oxidized proteins (Section 2.7.8).   
Utility of MOA−1 for Western blotting was tested with details described in Section 2.12.1.  
The binding of MOA−1 to MetO−containing apoA−I by surface plasmon resonance is 
described in Section 2.12.2.  
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4.3 Results 
4.3.1 Confirmation of authenticity of HPLC−purified, lipid−free apolipoproteins 
At first, the identity of HPLC−purified lipid−free apoA−I containing MetO was confirmed by 
mass spectrometry.  AAPH-oxidized HDL contains specifically oxidized forms of apoA-I and 
apoA-II, which exhibited shorter retention times upon subjecting to HPLC compared to their 
respective native forms (Fig. 3.1).  Oxidized forms of apoA-I were designated apoA-I+32 or 
apoA−I+16, and collected using a semi−preparative C18 RP column (250 x 10 mm, 10 µm, 
Vydac).  Specifically, apoA−I+32 eluted at ∼16 min, apoA−I+16 (MetO112) at ∼17 min and 
apoA−I+16 (MetO86) at ∼23 min.  The fractions collected were dried and reconstituted with 10 
mM PBS.  The identity of these HPLC−purified oxidized forms of apolipoproteins was 
verified by ESI−MS−TOF (Fig. 4.1).  The mass of apoA−I+32 (containing MetO86 and 
MetO112) (Fig. 4.1A) appeared 32 Da greater than that of native apoA−I (Table. 4.1), 
whereas, apoA−I+16 (containing Met112, Fig. 4.1 B, or Met86, Fig. 4.1C) was 16 Da heavier 
than native apoA−I.  Masses of both HPLC−purified native apoA−I and apoA−II and their 
oxidized forms are shown in Table. 4.1.  The results are consistent with the previous 
apolipoproteins characterizations by MS/MS (103). 
4.3.2 Production of anti−human apoA−I+32 monoclonal Ab 
To develop an ELISA for MetO-containing oxidized apoA-I, mice (n=6) were immunized 
with HPLC-purified human lipid−free apoA-I+32, because this form of oxidized apoA−I is 
relatively stable (103).  Of the sera from these mice, two showed increased recognition of 
apoA-I+32 over apoA-I (Fig. 4.2).  Hybridomas were generated by fusion of spleen cells from 
these mice with a myeloma cell line.  This yielded several different clones, of which two, 
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6.4.4.26 and 6.4.4.17.2.2 (yielding mAb17) were chosen for isolation of mAbs and 
subsequent experiments described herein.  Of these, 6.4.4.26 (hereafter referred to as 
MOA−1) demonstrated the highest response to apoA−I+32 (data not shown).  Isotype 
determination showed MOA−1 and mAb17 were subtype IgG1.  Therefore, a Hitrap protein 
G column that specifically binds all IgG, was chosen for FPLC purification of mAb from 
supernates harvested from hybridomas (Fig. 4.3A).  The purity of the antibody was 
confirmed by SDS−PAGE by comparing the MOA−1 with IgG standard (Fig. 4.3B).   
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Fig. 4.1.  ESI−MS analysis of HPLC−purified, human MetO−containing apoA−I.  A, 
typical mass spectra corresponding to apoA−I+32 (MetO86 and MetO112).  B, mass spectra of 
apoA−I+16 (MetO112); C, mass spectra showing apoA−I+16 (Met86).  Mass of native apoA−I is 
28079 (also seen in Table 4.1). 
A 
B 
C 
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Table 4.1.  Authenticity confirmation of HPLC−purified apolipoproteins and their 
oxidized forms by ESI-MS. 
 
 
 
 
 
 
 
 
 
 
 
Spectra were acquired using an API QStar Pulsar I hybrid tandem mass spectrometer (TOF) 
(Applied Biosystems).  ApoA-I contains three Met residues of which Met86 and/or Met112 
become oxidized during oxidation of HDL by AAPH.  The resulting apoA−I+32 and 
apoA−I+16 were 32 and 16 Da heavier than native apoA−I, respectively.  ApoA-II contains 
one Met residue (Met26), and exists as a disulfide-linked homodimer.  It elutes as three 
distinct species with both N−terminal Glu residues cyclized (predicted mass 17,380), or with 
one or both of C−terminal Glu residues removed (predicted mass 17,252 and 17,123, 
respectively) (260).  
Protein  Predicted mass  ESI-MS 
Apo A-I   
ApoA-II 
 
 
 
ApoA-I +32(MetO86,plus MetO112) 
ApoA-I +16 (Met
112) 
ApoA-I +16 (Met
86)
 
 
ApoA-II +16 (Met
26)
 
 
28078.6 
17123 
17252 
17380 
 
28111 
28095 
28096 
17139 
17268 
17396 
28079 
17123.2 
17252.6 
17379.6 
 
28112 
28095 
28097 
17139.8 
17267.5 
17395.8 
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Fig. 4.2.  Representative result from the original screen of mouse serum.  Of six mice 
immunized with HPLC−purified human apoA-I+32, serum from mouse 1 (circles) and mouse 
6 (squares) showed preferred recognition of apoA-I+32 (open symbols) over apoA-I (closed 
symbols). 
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Fig. 4.3.  Purification of MOA-1.  A, representative FPLC trace of supernate containing 
MOA−1.  MOA-1 was eluted with glycine-HCl (pH=2.7) on a protein G Hi-trap column, 
with the eluant being monitored at 280 nm.  B, FPLC−purified MOA-1 was subjected to 10% 
SDS-PAGE under reducing conditions and proteins subsequently stained with Coomassie 
Blue.  The left lane shows IgG1 standard (1 µg); the right lane shows MOA-1 (2 µg) 
.  
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4.3.3 Optimization of dilutions of capture and detection Abs 
The ELISA initially used a polyclonal anti−human apoA−I antibody (pAb) as capture 
antibody and MOA−1 as detection antibody, respectively.  To test the specificity and 
sensitivity of the ELISA for recognition of apoA−1+32, several commercial pAbs were tested.  
The results revealed that pAb obtained from Chemicon (AB740) at 1:10,000 dilution had 
higher specificity and sensitivity towards apoA−I+32 than apoA−I (Fig. 4.4A).  In contrast, 
MOA−1 at 1:100 dilution showed recognition for apoA−I+32 without significant 
cross−reactivity for apoA−I (Fig. 4.4B).  Therefore, pAb from Chemicon (1:10,000 dilution) 
and MOA−1 (1: 100 dilution) were used for subsequent experiments. 
4.3.4 Specificity evaluation for apoA−I+32 
Initial specificity for apoA−I+32 was achieved, using the pAb (Chemicon) as capture Ab and 
MOA-1 as detection Ab.  As can be seen, the assay demonstrated superior recognition of 
lipid−free apoA−I+32 compared to apoA−I, without cross−reaction for apoA−II (Fig. 4.5A).  
Limited recognition of apoA−I was observed when the protein concentration was <400 
ng/mL (Fig. 4.5A).  However, at higher concentrations the assay detected apoA−I (Fig. 4.5B, 
triangles).  In addition, a linear response was recorded for increasing concentrations of 
apoA−I in the presence of 50 ng/mL of apoA−I+32 (Fig. 4.5B, diamonds), indicating poor 
specificity for apoA−I+32.  Together, the results suggested this version of the ELISA had 
limited sensitivity and specificity for apoA−I+32. 
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Fig. 4.4.  Optimizing dilution factors for capture and detection antibodies.  Several 
polyclonal anti−human apoA−I (pAb) were tested as capture antibody with MOA-1 as 
detection antibody.  Apolipoproteins (100 ng/mL) were applied to the assay.  A, 
pAb−Chemicon (▲) showed superior selectivity for apoA−I+32 than pAb−Rockland (■) and 
pAb−Biodesign (◆), as indicated by the absorbance obtained with apoA−I compared to 
apoA−I+32.  Dilutions of pAb of 1:1000 to 1:10,000 appeared to be optimal.  B, 
apolipoproteins (100 ng/mL) were applied to the ELISA with pAb−Chemicon as capture Ab 
(1:10,000 dilution) and increasing dilutions of MOA−1.  A 1:100 dilution of MOA-1 
demonstrated the highest sensitivity for apoA−I+32 (●) without significant cross−reactivity 
with native apoA−I (■) and apoA−II (▲).  The results show mean ± SEM of one 
representative of three separate experiments each carried out in triplicates.  The error bars are 
smaller than symbols. 
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Fig. 4.5.  Specificity assessment for lipid−free apolipoproteins.  pAb−Chemicon was used 
as capture (1:10,000 dilution) and MOA-1 (1:100 dilution) as detection Ab.  A, selective 
detection of lipid−free apoA−I+32.  Serial concentrations of apoA−I+32 (●), apoA−I (■) and 
apoA−II (▲) ranging from 0−400 ng/mL were added to the plate as described in Materials 
and Methods.  B, limited selectivity for apoA−I+32 when combined with large molar excess of 
native apoA−I.  ApoA−I+32 (50 ng/mL) was added to increasing concentrations of apoA−I 
(◆, 0−2.5 µg/mL), and ELISA results compared with those obtained with apoA−I (▲, 0−2.5 
µg/mL) without added apoA−I+32.  The results show mean ± SEM of three separate 
experiments, each carried out in triplicate.  The error bars are smaller than symbols in A.   
 
Chapter 4 Development of A New ELISA For The Detection of MetO−containing ApoA−I 
  147 
 
4.3.5 Optimized ELISA  
To improve sensitivity, mAb17 and MOA−1 were labelled with biotin.  This overall 
increased sensitivity for apoA−I+32, and B−MOA-1 showed higher response than B−mAb17 
(Fig. 4.6).  Therefore, biotinylated mAbs were used subsequently.   
To achieve satisfactory specificity and sensitivity, it was crucial to choose a pair of capture 
and detection antibody that bind to different epitopes.  Therefore, competition experiments 
were carried.  These revealed that B−MOA-1 and B−mAb17 recognized the same epitope 
(Fig. 4.7B), as did several commercial polyclonal anti-human apoA-I antibodies (i.e., 
600−101−109 from Rockland, A95120H from Biodesign, and AB740 from Chemicon) (Fig. 
4.7A).  In contrast, mAb010-A/11 (from Chemicon) and B−MOA-1 bound mutually 
exclusive epitopes, as absorbance remained unchanged (Fig. 4.7B).  Therefore, mAb010-
A/11 was used as capture and B−MOA−1 as detection antibody in all subsequent 
experiments. 
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Fig. 4.6.  Increased sensitivity for detection of apoA−I+32 using biotinylated MOA−1.  
Polyclonal anti−human apoA−I (1:10,000) was used as capture Ab.  Increasing 
concentrations of apoA−I+32 (0−400 ng/mL) were then added to the plate before an equal 
amount (6.5 µg/mL) of B−MOA-1 (●), B−mAb17 (■) or non−biotinylated MOA-1 (▲) 
was added as detection antibody.  The relative sensitivities for the detection of apoA−I+32 
were compared, as indicated by the absorbance at 450 nm.  The results show mean ± SEM of 
a representative of three separate experiments carried out in triplicate.  The error bars are 
smaller than symbols. 
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Fig. 4.7.  Binding of various antibodies to apoA−I+32. Mouse monoclonal anti-human 
apoA-I (MAb010-A/11) and anti apoA-I+32 (MOA-1) Ab recognize different epitopes on 
apoA−I+32.  Goat polyclonal anti human apoA-I (1:10,000 dilution) was used as the capture 
Ab.  ApoA-I+32 (400 ng/mL) was then added, followed by competitive ELISA as described in 
Section 2.7.3. and (A) using B−mAb17 (600 ng/mL) together with either pAb 600−101−109 
from Rockland (■), A95120H from Biodesign (●), AB740 from Chemicon (▲) or control 
antibody (◆, anti-human smooth muscle actin ) as competing antibody at the molar ratio 
indicated.  (B).  B−mAb17 added in conjunction with either mAb MAb010-A/11 from 
Chemicon (■), MOA-1 (▲) or control antibody (◆, anti-human smooth muscle actin) as 
competing antibody at the molar ratio indicated.  The results show mean ± SEM of four 
separate experiments, each carried out in triplicate. 
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4.3.6 Recognition of lipid−free oxidized apoA−I by MOA−1 
The specificity of B−MOA−1 for various HPLC-purified, oxidized species of lipid−free 
apoA−I was tested next.  As can be seen, MOA−1 detected apoA−I+32 in a concentration-
dependent manner and yielding a linear response (Fig. 4.8A).  There was no cross-reactivity 
with apoA−I and apoA−II (Fig. 4.8A), and comparatively modest recognition of apoA−I+16 
(MetO112 or Met86) (Fig. 4.8B).  Intra− and inter−assay CV for apoA-I+32 were 3.8 ± 2.7 and 
6.3± 2.9%, respectively.  The sensitivity of the ELISA for apoA-I+32 was nearly three orders 
of magnitude greater than that of the HPLC method, with detection limits of 3 ng/mL (Fig. 
4.9A) and 1 µg/mL (Fig. 4.9B), respectively. 
4.3.7 Detection of oxidized apoA−I in HDL 
In a second part of the studies, the suitability of the ELISA to detect MetO−containing 
apoA−I in HDL and plasma was examined.  For this a constant amount of apoA-I+32 was 
added to increasing concentrations of native HDL.  As can be seen, the ability of MOA−1 to 
detect apoA−I+32 in such HDL was modest.  In fact, for HDL concentrations >0.1 mg/mL, 
decreased absorbance was recorded (Fig. 4.10, open bars), when compared to lipid−free 
apoA−I+32 (Fig. 4.10, gray bars).  Therefore, acetonitrile was chosen to ‘delipidate’ 
MetO−containing apoA−I in AAPH−oxidized HDL because of its proven efficacy for this 
purpose in the HPLC assay.  Optimization experiments revealed that acetonitrile at 40% final 
concentration (HDLox:50% acetonitrile, vol:vol, 1:4) gave best results (data not shown).  
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Fig. 4.8.  Specificity of MOA-1 for apoA-I+32.  Increasing concentrations (0-500 ng/mL) of 
(A) apoA-I+32 (◆), apoA-I (■) or apoA-II (▲), or (B) apoA-I+32 (◆), apoA-I+16 (MetO86, 
▲) or apoA-I+16 (MetO112, ■) were added, followed by the addition of detection antibody 
(B−MOA-1), as detailed in Materials and Methods (Section 2.7.4).  The results show mean ± 
SEM of three separate experiments, each carried out in triplicates. 
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Fig. 4.9.  Sensitivity comparison between ELISA and HPLC for the detection of 
apoA-I+32.  A and B show standard curves for apoA-I+32 in the ELISA and HPLC assay, 
respectively.  ELISA and HPLC were carried out as described in the Materials and Methods 
section, using HPLC-purified apoA-I+32.  The results show mean ± SEM of a representative 
comparison carried out in triplicates.  Error bars are smaller than symbols.  Similar results 
were obtained in four separate experiments. 
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Fig. 4.10.  Detection of apoA-I+32 in HDL.  ELISA signals were recorded for 100 ng/mL of 
apoA−I+32 (grey bar) and in the presence of increasing concentrations of native HDL (0−0.8 
mg/mL, open bars).  The results show mean ± SEM of three separated experiments each 
carried out in triplicate. 
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Fig. 4.11.  Detection of MetO−containing apoA−I (apoA−I+32) associated with HDL.  
AAPH-oxidized HDL (0-15 µg protein/mL) in PBS (●) or solvent (◆) were applied to the 
ELISA with the ratio of the oxidized HDL to 50% acetonitrile being 1:4 (vol:vol).  The final 
acetonitrile concentration is 40 %.  The results show mean ± SEM of three separated 
experiments each carried out in triplicates. 
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Fig. 4.11 shows that the sensitivity was enhanced substantially when acetonitrile was added 
to the oxidized HDL prior to its application to the ELISA, compared to the modest detection 
of oxidized HDL in PBS.  At 40% acetonitrile, the ELISA response for ‘delipidated’ 
apoA-I+32 contained in oxidized HDL was similar to that observed with lipid-free apoA-I+32 
(Fig. 4.12A).  The slightly higher response seen with oxidized HDL was likely due to the 
presence of some apoA-I+16 in oxidized HDL but not purified, lipid-free apoA-I+32.  
Compared to AAPH-oxidized HDL, the ELISA did not detect native LDL, while reaction 
with freshly isolated, native HDL was low (Fig. 4.12B).  Detection of AAPH-oxidized HDL 
was highly reproducible, with intra- and inter-assay CV of 4.1 ± 3.2 and 9.3 ± 4.6%, 
respectively (n = 4 separate experiments, each carried out in triplicate). 
4.3.8 Detection of MetO−containing apoA−I in plasma 
The ELISA was applied next to freshly obtained human plasma samples.  Initial experiments 
revealed high background readings in diluted and lipid−extracted plasma samples in the 
absence and presence of acetonitrile (data not shown).  Several lipoprotein precipitation 
approaches were used and revealed satisfactory recovery of HDL (i.e., >95%) as verified by 
HPLC analysis.  However, this did not overcome the problem of high background (Table 
4.2).  Instead, albumin was found to be responsible for high background (Fig. 4.13). 
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Fig. 4.12.  Specific detection by ELISA of apoA-I+32 associated with HDL.  A, comparison 
of ELISA response to HDL-associated apoA-I+32 (■) versus isolated, lipid-free apoA-I+32 
(◆).  The amount of apoA-I+32 contained in AAPH−oxidized HDL was determined by HPLC 
as described in Materials and Methods.  B, specificity of MOA−1 for AAPH-oxidized HDL 
in 40% acetonitrile (■) versus native HDL (●) and LDL (▲) in 40% acetonitrile.  Results 
show mean ± SEM of four separate experiments, each performed in triplicate. 
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Table 4.2.  Lipoproteins precipitation from human plasma by different methods. 
Various lipoprotein precipitation methods were used.  All showed HDL recovery of 90−95%, 
as verified by HPLC, yet high background in the ELISA remained.   
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Fig. 4.13.  Effect of bovine (BSA) and human serum albumin (HSA) on background 
absorbance in ELISA.  BSA or HSA (100 µL of a 2% solution each) was applied to the 
ELISA in the absence of apolipoproteins, and the ELISA readings recorded.  Results show 
mean ± SEM of one representative of three separate experiments, each performed in 
triplicate.  
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Efficient (i.e., ~98%) removal of albumin was achieved using the SwellGel Blue Albumin 
Removal Kit (Fig. 4.14A).  However, such removal was not specific for albumin, as it also 
removed ~50−60% of apoA-I (Fig. 4.14B&C).  The loss of apoA−I was associated with 
decreased HDL cholesterol levels as measured by HPLC after albumin removal (data not 
shown).  To increase the recovery of apoA−I after albumin removal, an optimization 
experiment was carried out.  Specificity for albumin removal, i.e., >80% removal of albumin 
with essentially ~100% of apoA-I retained, was achieved with the SwellGel Blue approach 
using plasma volumes <10 µL and 300 mM NaCl, 25 mM Tris, pH 7.4 as the washing buffer 
(Fig. 4.15A&B).  This method was then used to examine the extent of the ELISA response to 
plasma containing increasing amounts of AAPH-oxidized HDL.  As can be seen, the ELISA 
response to plasma containing increasing amounts of oxidized HDL was linear (Fig. 4.15C).  
Importantly, the extent of the response was comparable for isolated oxidized HDL (diamonds 
in Fig. 4.15C) and oxidized HDL added to plasma (circles in Fig. 4.15C).  The intra- and 
inter-assay CV for oxidized HDL in plasma was 7.6 ± 3.6 and 13.3 ± 5.3%, respectively.  
Together, these results indicate the usefulness of the ELISA for the determination of MetO-
containing, HDL-associated apoA-I in human plasma. 
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Fig. 4.14.  Efficacy of albumin removal and recovery of apoA−I following the SwellGel 
Blue process.  A, albumin was removed efficiently (~98%) by the use of SwellGel Blue 
Albumin Removal Kit.  10 µL of diluted fresh plasma (1:10) before “B” or after “A” passing 
through SwellGel column was subjected to SDS−PAGE as described in the Methods.  The 
efficacy of albumin removal was assessed by comparison of the albumin content in “B” 
versus “A” using Quantity One 1D analysis of the Gel−Doc XR system (Bio−Rad).  Lane 1, 
SeeBlue Plus2 protein standard.  Lanes 2 to 7, diluted plasma (10 µL) before (‘B’) or after 
(‘A’) passing through the SwellGel column carried out in triplicates.  Lane 8, apoA−I (50 
ng); Lane 9, human serum albumin (1 µg).  B, representative Western blots showing the poor 
recovery of apoA−I after albumin removal using the SwellGel Blue Albumin Removal Kit.  
Fresh plasma (10 µL) spiked with decreasing concentrations of AAPH−oxidized HDL (15−0 
µgp/mL) before (‘B’) or after (‘A’) passing through SwellGel column was subjected to 
SDS−PAGE/Western as described in the methods.  C, quantification of the Western data 
shown in B.  Results are expressed as the ratio of apoA-I before to after SwellGel Blue 
process. 
Chapter 4 Development of A New ELISA For The Detection of MetO−containing ApoA−I 
  161 
  
Fig. 4.15.  ELISA determination of MetO−containing apoA−I in HDL added to plasma.  
A, recovery of apoA-I after albumin removal by SwellGel Blue Albumin Removal Kit using 
25 mM Tris, pH 7.4 and the NaCl concentration indicated.  Filtered and 1:10 diluted plasma 
(total volume 100 µL) before (‘B’) or after (‘A’) SwellGel Blue column filtration was 
subjected to SDS-PAGE/Western as described in the Materials and Methods (Sections 2.10.2 
and 2.11.4).  Representative Western blots are shown.  B, quantification of the Western data 
shown in A.  Results are expressed as the ratio of apoA-I before to after SwellGel Blue 
albumin removal process.  C, ELISA detection of MetO−containing apoA−I in HDL and 
added to human plasma.  Fresh plasma (10 µL) was spiked with increasing concentrations of 
AAPH-oxidized HDL (0−15 µgp/mL) and then passed through SwellGel Blue column, 
washed with optimized buffer (300 mM NaCl, 25 mM Tris pH 7.4) and the combined flow-
through and wash sample applied to ELISA as described in Section 2.7.5.2.  For comparison, 
the response to AAPH−oxidized HDL added to plasma and passed through the SwellGel Blue 
column (●) was plotted against a standard curve obtained with AAPH-oxidized HDL alone 
(◆).  Results show mean ± SEM of a representative of four separate experiments each 
carried out in triplicates. 
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4.3.9 Reactivity of MOA-1 towards apoA−I oxidized with different oxidants  
The ELISA was also applied to apoA-I oxidized in vitro by different radical and non-radical 
oxidants.  The results show that MOA-1 recognized apoA-I oxidized with the 2e-oxidants 
HOCl, H2O2 and ONOO− (derived from sydnonimine-1) (Fig. 4.16).  These 2e-oxidants are 
well known to oxidize Met residues in proteins to MetO.  In the case of apoA-I, this results in 
formation of MetO−containing oxidized apoA−I (50,102), as verified by HPLC (Fig. 
4.17B&C).  In contrast, lipid−free apoA-I oxidized by 1e-oxidants (i.e., hydroxyl radical and 
metal ions) was poorly recognized by MOA-1 (Fig. 4.16), and did not contain substantial 
amounts of apoA-I+32 or apoA-I+16, as verified by HPLC (Fig. 4.17D, E & F).  Together these 
observations suggest that MOA-1 recognizes MetO-containing, oxidized apoA-I. 
4.3.10 Specificity of MOA−1 towards MetO in oxidized apoA−I mutants 
To examine the relative contribution of the 3 Met residues of apoA-I (i.e., Met86, Met112 and 
Met148) to recognition by MOA-1, mutant apoA-I were employed in which a single, two, or 
all three Met residues were replaced with Leu.  The sequences of wild type and mutant 
apoA−I were confirmed by LC−ESI−MS/MS (data not shown).  These proteins were then 
oxidized by exposure H2O2, the resulting formation of MetO confirmed by LC−ESI−MS/MS 
(Table 4.3), and the proteins then subjected to ELISA.  As expected, H2O2-oxidized, wild 
type apoA-I yielded a high signal compared to the corresponding non-oxidized 
apolipoprotein (Fig. 4.18A).  Compared with oxidized wild type apoA−I, oxidized single Met 
to Leu substituted apoA−Is gave comparatively smaller signals, although they were still 
recognized to a greater extent than the corresponding non-oxidized counterparts, except for 
M148L apoA-I (Fig. 4.18A). 
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Fig. 4.16.  Detection of MOA−1 for differently oxidized apoA−I.  Specificity of ELISA 
shows the recognition of HPLC−purified lipid−free apoA−I oxidized by 2e−, but not 
1e−oxidants.  Native apoA−I (5 µM) was oxidized with one of the different 1e− and 
2e−oxidants indicated before being applied to the ELISA (250 ng protein/mL) as described in 
Materials and Methods.  Abbreviations: As, ascorbic acid; SIN−1, sydnonimine−1. 
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Fig. 4.17.  Representative HPLC traces of differently oxidized apoA−I.  HPLC−purified 
lipid−free apoA−I (5 µM) was incubated without or with different oxidants at 37 ℃ for 2−24 
h and subjected to HPLC analysis (5 µg protein) after gel−filtration as described in Methods.  
A, apoA−I (control) incubated in the absence of oxidants for 24 h.  B, apoA−I incubated with 
H2O2 (5 mM) for 24 h and loss of 60% apoA−I was accounted for.  C, apoA−I incubated with 
SIN−1 for 2 h which caused 76% loss of apoA−I.  D, apoA−I was incubated with FeCl3 and 
H2O2 for 2 h and apoA−I decreased about 20%, compared to the control.  E, apoA−I 
incubated with FeSO4 and ascorbic acid for 2 h and did not show the decrease of apoA−I 
peak.   F, apoA−I incubated with CuSO4 for 2 h and showed 18% decrease of apoA−I peak. 
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Table 4.3.  Yield of MetO in H2O2-oxidized recombinant wild type and mutant apoA-I 
ApoA-I MetO86 MetO112 MetO148 
Wild type 
Wild type ox 
0.6 
94 
0.8 
100 
0.5 
99 
M86L 
M86Lox 
n/a 
n/a 
0.3 
100 
0.3 
98 
M112L 
M112Lox 
0 
88 
n/a 
n/a 
0.5 
95 
M148L 
M148Lox 
0 
67 
0.2 
100 
n/a 
n/a 
M86L/M148L 
M86L/M148Lox 
n/a 
n/a 
0.3 
100 
n/a 
n/a 
M112L/M148L 
M112L/M148Lox 
0 
60 
n/a 
n/a 
n/a 
n/a 
M86L/M112L/M148L 
M86L/M112L/M148Lox 
n/a 
n/a 
n/a 
n/a 
n/a 
n/a 
Wild type and mutant forms of apoA-I were expressed, purified and then oxidized with 
reagent H2O2 (50 mM) for 24 h at 37 ℃ as described in Materials and Methods.  Oxidized 
proteins were then analyzed by LC-ESI-MS/MS to verify the extent of oxidation of 
methionine residues to MetO.  Yield of MetO (%) = peak area of product ion / sum (peak 
area of precursor ion + peak area of product ion) × 100.  The data represent averages of two 
sets of independent analyses, with the variation between the respective two values <3%. 
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Fig. 4.18.  Specificity of ELISA.  A, Recognition of recombinant human wild type and 
mutant apoA−I before and after H2O2−mediated oxidation.  Native and H2O2−oxidized wild 
type and single Met apoA−I mutants, or native and H2O2−oxidized double and triple Met 
apoA−I mutants were subjected to ELISA at 500 ng/mL.  B, Recognition of apoA-I 
containing 0, 1, 2 or 3 MetO.  Recombinant apoA-I without (▲) and with H2O2 treatment (50 
mM H2O2, 5 µM apoA-I, 37 °C, 24 h) and containing all three Met residues as MetO (Table 
4.3.1) (■), or HDL-derived, HPLC-purified apoA-I containing MetO86 (●) or MetO86 plus 
MetO112 (◆) were subjected to ELISA at the serial dilutions indicated.  The results show 
mean ± SEM of three separate experiments carried out in triplicate.   
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Consistently smaller signals were recorded with the oxidized double mutants (M86L/M148L 
and M112L/M148L) and the oxidized triple mutant (Fig. 4.18A).  Fig. 4.18B compares the 
immunoreactivity of recombinant and naturally occurring MetO−containing apoA−I, with the 
extent of recognition by MOA−1 increasing with increasing numbers of MetO.  HPLC 
analyses of the respective wild type and mutant apoA-I revealed that high ELISA reactivity 
was associated with substantially shorter retention time of the oxidized compared to the non-
oxidized protein (Fig. 4.19). 
4.3.11 Reactivity of MOA−1 towards Met−containing proteins oxidized with 
2e−oxidants   
Finally, the specificity of MOA-1 for MetO contained in apoA-I versus other proteins was 
assessed.  As detailed in Methods, apoA-I, BSA, ferritin, myoglobin and fibrinogen were 
exposed to H2O2 or HOCl to convert their Met residues to MetO prior to ELISA.  As can be 
seen, of these proteins only oxidized apoA-I yielded positive ELISA readings (Fig. 4.20).  
Together, these results indicate that MOA-1 recognizes MetO specifically in apoA-I, and that 
the extent of this recognition increases with increasing MetO content. 
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Fig. 4.19.  Representative HPLC chromatograms of apoA−I mutants and their oxidized 
forms.  Recombinant human wild type (Wt) and mutant apoA−I before and after 
H2O2−mediated oxidation (50 mM H2O2, 5 µM apoA−I, 37 °C, 24 h) were analyzed by 
HPLC.  Native and H2O2−oxidized wild type apoA−I (Wt) and single Met mutant apoA−I 
mutants (M86L, M112L, and M148L), or native and H2O2−oxidized double (M86/148/L and 
M112/148/L) and triple Met apoA−I mutants (M86/112/148/L) were subjected to HPLC at 5 
µg protein.  HPLC traces in solid line represent native Wt and various apoA−I mutants, 
whereas broken lines indicate traces of H2O2−oxidized proteins.  Wt−control shows native 
Wt before (solid line) and after (broken line) incubated at absence of H2O2 at 37 °C for 24 h.  
Chapter 4 Development of A New ELISA For the Detection of MetO−containing ApoA−I  
  169 
 
 
Fig. 4.20.  Reactivity of MOA−1 towards Met−containing proteins oxidized with 
2e−oxidants.  ApoA−I or other Met−containing proteins (1 mg/mL) were oxidized with H2O2 
(100 mM, filled bar) or HOCl (250 µM, open bar) and each oxidized protein (0.5 µg for 
apoA−I and 10 µg for all other proteins) then applied to ELISA.  A-C, oxidized 
apolipoproteins and proteins were generated as described in Section 2.12.3.3.  The results 
show mean ± SEM of three separate experiments, each carried out in triplicates.  
Abbreviations: Ft, ferritin, Mb, myoglobin, and Fg, fibrinogen. 
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4.3.12 Reactivity of MOA−1 towards HDL oxidized with 2e−oxidants 
As shown earlier, AAPH−oxidized HDL was recognized by the ELISA after solvent 
“delipidation” (Fig. 4.21A).  We next tested whether the ELISA was suitable to detect HDL 
oxidized by oxidants other than AAPH.  HDL was oxidized with H2O2 or HOCl, i.e., 2e-
oxidants that directly convert Met in apoA-I to MetO.  H2O2- and HOCl-oxidized HDL were 
recognized by MOA-1 (Fig. 4.21B).  Interestingly, and in contrast to the situation with 
AAPH-oxidized HDL, delipidation with acetonitrile was not required to detect H2O2- and 
HOCl-oxidized HDL.  Importantly, the ELISA did not detect LDL oxidized with either H2O2 
or HOCl (Fig. 4.21B), indicating specificity of the assay for HDL.  Parallel HPLC analyses 
showed that HDL oxidized with either H2O2 or HOCl had apoA−I with shorter respective 
retention times than the apolipoproteins in control HDL (Fig. 4.22). 
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Fig. 4.21.  Recognition of HDL oxidized with 1e− and 2e−oxidants.  A, AAPH−oxidized 
HDL was detected by ELISA after solvent ‘delipidation’.  HDL (1 mg/mL) was oxidized at 
37 ºC with AAPH (2 mM, 3 h) and analyzed in ELISA (5 µg protein per well) either in PBS 
(filled bar) or in 40% acetonitrile (grey bar).  Controls were carried out using HDL incubated 
in the absence of AAPH, and applied to ELISA in PBS (filled bar) or in 40% acetonitrile 
(grey bar).  B, comparison of MOA-1 reactivity for H2O2- and HOCl-oxidized HDL (5 µg 
protein) and LDL, (5 µg protein).  1 mg protein/mL of HDL and LDL were oxidized with 
H2O2 (100 mM, 37 ºC, 24 h), or HOCl (500 µM, 37 ºC, 1 h) as described in Methods.  
Results show mean ± SEM of three separate experiments, each performed in triplicate. 
Abbreviation: ACN, acetonitrile. 
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Fig. 4.22.  Representative HPLC traces of HDL oxidized with 1e− and 2e−oxidants.  
HDL (1 mg/mL) was incubated with different oxidants at 37 ℃ and then subjected to HPLC 
after gel−filtration as described in Methods.  A, HDL incubated in the absence of oxidants for 
24 h.  B, HDL oxidized with AAPH (1 mM) for 3 h.  C, HDL oxidized with H2O2 (50 mM) 
for 24 h.  D, HDL oxidized with HOCl (250 µM) for 1 h. 
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4.3.13 Reactivity of MOA-1 with apolipoproteins following PAGE with Western 
Blotting 
The immunoreactivity of MOA−1 for apolipoproteins by Western blotting was also 
examined.  MOA−1 detected apoA−I and apoA−I+32.  As can be seen, apoA−I and apoA−I+32 
migrated differently, despite the fact that there was only a 32 Da difference in their respective 
molecular weights and proteins were electrophoresed under reducing conditions (Fig. 4.23A).  
However, MOA−1 did not detect apoA−II or apoA−II+16 (Fig. 4.23B).  In contrast to the 
ELISA results, the reactivity of MOA−1 towards apoA−I and apoA−I+32 in Western blotting 
were comparable.  Dimers of apoA−I, apoA−I+32 and apoA−I+16 (Met112) were also observed.  
In addition, apoA−I+16 (MetO112), but not apoA−I+16 (MetO86) showed trimers and tetramers 
(Fig. 4.23C).  Furthermore, apoA−I+16 (MetO86) migrated similar to apoA−I and different to 
apoA−I+16(MetO112) (Fig. 4.23C).  Overall, MOA−1 detected apoA−I, irrespective of native 
or oxidized forms (containing MetO) (Fig. 4.23).  Similar results were obtained when 
SDS−PAGE/Western blot was carried out under non−reducing conditions (data not shown).  
Together, the results demonstrate that, in contrast to the ELISA, MOA−I did not have 
specificity towards apoA−I+32, compared to apoA−I.  This is likely due to MOA−I 
recognizing structure conformational change of MetO in apoA−I as shown in ELISA results, 
whereas, MOA−1 detected primary sequences in Western blot that demonstrated different 
extent of recognition for MetO in apoA−I. 
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Fig. 4.23.  Reactivity of MOA-1 towards apolipoproteins subjected to 
SDS−PAGE/Western blotting.  A, apoA−I (‘1’) and apoA−I+32 (‘2’, 20 ng/each) were 
electrophoresed under reducing conditions using MOPS as the running buffer.  B, apoA−I 
(lane 1), apoA−II (lane 2) and apoA−II+16 (lane 3, 20 ng/each) were electrophoresed under 
non−reducing conditions using MES as the running buffer.  C, apoA−I (‘1’), apoA−I+32 (‘2’), 
apoA−I+16 (MetO112, ‘3’) and apoA−I+16 (MetO86, ‘4’) (20 ng/each) were electrophoresed 
under reducing conditions using MOPS as running buffer.  Following electrophoresis, 
proteins were transferred to nitrocellulose and Western blotting carried out as described in 
Section 2.12.1.  Results show mean ± SEM of one representative experiment carried out in 
triplicate.  Similar results were obtained from four separate experiments.   
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4.3.14 Reactivity of MOA−1 characterization by surface plasmon resonance technology 
In an attempt to further characterize the binding specificity of MOA−1, surface plasmon 
resonance technology was applied to apoA−I, apoA−I+32 and apoA−II with MOA−1 being 
immobilized on the sensor chip.  As can be seen, low concentration (100 nM) of apoA−I, 
apoA−I+32 and apoA−II were beyond the sensitivity of detection (Fig. 4.24A).  When used at 
1000 nM, apoA−I and apoA−I+32 showed similar strengths of binding to MOA-1, whereas, a 
more modest binding was recorded for apoA−II (Fig. 4.24B−D).  Alternatively, following 
immobilization of MOA-1, the chip was saturated with apoA−I before apoA−I+32 was 
introduced.  This yielded only a modest response (Fig. 4.25A); whereas, a comparatively 
greater response was recorded when the chip was saturated with apoA−I+32 followed by 
addition of apoA−I (Fig. 4.25B).  The results suggest that, in contrast to the ELISA 
conditions, immobilized MOA-1 has superior binding for apoA−I than apoA−I+32.  This 
difference was likely due to the HBS buffer used in surface plasmon resonance because 
higher reactivity of MOA-1 for apoA−I over apoA−I+32 was observed when apolipoproteins 
were presented in HBS buffer (Fig. 4.26A).  This contrasted the higher specificity of MOA-1 
for apoA−I+32 over apoA−I in PBS (Fig. 4.26B).  Therefore, filtered PBS was also substituted 
for HBS as running buffers in surface plasmon resonance. Unfortunately, however, this 
resulted in unstable baselines (data not shown).  To further assess the binding of MOA-1 to 
native and oxidized apolipoproteins by surface plasmon resonance, biotinylated MOA-1 was 
immobilized.  However, neither native nor oxidized apolipoproteins showed specific bindings 
to MOA-1 (data not shown).  Together, these results suggested that immobilization of 
apoA−I in the matrix used for surface plasmon resonance alters the immunoreactivity of the 
protein. 
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Fig. 4.24.  Binding of MOA−1 to apolipoproteins as determined by surface plasmon 
resonance.  MOA-1 was immobilized onto the CM5 sensor chip and apolipoproteins 
(100−1000 nM) in HBS−N were injected at the time indicated (arrow) as described Section 
2.12.2.  A, no binding activity was detected when 100 nM of apoA−I, apoA−I+32 and apoA−II 
were injected.  Comparable resonance signals (RU) were observed for apoA−I+32 (B), apoA−I 
(C) and apoA−II (D), when used at 1000 nM. 
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Fig. 4.25.  Immobilized MOA−1 reacting with apoA−I stronger than apoA−I+32.  The 
chip containing immobilized MOA−1 was saturated with apoA−I (A) by injecting apoA−I 
(1000 nM) 5 times (single arrow) before injection of apoA−I+32 (double arrow) in HBS−N 
buffer.  Alternatively, the chip was saturated with apoA−I+32 first before addition of apoA−I 
(B). 
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Fig. 4.26.  Effects of HBS buffer and PBS on apolipoproteins recognition by MOA-1 in 
ELISA. MOA−1 showed different responses to apolipoproteins in HBS buffer (A) compared 
to PBS (B).  Increasing amounts (0−400 ng/mL) of apoA-I+32 (◆), apoA-I (■) or apoA-II 
(▲) were added, followed by the addition of detection antibody (MOA-1) as detailed in 
Section 2.7.2.  The results show mean ± SEM of a representative of three experiments each 
done in triplicate.  Error bars are smaller than the symbols. 
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4.5 Discussion 
Oxidized HDL is thought to play a major role in atherogenesis, yet most presently available 
methods to detect oxidized HDL are not readily applicable to large numbers of clinical 
samples because they are time consuming and require specialized and expensive equipment, 
such as HPLC and mass spectrometry.  The work in this chapter describes a simple and 
robust ELISA for the specific detection of MetO−containing apoA−I in HDL as a novel tool 
potentially useful for evaluating the relationship between oxidized HDL, oxidative stress, 
atherosclerosis and CAD.   
The ELISA described here is based on MOA−I, a monoclonal antibody that was raised 
against HPLC-purified, lipid-free human apoA−I+32 containing two (Met86 and Met112) of its 
three methionine residues as MetO.  Initial experiments investigated optimal pair of capture 
and detection antibody which showed different binding sites on apoA−I+32, hence enhancing 
specificity of the assay to apoA−I+32 (Fig. 4.7B).  The sensitivity was also greatly improved 
by biotin−labelling MOA−1, compared to non−biotin labelled MOA−1(Fig. 4.6).  Several 
independent lines of evidence support the specificity of MOA−I for MetO−containing 
apoA−I.  First, MOA−I readily recognized apoA−I+32 but not native apoA−I (Fig. 4.8) 
purified from oxidized and native human HDL by HPLC.  Second, the experiments with 
recombinant human wild type and mutant apoA−Is (Fig. 4.18A) showed that methionine 
residues were required for MOA−I to recognize H2O2−oxidized apoA−I.  In the absence of 
Cys residues in apoA−I, H2O2 selectively oxidizes Met to MetO.  Importantly, MS−based 
methods were used to unambiguously identify and confirm MetO as the only modified 
chemical moiety in the different forms of oxidized apoA−Is used in these experiments.  In 
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addition to H2O2−oxidized apoA−I, MOA−I also recognized lipid−free apoA−I oxidized by 
other 2e-oxidants (HOCl and ONOO−), whereas the antibody was non-reactive towards 
apoA−I modified by 1e-oxidants (Fig. 4.16).  It is well established that 2e−oxidants, but not 
1e−oxidants, effectively convert methionine residues into MetO (50,102).  Finally, specificity 
of MOA−I for MetO−containing apoA−I is indicated by the fact that the ELISA did not 
detect H2O2− or HOCl−treated, Met-containing proteins other than apoA−I.   
In contrast to isolated, lipid−free apoA−I, MOA−I recognized HDL oxidized by 2e−oxidants 
and 1e−oxidants, i.e., peroxyl radicals.  This observation is explained readily by the fact that 
1e−oxidants, like AAPH−derived peroxyl radicals, preferentially react with the lipoprotein’s 
lipids.  This causes lipid peroxidation with the resulting accumulation of hydroperoxides of 
phospholipids and cholesterylesters (168) that then oxidize apoA−I’s Met to MetO (48-
50,102).  The fact that the ELISA recognizes HDL oxidized by a range of different oxidants 
increases its likely applicability to biological samples, at least in the context of CVD.  This is 
because various oxidants contribute to oxidative modifications taking place in the affected 
arterial wall during atherogenesis (1).  Thus, while “oxidized HDL” is not a chemically 
defined term, the presence of MetO containing apoA−I in such modified lipoproteins likely 
represents a feature of oxidative damage required for MOA−I recognition.   
MOA−I was raised by using apoA−I+32 as the immunogen because this specifically oxidized 
apoA−I is formed as a major and relatively stable oxidation product when HDL is exposed to 
radical oxidants in vitro (103).  Also, apoA−I+32 has physical properties clearly distinct from 
native, non−oxidized apoA−I that allows the two forms of the apolipoprotein to be separated 
by HPLC (Fig. 3.1), and it was hypothesized that would generate antigen(s) suitable for the 
generation of mAbs.  Indeed, sera from two of the six animals immunized with apoA−I+32 
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showed increased recognition of apoA−I+32 over apoA−I (Fig. 4.2).  Perhaps more 
surprisingly, it was noticed that most commercially available monoclonal and polyclonal 
anti−human apoA−I antibodies also preferentially recognized apoA−I+32 over native apoA−I 
(not shown).  This may explain the limited sensitivity and specificity towards apoA−I+32 in 
the initial ELISA design (Fig. 4.5).  A likely explanation for this is LOOH-mediated 
conversion of Met residues to MetO when apoA−I is associated with lipids as in HDL, and 
samples are worked up or stored under conditions that do not effectively prevent inadvertent 
lipid oxidation.  The findings presented in this chapter may also explain why antibody−based 
assays are not commonly employed in clinical biochemistry laboratories for the 
determination of HDL, if the antibodies used preferentially recognize oxidized apoA-I and 
samples are stored in the absence of added antioxidants for varying times (261).  That most 
commercial antibodies recognize oxidized apoA−I in preference to non-oxidized apoA−I also 
suggests that caution is needed when interpreting data based on antibody-dependent 
quantification of apoA-I in biological samples.  In atherosclerosis research, for example, 
samples often vary in terms of lipid content and are processed (e.g., fixed or homogenized) 
and/or stored without controlling for ex vivo oxidation events.   
There are two previously reported antibodies against oxidized apoA-I or HDL, i.e., mAb 
C311 raised against AAPH-oxidized apoA-I (262), and mAb 9F5-3a raised against HDL 
oxidized by CuSO4 (263).  Both these mAbs likely recognize epitopes not directly related to 
MetO, as MetO is not a major product in apoA-I oxidized with AAPH (102), and it is not 
responsible for cross-linked apoA-I that is recognized by mAb 9F5-3a (264).  Irrespective, 
Nakajima and co-workers reported increased levels of ‘oxidized HDL’, defined by 
immunoreactivity with mAb 9F5-3a, in plasma from patients with CAD compared to healthy 
subjects and patients with non-insulin-dependent diabetes mellitus (264).  It remains to be 
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established how this finding relates to the presence of ‘oxidized HDL’ with MetO−containing 
apoA−I.   
The results with isolated mutants (Fig. 4.18A) indicate that the extent of recognition by 
MOA−1 is higher for apoA−I with all three Met residues present as MetO than for apoA−I+32, 
the immunogen used in the present study.  Thus, rather than directly recognizing MetO, 
MOA−1 appears to bind a conformational epitope of apoA−I that is generated as its three Met 
residues become converted to MetO.  This interpretation is consistent with the lack of ELISA 
response to Met−containing proteins other than apoA−I, oxidized by H2O2 or HOCl.  In 
apoA−I, the hydrophobic Met residues are located at the boundary between polar and 
non−polar faces of amphipathic helices, such that introduction of the more polar MetO could 
alter the hydrophobic moment and hence secondary structure of the apolipoprotein (227).   
Interestingly, MOA−1 reacted comparably with native apoA−I and MetO−containing apoA−I 
including apoA−I+32 (MetO112 plus 86) apoA−I+16 (MetO112, or MetO86) in Western blotting 
(Fig. 4.23).  This result contrasted the ELISA results that MOA−1 recognized all three 
MetO−containing apoA−I, but not native apoA−I, suggesting that MOA−1 might recognize a 
specific structural conformation for MetO in apoA−I in ELISA, rather than primary 
sequences as shown in Western blotting.  It is likely that primary sequence was masked in 
native apoA−I by tertiary conformation in ELISA, whereas oxidation of Met residues in 
apoA−I unmasked this primary sequence.  Therefore, MOA−1 also detected apoA−I in 
Western blotting.  It is also possible that MAb010−A/11 (anti−human apoA−I used as capture 
Ab in ELISA) hindered MOA−1 bindings of native apoA−I, conformational change as a 
result of Met oxidation leads to the separation of the binding sites of the two antibodies 
relieving the hindrance.  Therefore, MOA−I readily detected apoA−I in western blotting 
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when competition was not present.  However, competition ELISA is required in the future to 
confirm this hypothesis.  Surprisingly, MetO contained in apoA−I at different positions 
demonstrated different multimers in Western blotting (Fig. 4.23C).  Considering of absence 
of Cys residue in apoA−I and running under reducing conditions, the formation of high 
molecular weight bands might suggest aggregation induced by oxidation.  In fact, apoA−I has 
shown to undergo aggregation caused by HOCl (99,219).  Similarly, other proteins have also 
shown the formation of aggregations induced by HOCl, such as, apoB, fibronectin and 
ovalbumin (265).  Furthermore, the formation of MetO alters protein folding to expose 
hydrophobic areas on neighbouring amino acids that associate to form dimmers and 
higher−molecular mass aggregates (265).  Indeed, it is suggested that oxidation of Met in 
apoA−I causes a dramatic conformation change of apoA−I, with the N−terminal region 
becoming more exposed than in its native form (266,267).  However, the aggregates formed 
during the oxidation of HDL by peroxyl radicals need to be confirmed in the future studies. 
The ELISA described in this chapter may be applicable relevant to clinical samples, at least 
as judged by its limits of detection of MetO-containing apoA-I compared to the HPLC-based 
assay. The latter indicated that up to 15% of endogenous apoA-I may be present as apoA-I+32  
in clinical samples (103).  The amount of MetO-containing apoA-I (MetO86, MetO112, or 
MetO86 plus MetO112) added as “HDLox” to the 1/10 diluted plasma in Fig. 4.15C ranged 
from 0 – 0.525 µg, as determined by HPLC analysis of the AAPH-oxidized HDL used.  This 
corresponds to 0 – 7% of the endogenous apoA-I being oxidized in the plasma samples used, 
given that apoA-I constitutes ~70% of HDL’s protein and the concentration of apoA-I in 
human plasma is ~1.5 mg/mL (268). 
While feasible, the biological or pathological role of MetO−containing apoA−I is presently 
not established.  This could limit the importance of the ELISA described herein.  Also, in 
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vitro generated oxidized forms of apoA−I and HDL were exclusively used in this chapter, 
whereas the oxidative modifications occurring to apoA−I in the diseased artery wall are 
conceivably more complex.  For example, it is not known whether, and if so to what extent, 
oxidative modifications in addition to MetO formation, such as chlorination or cross−linking 
of apoA−I, affect the response of the ELISA described here.  An additional potential 
limitation of the present assay is that HDL is subject to continuous remodeling in vivo.  This 
includes dissociation of apoA−I from the lipoprotein particle, a process that could be 
increased by oxidation (100).  Furthermore, methionine sulfoxide reductases is an important 
enzyme to protect cells from oxidative stress throughout many species from bacteria to 
mammals (269).  It is assumed to be an intracellular enzyme (227).  It would be interesting to 
investigate the presence of methionine sulfoxide reductases in human lesions within artery 
wall.  Clearly, future studies are required to assess these various aspects, as well as the utility 
of the ELISA described for clinical studies and/or the use of MOA−I to immunoprecipitate 
modified apoA−I from biological materials for subsequent characterization. 
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Summary 
The present pilot study assessed the levels of MetO−containing apoA−I using the newly 
developed ELISA.  Plasma was obtained from patients without and with established CAD as 
assessed by angiography and before and after PCI.  There were elevated levels of 
MetO−containing apoA−I in CAD patients compared to control subjects; whereas, plasma 
concentrations of F2−isoprostanes were decreased significantly in patients compared to 
controls.  Unexpectedly, MetO−containing apoA−I decreased significantly in CAD patients 
after PCI, an observation supported by parallel HPLC analyses of HDL samples isolated from 
respective plasma samples.  In contrast, plasma F2−isoprostanes increased significantly in 
CAD patients after PCI.  As serum amyloid A has been reported to both increase after PCI 
and to displace apoA−I from HDL, it will be important to determine the relationship of 
lipoprotein−associated SAA and other inflammatory proteins with apoA−I and oxidized 
apoA−I in HDL following PCI. 
Chapter 5 
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5.1 Introduction 
Percutaneous coronary intervention (PCI), previously called transluminal coronary 
angioplasty, is an effective and safe method to achieve coronary blood flow in patients with 
symptomatic CAD (270-272).  However, primary PCI may generate oxidative stress due to 
the insufficient myocardial perfusion and microcirculatory failure induced by the procedure 
(273,274).  It has been reported that the successful revascularization of blocked arteries by 
PCI is associated with the generation of free radicals that peaks between 1.5 and 3.5 hours 
(275,276).  Consistent with this, PCI induces an increase in circulating concentration of 
F2−isoprostanes (277), i.e., chemically stable end products of lipid oxidation that are 
recognized as a “gold standard” for oxidative stress (126,127).  Therefore, PCI is associated 
with an inflammatory response characterized by increased oxidative stress. 
In addition, the restoration of coronary flow by PCI correlates with an enhanced 
inflammatory response that is characterized by increased levels of CRP, serum amyloid A 
protein, and interleukin−6 (278).  Circulating levels of CRP and serum amyloid A also 
increase following diagnostic coronary angiography (279).  Both CRP and serum amyloid A 
are acute−phase proteins, the hepatic synthesis of which is induced in response to tissue 
injury or infection (280).  CRP is a sensitive marker of inflammation and has been associated 
with increased risk of CVD (281).  Serum amyloid A refers to a family of four homologous, 
amphipathic, alpha-helical proteins, which are transported in the circulation predominantly on 
HDL (282).  Like CRP, hepatic expression of serum amyloid A is increased markedly in 
response to a variety of inflammatory stimuli (282).  For example, levels of serum amyloid A 
are increased rapidly during acute and chronic inflammation in the blood of both human and 
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animals (283).  Thus, it is clear that the increased levels of acute−phase proteins, such as CRP 
and serum amyloid A are associated with PCI (284).   
As mentioned in previous chapters, oxidized HDL formed in the arterial wall may re−enter 
the circulation as a consequence of PCI since HDL is small compared to LDL (227).  There is 
evidence that MetO−containing, oxidized apoA−I presents in circulation in subjects with 
increasing risk of CHD (103) and type 1 diabetes, for which cardiovascular events are a 
significant complication (104).  Therefore, MetO−containing apoA−I may be present in the 
circulation in subjects with established CVD and in patients after angioplasty.   
The aim of this pilot study was to assess the levels of oxidized apoA−I containing MetO in 
patients with angiographically defined CAD before and after PCI using the newly established 
ELISA method.  To ensure the accuracy of the measurement, HPLC analysis of isolated HDL 
from the same plasma samples was carried out at the same time, along with the analysis of 
F2−isoprostanes. 
5.2 Materials and Methods 
Subjects with and without CAD were determined by angiography performed at Prince of 
Wales Hospital (Sydney, NSW, Australia).  Angiographically proven CAD patients 
underwent PCI carried out in the same hospital. Blood samples were collected from the 
subjects before and after angiohraphy/PCI with details described in Section 2.13.2. 
ELISA measurement of MetO−containing apoA−I in plasma samples obtained from subjects 
with and without CAD, and before and after angiography/PCI is described in Section 2.7.5.2. 
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HPLC analysis of isolated HDL from plasma samples of subjects with and without CAD, and 
before and after angiography/PCI was performed in parallel with ELISA according to the 
details described in Sections 2.2.5 and 2.4.2. 
Levels of plasma F2−isoprostanes were measured by GC−MS in aliquots of the same plasma 
samples used for ELISA and HPLC as described in Section 2.5.2. 
Similarly, plasma levels of CRP were determined in additional aliquots of the plasma samples 
using the Roche Tina−quant CRP assay as described in Section 2.8. 
5.3 Results 
5.3.1 Levels of MetO−containing apoA−I in plasma of CAD subjects 
Plasma levels of MetO−containing apoA−I determined by ELISA were significantly higher in 
CAD patients (n=10) compared to control subjects (n=10, Fig. 5.1), indicating the presence 
of oxidized HDL in the circulation of patients with CAD.   
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Fig. 5.1.  Content of MetO−containing apoA−I in plasma of subjects without and with 
CAD.  Plasma from control subjects (n=10) and from subjects with established CAD as 
determined by angiography (n=10) was subjected to the ELISA.  The Wilcoxon rank sum test 
was used to analyze the data for statistical difference.  A p−value of <0.05 was considered 
statistically significant. 
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5.3.2 Plasma levels of MetO−containing apoA−I in CAD patients before and after PCI 
Plasma concentrations of MetO−containing apoA−I were also determined in angiographically 
proven CAD patients before (n=5) and after (n=5) PCI.  Unexpectedly, levels of 
MetO−containing apoA−I decreased significantly patients after PCI, whereas, angiography 
itself did not affect the plasma content of MetO−containing apoA−I (Fig. 5.2).  Parallel 
HPLC analyses of HDL isolated from these plasma samples yielded consistent results (Fig. 
5.3), although 5 of the 10 CAD samples analyzed showed evidence for MetO.  For example, 
HDL from patients B and C contained 18 and 1.5% of apoA−I’s Met as apoA−I+16, 
respectively (Fig. 5.3B1 & C1).  Following PCI, the proportion of Met oxidation decreased to 
1% for HDL of patient B and there was no Met oxidation detectable in HDL of patient C 
(Fig. 5.3.B2 & C2).   
5.3.3 Plasma levels of F2−isoprostanes in CAD patients  
Plasma concentrations of F2−isoprostanes, measured by GC−MS, were significantly lower in 
CAD patients than those in control subjects (Fig. 5.4).  As expected, there was a significant 
increase in plasma of F2−isoprostanes in CAD patients after PCI (Fig. 5.5).  Angiography 
alone did not affect plasma F2−isoprostanes (Fig. 5.5), suggesting that the formation of 
F2−isoprostanes is increased as a result of PCI. 
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Fig. 5.2.  Effect of PCI on plasma levels of MetO−containing apoA−I in CAD patients.  
The levels of MetO−containing apoA−I in CAD patients were significantly higher before 
(n=5) than after angioplasty (n=5).  ‘B’ indicates before angiography/PCI; ‘A’ indicates after 
angiography/PCI.  Wilcoxon test was used for statistical analysis.  A p−value of <0.05 was 
considered statistically significant. 
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Fig. 5.3.  Representative HPLC traces of HDL isolated from the plasma samples of CAD 
patients used for the ELISA.  A, B and C refer to chromatograms of HDL isolated from 
plasma of control, CAD and CAD+PCI patients before (1) and after (2) PCI, respectively.  
HDL isolated from control plasma contained apoA−I and apoA−II as two major 
apolipoproteins.  HDL isolated from plasma of CAD patients contained MetO, the 
concentration of which decreased after angioplasty.  Arrow ‘a’ indicates apoA−I+16 
containing MetO86. 
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Fig. 5.4.  Plasma levels of F2−isoprostanes in subjects without and with CAD.  Plasma 
samples from control subjects (n=10) and from subjects with established CAD as determined 
by angiography (n=10) were subjected to ECNI−NC−MS as described in Section 2.5.2.  The 
Wilcoxon rank sum test was used to analyze the data for statistical difference.  A p−value of 
<0.05 was considered statistically significant. 
 
Chapter 5 Pilot Study of Clinical Samples  
  195 
 
 
Fig. 5.5.  Plasma levels of F2−isoprostanes in control and CAD patients undergoing PCI.  
The levels of F2−isoprostanes in plasma was increased significantly in CAD patients after 
(n=5) than before (n=5) angioplasty.  There was no significant difference of plasma 
F2−isoprostanes for control subjects and CAD patients following angiography.  ‘B’ indicates 
before angiography/PCI; ‘A’ indicates after angiography/PCI.  The Wilcoxon test was used 
for statistical analysis.  A p−value of <0.05 was considered statistically significant. 
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5.3.4. Plasma levels of CRP in CAD patients 
Levels of CRP in plasma of control subjects and CAD patients before (n=5) and after (n=5) 
angiography or angioplasty were measured using the Roche Tina−quant CRP method.  As 
can be seen, there was no significant difference between control subjects and CAD patients.  
No statistically significant increase of CRP was observed following PCI.  CRP and 
F2−sioprostanes were also explored for individual subjects and before and after angiography / 
PCI.  However, no significant correlations were found. 
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Fig. 5.6. Plasma CRP levels in control and CAD patients.  The levels of CRP were 
measured in plasma of control subjects and CAD patients before (n=5) and after (n=5) 
angiography or PCI using the Roche Tina−quant CRP method.  ‘B’ indicates before 
angiography/PCI; ‘A’ indicates after angiography/PCI.  The Wilcoxon test was used for 
statistical analysis.  A p− value of <0.05 was considered statistically significant. 
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5.4 Discussion 
In humans, PCI is an established and successful method to restore coronary blood flow in 
patients with symptomatic CAD (270-272).  However, it has been reported that this 
procedure may induce oxidative stress evidenced by increased plasma levels of 
15−F2−isoprostanes and serum CRP following PCI (277,285), and elevated levels of markers 
of inflammation, such as CRP and serum amyloid A (278) after PCI procedure.  Serum 
amyloid A is an HDL−associated protein and transported in the circulation mainly in HDL 
particle (282).  To date, levels of MetO−containing apoA−I in HDL have not yet been tested 
in plasma of subjects with CAD before and after PCI.  Therefore, using the newly developed 
ELISA, the present pilot study assessed levels of MetO−containing apoA−I in plasma of 
subjects without and with angiographically proven CAD.  The results obtained suggest that 
Met oxidation in circulating apoA−I was elevated in CAD patients compared with control 
subjects (Fig. 5.1).  Unexpectedly, however, Met oxidation decreased significantly in these 
CAD patients following PCI, as assessed by ELISA (Fig. 5.2) and HPLC (Fig. 5.3).  In 
contrast, the general lipid oxidation marker, F2−isoprostanes, increased in CAD patients as a 
result of PCI (Fig. 5.5), although plasma levels of F2−isoprostanes were significantly lower in 
CAD patients compared to control subjects (Fig. 5.4). 
The preliminary data showing increased levels of MetO−containing apoA−I in plasma of 
CAD patients adds to previous reports documenting Met oxidation in apoA−I in the 
circulation of patients with increasing risk of CVD and established CAD (103,106,107,224).  
The presence of MetO−containing apoA−I are usually analyzed by MS, HPLC or 
SDS−PAGE (106,107,110).  A limitation of the present study is the small sample size.  
Larger numbers of clinical samples will need to be analyzed in the future to validate the 
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usefulness of the ELISA and to investigate the relationship between MetO−containing 
apoA−I and CAD.   
Lower levels of plasma F2−isoprostanes were observed in CAD patients compared to controls 
(Fig. 5.4).  This results contrasted previous findings that elevated plasma levels of 
F2−isoprostanes are associated with the extent and severity of CAD (286,287).  One 
explanation for this is small sample size used in this study because results from previous 
studies obtained from larger sample size ranging from 60 to 250 (286,287).  More plasma 
samples are required in the future studies in the analysis of F2−isoprostanes.  Previous studies 
have also reported PCI increases plasma concentrations of F2−isoprostanes (277).  The 
present results confirmed this earlier finding (Fig. 5.5).  Increased plasma F2−isoprostanes is 
thought to reflect enhanced oxidative stress in a local milieu in vivo (277).  Similarly, it has 
also been reported that PCI is associated with an inflammatory response manifested as 
increased levels of the acute−phase protein, CRP and serum amyloid A (278,279,284).  In 
contrast, an increase in CRP was not observed following PCI in the present study, employing 
a small sample size (n=10).  In humans, plasma levels of CRP strongly correlate with serum 
amyloid A (282,288) that was not determined in the present study.  As serum amyloid A is an 
HDL−associated protein that can displace apoA−I (280,289,290).  It is possible that an 
increase in serum amyloid A following PCI, if occurring, could conceivably decrease the 
levels of MetO−containing apoA−I.  To address this issue, future studies will have to also 
determine the levels of total apoA−I in CAD patients before and after PCI, together with 
serum amyloid A. 
Indeed, plasma serum amyloid A is elevated markedly during acute and chronic inflammation 
in humans (283), and in CVD, increased serum amyloid A is associated with decreased levels 
of apoA−I (280).  It has been suggested that as serum amyloid A associates with circulating 
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HDL, the particle undergoes remodelling resulting in the depletion of apoA−I in HDL (289).  
In addition, MetO−containing apoA−I (i.e., apoA−I+32) has been found to dissociate from 
HDL more readily than native apoA−I (100).  Therefore, it will be important to evaluate the 
role of HDL−associated serum amyloid A and apoA−I before and after PCI in future, larger 
studies.   
In conclusion, the present pilot study suggests that increased levels of Met oxidation in 
apoA−I may be present in plasma of patients with angiographically proven CAD, supporting 
the notion that the newly developed ELISA is suitable to assess a contribution of HDL 
protein oxidation to oxidative stress, atherosclerosis and CVD. 
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It has long been known that a low level of HDL cholesterol is a powerful predictor of 
increased risk for CVD (268,291).  Thus, in the past decade, increasing HDL has emerged as 
a new potential therapeutic target for the treatment of CVD (34).  However, the relationship 
between HDL oxidation and CVD remains unclear, just as it remains to be established 
whether HDL oxidation is a useful indicator of oxidative stress and/or CVD.   
Atherosclerosis represents a state of increased oxidative stress, characterized by comparable 
lipid oxidation of all lipoproteins in the affected arterial wall (1).  While the relationship 
between LDL oxidation and atherosclerosis has received much attention (1), recent interest 
has focused on HDL oxidation and its consequences for atherosclerosis.  However, oxidation 
of HDL is a complex process.  In general, oxidation mediated by 1e− (or radical) oxidants 
initially results in lipid oxidation, including the formation of LOOH, which may be reduced 
by apolipoprotein-associated Met residues,  In the case of HDL, LOOH are reduced to the 
corresponding LOH by Met in apoA−I and apoA−II.  This gives rise to specifically modified 
forms of apolipoproteins containing MetO (50,102,292).  Such selectively oxidized 
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apolipoproteins are generated during the initial stages of HDL oxidation, i.e., when the 
lipoprotein still contains α-tocopherol.  In the absence of Cys, Met residues in apoA-I are the 
major reducing amino acids (48,50,102). 
LOOH may also degrade and become further oxidized to secondary lipid oxidation products, 
including F2-isoprostanes and fragmented lipids containing reactive groups.  F2-Isoprostanes 
are known as the “gold standard” marker for lipid oxidation (204).  These secondary 
processes also commonly lead to protein oxidation, as reviewed comprehensively by Davies 
(205,206). 
Unlike 1e−oxidants, 2e−oxidants, such as H2O2, HOCl and ONOO− initially react with the 
apolipoproteins associated with lipoproteins (1).  The resulting primary protein oxidation 
products can also degrade, giving rise to further radical species that may themselves initiate 
lipid peroxidation (207,293).  Given this complexity, it is not surprising that there is 
considerable diversity in the methods used to evaluate HDL oxidation. 
In the present study, evaluation of HDL oxidation was focused on the specifically oxidized 
apolipoproteins containing MetO.  In vitro experiments show Met residues in apolipoproteins 
initially are selectively oxidized to MetO when HDL is exposed to peroxyl radicals (103).  In 
addition, HDL is the major carrier for circulating cholesterol ester hydroperoxides (168) and 
F2−isoprostanes (167).  These observations are consistent with the notion that lipids in HDL 
become oxidized before those in LDL (168).  Strikingly, apoA−I containing two MetO has 
been detected in subjects with increasing risk of CVD (103). 
It is also noted that HOCl, a powerful 2e−oxidant, produced from MPO/H2O2/Cl− system can 
convert apoA−I Tyr residues into 3−chlorotyrosine and Met residues into MetO (106,107).  
Similarly, H2O2 can convert all three Met residues of apoA−I into MetO, at least when high 
Chapter 6 General Discussion 
  204 
molar ratio of oxidant to apoA−I are used (229).  Such oxidations can have functional 
consequences on apoA−I/HDL potentially relevant to reverse cholesterol transport.  For 
example, oxidized apoA−I shows impaired ability to promote cholesterol efflux via the 
ABCA1 pathway and to activate lecithin cholesterol acyltransferase (106,107,220,229). 
Therefore, with the emerging potential importance of MetO−containing apoA−I in the 
context of CVD, this study initially investigated the usefulness of MetO−containing apoA−I 
for oxidative stress and/or CVD using an HPLC−based method applied to isolated HDL.  The 
results obtained indicated that MetO−containing apoA−I is a potentially useful marker for in 
vivo protein oxidation.  Therefore, a mouse monoclonal antibody against human apoA−I+32 
(MOA−1) was then raised and a sensitive and specific ELISA developed, for the detection of 
MetO−containing apoA−I in HDL and plasma.  Preliminary clinical experiments were also 
carried out and demonstrated the usefulness of MOA−I and the ELISA assay in detecting 
Met−containing apoA−I in human samples and future clinical studies. 
In the first part of present study, the apoA−I and apoA−II containing specifically oxidized 
MetO in HDL were measured by HPLC in a prospective, cohort study of a general population 
(Fletcher−Challenge study), along with F2−isoprostanes and other established risk factors.  
The relationship between CVD and these parameters were also investigated.  The results 
revealed that there was no direct correlation between the markers of oxidative stress, 
including F2−isoprostanes, and CVD outcome in a general population.  These results are 
inconsistent with the commonly held notion that oxidative damage significantly contributes 
to CVD outcome.  It was the first study to examine the correlation between CVD and markers 
of oxidative damage to both lipid and protein in a general population.  Nevertheless, and 
importantly, the results demonstrated a significant correlation between MetO−containing 
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apoA−I and F2−isoprostanes, in support of the potential usefulness of MetO−containing 
apoA−I as a marker of in vivo protein oxidation.   
In the Fletcher−Challenge study, apoA−II was also analyzed by HPLC.  Unexpectedly, the 
increase of apoA−II−1, a species newly characterized by mass spectrometry (260), was 
associated significantly with increasing risk of CVD.  ApoA−II−1 has been characterized as 
apoA−II isomers with loss of C−terminal one Glu residue (260).  Limited information is 
known about apoA−II and its role in CVD, except that apoA−II is involved in the regulation 
of VLDL metabolism and insulin resistance (179), and that it inhibits lecithin cholesterol 
acyltransferase and cholesterol ester transfer protein (258,294).  Based on the association 
between apoA−II−1 and increasing risk of CVD observed in the present study, it would be 
interesting to investigate the mechanism involved in the future studies. 
At present, a ‘gold standard’ for in vivo protein oxidation is not available.  Most existing 
methods to detect oxidized HDL are complex and time consuming, and they require 
expensive and specialized equipments, such as HPLC and MS.  Based on the findings that 
MetO−containing apoA−I might be a potential useful marker for in vivo protein oxidation, a 
new ELISA method to detect MetO−containing apoA−I was developed and validated in the 
second part of the study. 
MOA−1 was raised in mice against HPLC−purified human apoA−I+32 containing MetO86 and 
MetO112, and derived from AAPH−oxidized HDL.  The initial specificity for the sandwich 
ELISA design was achieved after choosing an optimal pair of capture and detection 
antibodies that recognized different epitopes on apoA−I+32.  Then, several lines of evidence 
supported the specific detection of MetO in apoA−I in lipid−free forms.  MOA−1 recognized 
neither native apoA−I nor apoA−II.  Experiments with mutant apoA−I(s) and their 
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H2O2−oxidized forms demonstrated that MOA−1 recognizes apoA−I containing one, two or 
three MetO.  This finding suggests that MOA−1 is suitable to detect apoA−I containing any 
MetO, rather than MetO86 plus MetO112 only.  Interestingly, MOA−1 readily detected apoA−I 
oxidized by 2e−oxidants, but did not recognize apoA−I oxidized by 1e−oxidants.  It is known 
that 2e−oxidants such as ONOO¯ , H2O2 and HOCl directly convert Met of apoA−I into MetO 
(1,50,102).  Importantly, MOA−1 was unreactive to 2e−oxidant−oxidized proteins other than 
apoA−I, even if the proteins contain Met residues.  This result further supported the 
specificity of MOA−1 for the recognition of MetO−containing apoA−I only. 
Interestingly, for MOA−1 to detect peroxyl radical−oxidized HDL required apoA−I to be 
‘delipidated’, whereas MOA−1 readily recognized H2O2−or HOCl− oxidized HDL without 
delipidation.  The fact that the ELISA detects differently oxidized HDL likely increases its 
applicability to clinical samples, such as those relevant to CVD and other oxidative stress 
related diseases, because various oxidants contribute to oxidative modifications in the 
affected arterial wall in atherosclerosis (1).  Thereby, MetO−containing apoA−I may 
represent a general feature of oxidative damage in oxidized HDL (50,102) and is recognized 
by MOA−1. 
Plasma contains a large number of proteins, and MOA−1 was able to detect MetO−containing 
apoA−I in human plasma only after albumin removal.  Albumin was identified as the major 
interfering protein.  Interestingly, apoA−I was largely depleted while albumin was removed 
in SwellGel Blue process, though recovery of apoA−I was enhanced by using optimized 
buffer.  This phenomenon is explained by previous findings that apoA−I associates with 
albumin (295) and oxidized apoA−I (i.e., apoA−I+32) associates more readily than native 
apoA−I (100). 
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Finally, the developed ELISA was then applied to clinical plasma samples.  Preliminary 
results demonstrated significantly elevated levels of MetO−containing apoA−I in plasma of 
subjects with proven CAD compared to that of control subjects.  Unexpectedly, the levels of 
oxidized apoA−I containing MetO decreased following angioplasty.  Such a decrease of 
MetO−containing apoA−I could be due to the displacement of apoA−I by an increase in 
HDL−associated serum amyloid A following PCI. 
While the ease of an ELISA method makes it feasible for clinical applications, it is noted that 
HDL isolation continued with conventional HPLC was used in parallel throughout the study 
to validate the ELISA assay.  The HPLC method was used to analyze lipid−free apoA−I 
oxidized by different oxidants and mutant apoA−I(s) as well as their oxidized forms.  The 
initial quantification of oxidized apoA−I contained in HDL was also carried out by the HPLC 
method.  Most importantly, the authenticity of MetO−containing apoA−I was identified by 
mass spectrometry.  It is also worthy to note that under the oxidation conditions described in 
this study, the modified amino acids were limited to Met residues as characterized previously 
(50,102,103,229).  Throughout, the ELISA method showed consistent results when compared 
with the HPLC method, although the former had a sensitivity of 2−3 orders greater than the 
HPLC method. 
As discussed in earlier sections, MetO in apoA−I can be formed in vivo by direct reduction of 
naturally occurring, hydroperoxides of core and surface lipids of HDL (49,50,102,248), as 
well as by direct oxidation mediated by MPO/H2O2/Cl¯  system.  Such oxidation has been 
shown to impair the ability of apoA−I to promote the efflux of cholesterol from model foam 
cells (106,107,220).  In vitro experiments have demonstrated that such compromised 
cholesterol removal and LCAT activation is due to MetO in apoA−I (229).  The in vitro 
Chapter 6 General Discussion 
  208 
oxidation of Met112 and Met148 in apoA−I by H2O2 results in significantly decreased 
thermodynamic stability of apoA−I with substantially altered structure in the centre region of 
apoA−I in HDL, indicating altered functional properties of apoA−I (230).  Indeed, it has been 
reported that the central region of apoA−I is important in the efflux of cholesterol (296) and 
in activation of LCAT (297).  Together, it is apparent that such functionally important 
alterations of the structure and stability of apoA−I caused by oxidative damage would be of 
potentially biological and pathological importance.  However, the physiological and 
pathological functions of MetO in apoA−I molecule are yet to be established unambiguously.   
There are potential limitations to the use of the ELISA described herein to evaluate the 
physiological and pathological role of MetO−containing apoA−I.  In this study, in vitro 
generated oxidized forms of apoA−I and HDL were exclusive used, whereas the oxidative 
modifications occurring to apoA-I in the diseased artery wall are likely more complex.  The 
MPO/H2O2/Cl¯  system also forms 3−chlorotyrosine, in addition to MetO (106).  Therefore, 
investigating the reactivity of MOA−I in MPO/H2O2/Cl¯  system and determining the effect 
of chlorination on MOA−1’s recognition of MetO in apoA−I are required in future studies.  
Secondly, HDL is also subject to continuous remodelling in vivo.  This includes dissociation 
of apoA-I from the lipoprotein particle, a process that itself that may be increased by 
oxidation (100).  Therefore, the impact of structural changes of apoA−I and HDL 
remodelling during different oxidation conditions on the ELISA are also required to assess in 
the future studies. 
MOA−1 was produced initially from immunizing mice with the lipid−free apoA−I+32, which 
contains two of the three Met residues as MetO.  The experiments using mutant apoA−I with 
different Met residues replaced and their H2O2−oxidized forms showed that MOA−I was also 
Chapter 6 General Discussion 
  209 
able to recognize MetO148.  In addition, MOA−1 was able to detect either one, two or three 
MetO in apoA−I and the extent of recognition by MOA−1 increased with increasing numbers 
of MetO.  Therefore, it is likely that MOA−1 binds a conformational epitope rather than 
directly recognizing MetO.  While these properties of MOA−1 likely increase the 
applicability of the ELISA method for the assessment of protein oxidation in CVD and 
perhaps other diseases, it is important to conduct more extensive epitope mapping for 
MOA−1.  For example, with the crystal structure of full−length apoA−I available and peptide 
synthesis techniques available, it may be possible to identify the epitope recognized by 
MOA−1.   
The present study for the first time investigated the relationship between CHD and markers of 
oxidative stress to both lipid (F2−isoprostanes) and protein (MetO−containing apoA−I) in a 
prospective study in a general population.  The results revealed that there was no direct 
association between oxidative damage and CHD outcome.  However, the results showed 
close correlation between F2−isoprostanes and MetO−containing apoA−I, indicating the 
potential usefulness of MetO−containing apoA−I as a marker for oxidative stress and protein 
oxidation.  Therefore, MOA−1, a mouse anti−human apoA−I+32 monoclonal antibody was 
raised and used to develop a novel ELISA to detect MetO−containing apoA−I in plasma.  
Several lines of evidence supported the specificity of MOA−1 for the recognition of MetO in 
apoA−I in human plasma.  Future studies are required to assess the role of MetO−containing 
apoA−I in both physiological and pathological conditions, as well as the use of MOA−1 for 
clinical studies.  To date, MOA−1 is the first and only monoclonal antibody raised against 
MetO in apoA−I molecule.  Therefore, the ELISA method described herein may be useful to 
assess the importance of in vivo HDL oxidation, in diseases associated with oxidative stress, 
including atherosclerosis and related disorders. 
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